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Abstract 
As of 2016, women make up the majority of people living with HIV globally, and especially in 
sub-Saharan Africa where women and girls make up 59% of all people living with HIV. Female 
sex workers (FSWs) are at even higher risk of acquiring HIV, given vulnerabilities in 
criminalization of their work and challenges in negotiating safer sex. HIV prevalence among 
FSWs in South Africa is higher than any other sub-population, with a recent study recording a 
prevalence of up to 72% in the greater Johannesburg area, and 40% and 54% prevalence in 
Cape Town and Durban respectively.  
 
To date, female-initiated HIV prevention options have been limited, with most interventions 
focused on male condom use. However, in the last few years, oral pre-exposure prophylaxis 
(PrEP) has been shown to be highly efficacious in preventing HIV infection among men and 
women, if taken consistently. To examine whether women, especially those who are 
considered part of key populations, will take up and use PrEP outside of clinical trials, many 
demonstration or pilot studies are underway around the world.  
 
This thesis explores the real-world applicability and acceptability of oral PrEP in order to inform 
intervention design, implementation, and product use for female sex workers in South Africa. 
A range of methods were used to answer this overarching aim including:  
 
 an adapted meta-ethnography to explore and understand previous research regarding 
motivations and barriers to uptake and use of female-initiated HIV prevention 
technologies that could be used by women in sub-Saharan Africa; 
 formative research in South Africa, using a grounded approach to examine the 
practical and contextual factors that might influence successful delivery of a PrEP 
intervention with the aim of designing an intervention; 
 focus group discussions with FSWs to examine community-level acceptability of PrEP 
with potential end users (the final activity in the formative research); 
 demographic and behaviour surveys conducted during the Treatment And Prevention 
for Sex workers (TAPS) Demonstration Project to identify key characteristics of FSWs 
who took up and used PrEP within the context of TAPS; and, 
 in the individual perspectives and lived experiences of PrEP users in TAPS are explored 
through analysis of in-depth face-to-face interviews with FSW.  
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The overall findings of this thesis point to the multi-dimensional aspects of individual needs, 
community perceptions and beliefs, clinic delivery platform and feasibility, as well as societal 
norms and environmental context which determine the ability of FSWs to successfully use 
PrEP. Recommendations for including and acknowledging these dimensions, as well as how to 
leverage them to develop more effective programmes are included.  
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1.0 General Introduction 
 
1.1 Overview 
This general introduction chapter provides the background, history, rationale and conceptual 
basis for this PhD research. The chapter is broken down into sections that examine:  
 
 the HIV epidemic;  
 the nature, definition, and importance of sex workers as a key population in relation to 
the HIV epidemic;  
 HIV prevention options for women;  
 ARV-based prevention and the product development pipeline;  
 the case for oral PrEP, in particular for sex workers;  
 the call for implementation research and the TAPS Demonstration Project providing 
the context for this PhD; and,  
 an outline of the PhD aims and objectives, underlying framework, and thesis structure.  
 
It is important to note that this PhD thesis has been prepared in a publication style. A total of 
six papers are presented throughout Chapters 2 - 6 which speak to the overarching aims and 
objectives, outlined in Section 1.11. In order to avoid repetition, certain issues are briefly 
introduced in the context of this introduction to help provide a clear rationale for the overall 
study, but are explored in more detail in the introduction sections of the papers that follow in 
later chapters.  
 
1.2 The public health problem 
The most recent World AIDS Day Report from the Joint United Nations Programme on 
HIV/AIDS (UNAIDS) highlighted that the decline in the global rate of new HIV infections has 
stalled, and that key populations including young women (YW), people who inject drugs 
(PWID), sex workers (SWs), men who have sex with men (MSM), and transgender people still 
remain at highest risk (1). Additionally, women in general are disproportionately affected by 
HIV due to both biological and social factors (2), although biological susceptibility is not yet 
fully understood (3,4). Issues of social and gender inequality, particularly in situations where 
gender-based violence is present, have been shown to increase a woman’s risk of HIV (5).  
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Female sex workers (FSWs) experience even higher rates of HIV and, at a global level, are 10-
13.5 times more likely to be living with HIV than other women (1,6). The most recent pooled 
analysis of FSWs in sub-Saharan Africa found the HIV prevalence rate to be 36.9% (7). Attempts 
have been made to estimate the size of sex worker populations globally and regionally, 
however this has proven to be a difficult undertaking since many countries have not conducted 
focused mapping exercises, and in those that have, counting strategies vary considerably (8,9). 
Additionally, sex worker populations can be highly mobile, and many women who sell sex do 
not actually consider themselves to be sex workers making them even more difficult to identify 
and assess their risks (10).  
 
Figure 1. Prevalence of HIV in FSWs by region (6).  
 
 
1.3 Definition of Sex Worker 
Given the varied nature of sex work, it is important to define here the term ‘sex worker’ as it is 
used throughout this PhD. In 2012, UNAIDS defined sex work as: 
 
“female, male, and transgender adults and young people (18 years of age and above) 
who receive money or goods in exchange for sexual services, either regularly or 
occasionally.”(11) 
 
This definition combines the notion of formalised sex work, in which a person may identify 
themselves as a sex worker and accept money or other goods in exchange for services, as well 
as transactional sex, which is defined by a less formalised interaction where sexual favours are 
exchanged for some type of material gain, while the person may not identify themselves as a 
sex worker. Specific definitions for transactional sex continue to evolve as more nuanced 
understanding of the interaction develops (12). The dynamics of HIV transmission are likely to 
be very different between those identifying as ‘sex workers’ and those engaging in 
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transactional sex, and HIV prevention programming often distinguishes the two for the 
purpose of targeting interventions.   
 
The definition of sex work utilised in the current research, draws on the formalised constructs 
reflected in the UNAIDS definition of 2000:   
 
‘‘any agreement between two or more persons in which the objective is exclusively 
limited to the sexual act and ends with that and which involves preliminary 
negotiations for a price.’’(13)  
 
This definition clearly excludes notions of love, relationships or security, limiting to services in 
exchange for money or what might constitute a price. This definition was chosen for this 
project in order to reflect the context in which the research was conducted, as it was 
imbedded within a larger study targeting interventions specifically for self-identified FSWs. 
 
1.4 Sex Workers as a Key Population 
Sex workers are defined as a key population since they are more likely to be exposed to HIV as 
part of their work, and may be more likely to engage in sex where onward transmission of HIV 
is possible, both with clients and regular partners. Indeed, in areas where education and 
empowerment programmes exist, sex workers report high rates of condom usage with clients 
(14), however, power and relationship dynamics, including trust, play a role in whether 
condoms are used with main or regular partners (15,16).  
 
The ability to negotiate condom use and prevent HIV among female sex workers, as well as 
preserve overall safety on a day to day basis, has been shown to be dependent on several 
factors (10,17): age and length of time in sex work as well as sex work locale (brothel or hotel, 
versus street based); structural issues related to criminalisation (whether police use the 
discovery of condoms to single out and arrest sex workers for instance), violence, substance 
use, and poverty (whether condomless sex is considered at premium prices) (18–23). A 
systematic review of alcohol use and risky sexual behaviour in populations in sub-Saharan 
Africa showed that alcohol use directly correlated to lower  rates of condom use (21). Another 
systematic review found that sex workers had a lifetime prevalence of any type of violence of 
45-75%, and 32-55% in the last year (19), which is also directly correlated to acquisition of HIV. 
This violence comes from a variety of sources including clients, pimps and other operators in 
the sex work trade, intimate partners, police, and community members who do not support 
the trade.  
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For these reasons, sex workers are considered a highly vulnerable population, and have been 
the focus of many efforts worldwide to try to remove, or at least reduce, some of these 
vulnerabilities (13,24–27). These efforts have in turn promoted national and local strategies to 
focus on improving specific contexts.  
 
1.5 Sex workers in South Africa 
In South Africa, the HIV epidemic continues to be one of the largest in the world, making up 
nearly half of the HIV burden in sub-Saharan Africa (1). The most recent Human Sciences 
Research Council (HSRC) HIV Prevalence, Incidence, and Behaviour Survey revealed an overall 
national HIV prevalence in women of 14.4%, with rates as high as 17.4% to 31.6% between the 
ages of 20 and 49, a segment of the population considered to be significant in driving the 
epidemic (28).  
 
The HIV prevalence among FSWs in South Africa was estimated to be between 44-69%, with 
19.8% of all new infections in South Africa originating from FSWs, their regular partners, and 
their clients (29,30). However, figures published more recently found a prevalence of 72% in 
the greater Johannesburg area, and 40% and 54% in Cape Town and Durban respectively (31). 
A report from the South African National AIDS Council (SANAC) estimated that sex workers 
make up 1.1% of the adult population in South Africa (132,000-182,000), with women 
comprising 91% of the sex worker population (32).  
 
The high prevalence of HIV among FSWs in South Africa, in combination with the many 
vulnerabilities inherently faced by sex worker populations in general, led to the development 
of a national sex worker plan by SANAC, highlighting sex workers as a priority population for 
tailored prevention and HIV treatment services (33). This plan is in the process of being 
implemented throughout all South African provinces in a number of sex worker specific clinics. 
In addition, interventions and policies targeting sex workers have also been prioritised in the 
former and most recent National Strategic Plans for HIV, Tuberculosis (TB), and Sexually 
Transmitted Infections (STIs) where the need for more HIV prevention options, especially for 
vulnerable populations, has been underscored (34,35). These plans are also linked to the sex 
worker specific plan (33).  
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1.6 HIV prevention options for women 
There have been limited choices for women in terms of HIV prevention methods, in spite of 
continued product and implementation development research to broaden the method mix. 
The use of male condoms, while efficacious in preventing HIV, heavily depends on the 
willingness of men to use them (36), therefore protection from HIV through the use of male 
condoms is dependent upon a woman’s ability to negotiate use (37).   
 
The female condom is a female-initiated HIV prevention option, but its accessibility has been 
variable at best (38). A report in 2009 from the Global Campaign for Microbicides cited that in 
2005 13.9 million female condoms were available for use, while somewhere between 6-9 
billion male condoms were available (39). More recently, efforts have focused on promoting 
female condom distribution in certain countries and globally (40–42).   
 
Additionally, there has been limited availability of post-exposure prophylaxis (PEP), a method 
in which antiretrovirals (drugs which target and treat retroviruses such as HIV - ARVs) are 
administered for a 28-day period to prevent HIV seroconversion following suspected exposure 
(43). PEP has been predominantly programmed for post-rape care or occupational exposure 
(44,45) in low and middle income countries, largely due to social biases against providing the 
medication for unexpected sexual exposure outside of rape. The World Health Organization 
(WHO) guidelines, however, recommend broader uses for PEP to cover more general, episodic 
cases of suspected exposure resulting from unprotected sex (46,47).  
 
The effect of these social and logistical circumstances is that, until very recently, there have 
been only two female-initiated prevention options: PEP and the female condom. Their limited 
availability and uptake, combined with the sustained rates of HIV among women, have 
demonstrated a clear need to provide more female-initiated and controlled technologies.  
 
1.7 ARV-based prevention and the prevention product pipeline   
To broaden the HIV prevention method mix, there have been wide-scale, concerted research 
efforts to expand the use of ARVs for prevention purposes (48). Following PEP and the ARV-
based prevention of mother to child transmission (PMTCT)(48), focus initially turned to 
developing a topical, or vaginally-based, female controlled product to prevent HIV (49,50). 
Products took the shape of vaginally applied microbicide gels, much like lubricants but 
requiring larger quantities to be applied. Unfortunately, most of these products showed a 
range from no to little efficacy, and in some cases, even harm (51–58). These studies did, 
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however, pave the way for further research and provided valuable knowledge around 
acceptability of such products. From these studies, the nuanced dimensions of acceptability 
including personal, social, political, and environmental, were illuminated from research which 
initially had focussed only on product attributes (59). These nuances are explored further in 
both Chapters 2 and 4. 
 
One other female initiated product, the diaphragm, was tested for protection against HIV but 
did not prove effective in preventing acquisition. Biological reasons are now known to be 
attributable to the failure of these, as diaphragms do not provide enough of a barrier to cover 
all vaginal tissues which may be exposed to HIV. With regards to the gel, and other ARV-based 
products, it has been shown that high drug concentrations in the vaginal tissues of a given 
product are needed in order to confer protection (60). This issue combined with the problems 
with adherence to the daily gel regimens, have made for ineffective products to protect 
against HIV.  
 
Given the high efficacy of PEP and PMTCT, options for oral pre-exposure prophylaxis (PrEP – 
described further in the following section) became part of the product development pipeline. 
The first study, iPrEX, was conducted among men who have sex with men (MSM) which found 
an initial low level of efficacy at 44% (61), however further analyses of high adherence sub-
groups found much higher rates of protection up to 90% compared to placebo (62). This same 
sub-study found that with perfect seven-day dosing, protection could be as high as 99% among 
MSM.  
 
Additional PrEP studies followed in several countries and among a variety of populations, 
including serodiscordant couples and high-risk women. Results from these studies further 
confirmed the efficacy of PrEP among those people who took the drugs regularly (63). 
However, the two studies conducted exclusively among high risk women did not show efficacy 
of the intervention due to lack of adherence (64,65), pointing to the need for further research 
around risk assessment and implementation.  
 
Concurrently, clinical trials also investigated the provision of antiretroviral treatment as soon 
as someone has an HIV-positive test, rather than waiting for their CD4 count to drop below a 
certain level as had previously been the case in most countries. This approach, now termed 
‘test and treat’ in most guidelines, has been found to reduce onward transmission of HIV and 
has produced better health outcomes (66,67). As a result, the standard of care recommended 
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by the World Health Organization (WHO) in 2016 now includes PrEP as an HIV prevention 
option and the test and treat approach (68).  
 
Studies to further expand the method mix continue, with recent results from the vaginal 
dapivirine ring (ARV-based) product trials with more promising, though still moderate results 
(37% and 31% efficacy in protecting against HIV acquisition in the two phase III studies) 
(69,70). The ring and other new and previously tested prevention options are providing the 
basis for further research into future stand-alone and multi-purpose technologies. Because of 
the significant behaviour requirements to maintain consistent pill taking in the case of oral 
PrEP, additional options for modes of preventive ARV delivery are in development. These 
include injectables, vaginal rings and films, and co-formulated products (for contraception, 
STIs, and HIV prevention), which are postulated to promote better uptake as people are able 
to make choices which fit best with their lifestyles (71–73).   
 
The history of ARV-based product development is illustrated in Figure 2 which shows more 
than 20 years of research consisting of a multitude of studies with dates of results, as well as 
when guidelines were released.  
 
Figure 2. An illustration of the last 20 year of ARV-based prevention product development 
 
Note: Dates and products represent results unless otherwise noted. Data for this timeline were 
extracted from several sources (51,54,55,74,75).  
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1.8 The case for Oral PrEP 
The oral PrEP regimen, as recommended by current guidelines (WHO, US Centers for Disease 
Control (CDC), and South Africa), entails taking a daily ARV, dual-drug combination pill 
(tenofovir and emtricitabine) and requires three monthly HIV testing to confirm continued HIV-
negative status in PrEP users (68,76,77). Due to this rigorous commitment, it is hypothesized 
that highly motivated populations, e.g. those at self-recognised higher risk, will be better 
candidates for PrEP than the general population (78). In this context, highly motivated 
populations may be defined as people in higher risk environments who also recognise their 
own risk, such as sex workers (22,27,79). Modelling studies have also shown that targeting 
high HIV incidence populations, even in generalised epidemics, such as sex workers or MSM 
should be prioritised where PrEP is likely to have the greatest impact, especially in generalised 
epidemics (80,81). Estimations of impact, however, are directly related to the HIV prevention 
and treatment programming context within a country. For instance, South Africa and 
Swaziland have shown success in the secondary prevention benefits of scaled-up ART 
programmes, reducing new infections by treating HIV-infected people thereby preventing 
onward transmission (82,83). However, even in these countries, it has been acknowledged by 
policy makers that HIV treatment must go hand in hand with all available HIV prevention 
options in order to fully control the epidemic (84,85).  
 
Interestingly, despite the considerable interest in preventing and treating HIV among sex work 
populations, very few models have been developed specifically for sex workers to examine the 
potential impact of PrEP. Those which have been developed have focused on the FSW 
population in Hillbrow, an inner-city district of Johannesburg, South Africa, as well as for the 
Avahan project in India (86,87). These models mostly explored the impact and cost-
effectiveness of vaginal microbicides within the context of STIs and prevention programming, 
however some models are now being adapted to explore strategic PrEP programming.  
 
Although it has been shown that PrEP can significantly reduce the risk of acquiring HIV, its 
development and implementation has been a significant source of debate. Concerns have 
included risk of generating additional resistance to ARVs, the potential for behavioural 
disinhibition, the potential for pill sharing or selling, the difficulty of delivery, ethics relating to 
supply and distribution of ARVs, and cost (88,89). These concerns have been voiced over time 
in an evolving fashion by certain groups of advocates, researchers, and policy makers, though 
these opinions continue to change as new evidence has emerged.  
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PrEP represents a new option for HIV prevention which may give key populations such as FSWs 
an opportunity to protect themselves beyond male and female condoms, or PEP. PrEP also 
relies on the person taking it, and while external factors may influence use, PrEP use does not 
necessarily require negotiation, as compared with male condoms for instance. In addition, 
PrEP can provide added protection in addition to condoms such as for the uninfected partner 
in a serodiscordant couple, or for women who experience repeated episodes of sexual 
violence. However, there has been very little concerted research among FSW populations 
regarding PrEP use. Some of the efficacy studies, such as FEMPrEP and VOICE (64,65), targeted 
women at high risk which inherently included sex workers, however  they were not the focus 
of the research.  
 
The ability to practically deliver PrEP, in particular among key populations, has been the largest 
open question, both in terms of whether people would take it consistently enough to benefit 
from its protection and in terms of cost-effectiveness. The two PrEP efficacy trials including 
only women and demonstrating lack of efficacy, failed largely due to issues with low 
adherence (64,65). However, the qualitative research published following the VOICE and 
FEMPrEP studies revealed highly nuanced reasons for lack of use, including: misconceptions 
about personal risk, logistical issues attending the clinic, apathy towards research, and 
asserted lack of interest in the product but intense interest in the high quality health services 
provided by the clinical trial clinics, which were otherwise scarce or completely unavailable 
through existing community services (90,91). Some questioned whether oral PrEP would ever 
be a viable product for women who, in large numbers in these studies, demonstrated little 
interest in consistent PrEP use (92–96). However, it was generally agreed that in the absence 
of many prevention choices, the product should be made available following additional 
research into the nuanced feedback received from the trials and previous prevention efforts. 
 
1.9 Acceptability, applicability, and the role of Implementation Science  
In light of the PrEP adherence issues, as well as the fact that PrEP represented a completely 
new modality of HIV prevention, there was a clear need for implementation research in order 
to develop best practices for successful delivery. As a result, and as a first step in this direction, 
the WHO called for demonstration projects to be conducted in advance of country 
programming in order to inform their eventual normative guidelines (97). This call, along with 
financial support from funders, pushed implementers to explore not only the mechanics of 
delivering PrEP (e.g. the logistics of which clinics, in which settings, using which supply chain 
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mechanisms, levels of staff needed, and cost), but also the qualitative perspectives of 
providers (98–101) as well as potential users (102,103), the latter of which has provided the 
basis for this PhD thesis. To date, this research has been focused largely within in the context 
of PrEP provision for MSM as this population was among the first to have access, in particular 
in more developed contexts. 
 
The principle or discipline of Implementation Science is defined by the Fogarty International 
Center at the United States National Institutes of Health (NIH) as:  
 
“the study of methods to promote the adoption and integration of evidence-based 
practices, interventions and policies into routine health care and public health settings. 
Implementation research plays an important role in identifying barriers to, and 
enablers of, effective global health programming and policymaking, and leveraging 
that knowledge to develop evidence-based innovations in effective delivery 
approaches.”  
 
The success of rolling out a new intervention, or improving existing ones, is dependent upon 
many things: political support from stakeholders including all levels of the health sector, 
education and support of providers, capacity of the health system including clinics and the 
supply chain, and strategic messaging for health promotion and communication. These are all 
overarching, structural aspects of the feasibility of intervention delivery that are critical to 
ensuring success.  
 
In terms of the research presented in this PhD, however, exploration of feasibility was included 
as it related to the design of the PrEP intervention, and in relation to the applicability and 
acceptability of PrEP for FSWs. Specifically, applicability as used throughout this PhD, refers to 
the relevance and responsiveness of the intervention to fill the needs of the women taking it 
up from more of an external, implementer perspective (or top-down). Acceptability, 
intrinsically linked to applicability, concerns a more internal user-centred (or emic (59)) 
perspective (or bottom-up) of whether a product ‘fits’ within their lives, fills a gap or makes a 
valuable addition. It also explores the meaning of the product or intervention to the user. 
These two aspects also exist at the core of Implementation Science efforts.  
 
Many strategies in the HIV/AIDS response have centred on top down approaches. For instance, 
some campaigns have focused on the dynamics of virus transmission for the purposes of policy 
making and national programming, such as “Know Your Epidemic, Know Your Response” (104). 
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At the surface, Implementation Science, lays out a process for studying and evaluating 
implementation of  interventions usually dictating the importance of incorporating policy 
makers and providers into the development and dissemination of intervention programming 
and often employing a top down approach (105,106). Programme Science is another similar, 
evolving approach, which further delineates specific spheres of knowledge and practice to 
achieve certain outcomes (107). While widely popular for designing intervention programming 
strategies, these approaches do not explicitly seek out the input and perspectives of the target 
population on intervention design.  
 
Schools of thought, such as the Diffusion of Innovations Theory, underscore the importance of 
including the target population during the conception of product and intervention design 
(108). This theory poses a process by which a new idea or innovation is taken up by a 
population or culture and incorporated into practice. The theory dictates that diffusion 
requires four elements: innovation, communication channels, time, and a social system. It is 
heavily dependent on the people within the social system. One of the core tenants of the 
theory is that the innovation must grow out of a specific need of the target population, and 
solve a perceived problem. Thus, understanding which problem an innovation solves and for 
which people, is as important as understanding how the innovation will be disseminated.  
 
The PrEP efficacy trials demonstrated that the product will prevent acquisition of HIV if taken 
correctly, but some individuals may not want to take a daily pill to prevent HIV, as suggested in 
the failed trials in women. Strategies for promoting and measuring adherence were not clearly 
understood as they related to the context of the study populations (109). However, as a new 
HIV prevention technology, PrEP represents an opportunity to build an in-depth understanding 
of whether it will be taken up and used, by whom, how, and why. To accomplish this task, it is 
necessary to engage the target population during the demonstration project stage to identify 
individuals who want to use PrEP and explore their perspectives. This engagement will help to 
develop an understanding of why the intervention may succeed or fail and can produce 
evidence that can be used in scale-up to implement PrEP in a way which is applicable (relevant 
and responsive) to their lives.  
 
In this spirit, Implementation Science plays a key role as the principle underpinning the 
research described throughout this PhD, in conjunction with the social ecological model 
further described in Section 1.11.3. 
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1.10 The TAPS Demonstration Project 
In response to the call for PrEP implementation research, the Treatment And Prevention for 
Sex workers (TAPS) Demonstration Project was designed and implemented in South Africa to 
assess the deliverability of PrEP among FSWs. TAPS was led by the Wits Reproductive Health 
and HIV Institute (RHI) based in Johannesburg. The study offered oral PrEP to HIV-uninfected 
FSWs as well as early HIV treatment (ART)1 to FSWs diagnosed with HIV (with a CD4 count 
outside of South African National Department of Health guidelines (NDoH)) in two urban sites 
in South Africa (Johannesburg and Pretoria) (110). The protocol for this study has been 
published in BMJ Open, and is included in Appendix xiii.  
 
In summary, the success of the demonstration project was evaluated based on the primary 
outcome which was the number of FSWs retained in the study at 12 months, with secondary 
aims to monitor and assess several outcomes and service delivery factors including: uptake 
and adherence, retention over time (3, 6, 12, 18, and 24 months), pregnancy rates, safety, side 
effects, patterns of PrEP use, sexual behaviour change, and the use of SMS technology for 
adherence support and healthy living2. A large component of the study was the qualitative 
research which aimed to understand FSW participation in the project and use of the PrEP and 
early ART interventions. A costing study and economic evaluation paired with transmission 
modelling were also included to assess cost-effectiveness and impact.  
 
No participation reimbursement was offered, except for the additional qualitative research 
which required selected participants to attend the clinic for in-depth interviews (IDIs). 
Participants were expected to be enrolled in the study for at least 12 months to meet the 
minimum follow-up time, however the study ran from March 2015 until July 2017.  The study 
design and flow, as well as points at which data were collected for this PhD, are shown in 
Figures 3 and 4. Figure 5 is a timeline for the entire span of the TAPS project, also included for 
publication in the supplementary material (Figure S1) in the paper presented in Chapter 5.  
 
 
 
 
 
                                                          
1
 This was originally called immediate treatment in TAPS, but changed over time with evolving NDoH 
guidelines in South Africa. It was later termed early ART, but in the new national programme is now 
called test and treat in line with WHO and UNAIDS terminology.  
2
 SMS reminders have been used in ARV treatment programmes to support adherence (111,112). This 
demonstration project incorporates them as a support mechanism for adherence and healthy living.  
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Figure 3. TAPS intervention screening and initiation flow 
 
Abbreviations: HCT/PICT = HIV testing and counselling/provider initiated counselling and testing (per South African 
guidelines); IC = informed consent; SoC = standard of care; Imm. Tx = immediate treatment (early ART). 
 
 
In Figure 4, red circles are drawn around where data were collected as part of this PhD project. 
Quantitative data for exploring characteristics of women taking up PrEP were collected in a 
baseline questionnaire just before enrolment. These data, along with the data collected in the 
design phase of TAPS (later described in Chapter 3) speak to the more formative elements of 
the research. The design phase is illustrated in Figure 5 as the formative research during which 
qualitative data were also collected through focus group discussions, and through in-depth 
interviews indicated in Figure 4. These data speak to the community and individual 
perspectives of acceptability from the user side.  
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Figure 4. Clinic and research flow of TAPS 
 
 
Figure 5. TAPS project timeline 
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1.11 PhD Research  
As a key population identified by South African policy makers in the national strategic plans, 
FSWs in South Africa were a logical starting point for the implementation of PrEP as a new HIV 
prevention intervention. However, in order to design an appropriate intervention for delivery 
which addresses the needs of this target population, it was necessary to first develop 
foundational knowledge of experiences with past interventions. Following that, came the 
process of developing a holistic understanding of the women most suited and motivated to use 
PrEP within the FSW population, understand how it could fit into their lives in terms of 
applicability, and why they might take it up which speaks to the larger notion of acceptability. 
This became the overarching purpose of this PhD.  
 
1.11.1. Primary Aim 
This thesis explores the real-world applicability and acceptability of oral PrEP in order to inform 
intervention design, implementation, and product use for female sex workers in South Africa.  
 
1.11.2. Objectives 
1. Explore previous research regarding motivations and barriers to uptake and use of 
female-initiated HIV prevention technologies by women in sub-Saharan Africa. 
2. Examine the practical and contextual factors that might influence successful design 
and implementation of a PrEP intervention for FSWs in South Africa.  
3. Examine community-level acceptability of PrEP among FSWs.  
4. Describe key demographic characteristics of FSWs who take up and use PrEP in South 
Africa.  
5. Explore individual perspectives and lived experiences of female sex workers who take 
up and use PrEP in the TAPS Demonstration Project. 
 
These objectives will be met via a diverse range of methods including: a systematic review, 
exploratory formative research, focus group discussions, descriptive review of quantitative 
cohort data, and in-depth interviews. These methods are described in detail in the subsequent 
chapters, however a brief summary (including how each method and analysis maps to each 
objective) is contained in Table 1.   
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Table 1. PhD Research Objectives, Methods/Analyses, and Papers 
Objectives Methods/Analysis (Chapter) Papers/Aims 
1. Explore previous research 
regarding motivations and 
barriers to uptake and use of 
female-initiated HIV prevention 
products by women in sub-
Saharan Africa. 
Systematic review 
and analysis in the 
form of an adapted 
meta-ethnography 
(2a) Protocol for a systematic review: understanding the motivations and barriers to uptake and 
use of female-initiated, primary biomedical HIV prevention products in sub-Saharan Africa. 
 
Aim: This protocol describes in detail the methods developed and used to conduct an adapted meta-
ethnography on the motivations and barriers to uptake and use of female-initiated, biomedical HIV 
prevention products in sub-Saharan Africa.  
(2b) Motivations and barriers to uptake and use of female-initiated, biomedical HIV prevention 
products in sub-Saharan Africa: an adapted meta-ethnography 
 
Aim: The primary aim is to identify and understand the motivations and barriers affecting uptake and 
use of female-initiated, primary biomedical HIV prevention products for women in sub-Saharan 
Africa. Findings and recommendations will aim to inform future HIV prevention policy and 
programming for women.  
2. Examine the practical and 
contextual factors that might 
influence successful design and 
implementation of a PrEP 
intervention for FSWs in South 
Africa.  
Systematic, 
iterative formative 
research and 
analysis based on a 
grounded approach 
(3) Designing PrEP and early HIV treatment interventions for implementation among female sex 
workers in South Africa: developing and learning from a formative research process 
 
Aim: This paper describes the detailed decision making and conduct of formative research 
undertaken to design two new HIV prevention and treatment interventions delivered to female sex 
workers in a demonstration project in South Africa. 
3. Examine community-level 
acceptability of PrEP among 
FSWs.  
 
Focus group 
discussions/themat
ic analysis 
(4) Exploring acceptability of oral PrEP prior to implementation among female sex workers in 
South Africa 
 
Aim: This paper focuses on aspects of PrEP acceptability as a new intervention within the context of 
a larger service delivery programme including the simultaneous roll-out of early ART. The aim of this 
paper is to explore PrEP acceptability among the FGD participants as future potential users. 
4. Describe key characteristics of 
FSWs who take up and use PrEP 
in South Africa.  
Baseline survey/ 
descriptive analysis 
(5) Antiretrovirals for HIV treatment and prevention among female sex workers: results from a 
real-world demonstration project 
 
Aim: This paper presents the final analysis of uptake, retention, and cost results, including 
characteristics of women taking up the interventions, adherence and clinical outcomes. 
5. Explore individual perspectives 
and lived experiences of female 
sex workers who take up and use 
PrEP in the TAPS Demonstration 
Project. 
In-depth 
interviews/themati
c analysis 
(6) The PrEP Life: female sex workers’ perspectives on uptake and use of daily pre-exposure 
prophylaxis for HIV prevention in South Africa 
 
Aim: This paper will explore the experiences of taking up and using PrEP among FSWs engaged in 
TAPS. 
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1.11.3. Underlying thesis framework: the Modified Social Ecological Model 
Theoretical models and frameworks have been developed over the years to describe and 
understand a multitude of domains relating but not limited to behaviour, individual and social 
change, communication, networks, and decision making (90). Models and frameworks can also 
be used to organise research around a given topic. For this PhD project, a review of models 
and frameworks relating to the HIV epidemic, social dynamics, behaviour change and decision 
making was undertaken to devise a means of organizing the thought process and progression 
of the research.  
 
Following the review, the Modified Social Ecological Model (MSEM) by Baral et al. was chosen 
to serve as the foundation of this PhD research in conjunction with the principles of 
Implementation Science. The model was used to situate and guide holistic thinking in 
designing each stage of the research, developing the research questions and objectives, 
designing the TAPS study, and developing analyses of the data. In this regard, the holistic 
nature of considering multiple social and environmental facets was critical in being able to 
understand how and why women would engage with the PrEP intervention, in terms of 
applicability and acceptability. It also helps to highlight where there might be gaps in 
knowledge in relation to intervention development. The model fits within the principles of 
Implementation Science to organise data into relevant categories starting from, or ending 
with, the individual. These categories span across the domains of practical delivery and user 
perspectives which have been the basis of this research.  
 
It is important to note, that the social ecological model is not a theory for change or decision 
making, but rather a framework for conceptualizing environments (113), and was used in this 
way throughout this research. A slight adaptation of the MSEM was developed for the FSW 
context in South Africa as shown in Figure 6. The adaptations include defining the individual at 
risk as a FSW, and then incorporate additional specificity in the other spheres in terms of how 
they relate to FSWs and their specific risk contexts. One other additional element is HIV 
prevention which is illustrated as spanning across all of the spheres.  
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Figure 6. PhD Modified Social Ecological Model for FSWs in South Africa 
  
 
 
1.11.4. Thesis narrative and structure 
This thesis is presented in research or journal paper style consisting of six research papers 
included as methods and results in chapters with chapter specific introductions at the 
beginning of each. Each chapter addresses key research questions arising from the PhD 
objectives. The research follows a flow of inquiry and learning as shown in Figure 7.  
 
Figure 7. PhD research flow 
 
 
 
Chapter 2 addresses the question: What are the motivations and barriers to uptake and use of 
female-initiated HIV prevention products in sub-Saharan Africa? This was a key question to 
address in order to explore the vast literature concerning HIV prevention for women, and to 
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establish their perspectives on use. PrEP is the latest in a long line of product research, and 
much can be learned for successful implementation by carefully examining reactions and 
responses to the products and research that came before. There are two papers in this chapter 
aimed at answering this question. Paper 1 is a methods paper in the form of a protocol for the 
systematic review conducted as part of this body of work. The protocol presents a novel 
methodological approach to an adapted-meta ethnography exploring the motivations and 
barriers to uptake and use of female-initiated, primary biomedical HIV prevention technologies 
in sub-Saharan Africa. This protocol was published in the BMC journal Systematic Reviews in 
2015 (114). Paper 2, is the adapted meta-ethnography itself presenting results of the search 
and synthesis of the data which was submitted to BMC Public Health in 2016 and has been 
provisionally accepted pending revisions.  
 
Chapter 3 focuses on the question: What are the practical and contextual factors which might 
affect the uptake and use of PrEP among FSWs in South Africa? Also a methods paper, Paper 3 
describes the formative research process and lessons learned through an iterative, grounded 
approach used in developing the PrEP and early ART interventions developed for the TAPS 
Demonstration Project. The details reported in this paper represent the first lessons learned 
regarding how and why PrEP might be taken up among FSWs in South Africa, and describes 
how the intervention was developed for implementation and evaluation. This paper was 
submitted to BMJ Open in July 2017 and is currently awaiting editorial decision following peer 
review.  
 
Chapter 4 addresses the question: What are the community-level perceptions of PrEP in terms 
of acceptability within the context of imminent implementation among FSWs in South Africa? 
Paper 4, an in-depth look at the FSW community perspectives of impending PrEP 
implementation, captures women’s perceptions of PrEP immediately before the launch of 
TAPS when PrEP will first be offered in this population. The FGD results presented in this paper 
build on the learning from the systematic review and represent the final piece of the formative 
research. This paper was submitted to the Journal of the International AIDS Society (JIAS) in 
July 2017.  
 
Chapter 5 addresses the question: What are key characteristics of FSWs who take up and use 
PrEP?  In addition to wanting to understand women’s uptake and use of PrEP in the 
demonstration project, it was also important to understand the characteristics of women 
taking it up in this early stage of implementation. Paper 5, which is the primary analysis paper 
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for the TAPS project, includes the key demographic and behavioural characteristic results of 
the PrEP users in TAPS. This paper was submitted to a special edition on PrEP at PLoS Medicine 
in July 2017. Revisions following reviewer comments are under final review with the journal. 
 
Chapter 6 is the final results chapter and addresses the question: What are the perspectives 
and lived experiences of FSWs taking up and using PrEP in South Africa? Paper 6, presents an 
in-depth view of individual PrEP user perspectives through an analysis of serial in-depth 
interviews. These are new PrEP users accessing the product and intervention in a ‘real world’ 
clinic for the first time, and the analysis of their perspectives builds on the previous work 
leading up to this point. This paper will be submitted to Social Science and Medicine.  
 
The thesis concludes with a discussion section including a summary of the key themes and 
findings, strengths and limitations, as well as recommendations for policy and practice, and 
future research. Note that references will be included separately in each section accordingly, 
and that each paper is preceded by an LSHTM Cover Sheet for research papers included in a 
research thesis. Where additional description of methods used or background information is 
needed beyond what can be included in a research manuscript for publication, this is included 
in the chapter introductions.  
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2.0 Chapter 2: What do women want? A qualitative meta-exploration 
of women’s perspective of female-initiated HIV prevention methods 
in sub-Saharan Africa.  
 
2.1 Introduction 
This chapter addresses the research question associated with Objective 1 of this PhD: What 
are the motivations and barriers to uptake and use of female-initiated HIV prevention products 
in sub-Saharan Africa? Before embarking on designing new research on uptake and use of PrEP 
among FSWs, it was important to investigate the existing literature on women’s preferences 
for and values in relation to HIV prevention methods or products, in particular the ones over 
which they could initiate and maintain control. It was a conscious choice not to limit this 
review to FSWs only, as first and foremost they are women and share the foundational issues 
of women in general. This was an important exercise in order to establish a base of knowledge 
around what women wanted out of HIV prevention beyond physical attributes, and delve into 
what would influence or deter uptake and use within women’s lives.  
 
This chapter includes a methods paper in the form of a protocol published in BMJ Open in 
2015. The protocol paper has been included since it describes in detail the process undertaken 
to conduct the systematic review, which included a novel methodological approach combining 
an adapted meta-ethnography of data synthesis and a weight of evidence review which 
comparatively assessed the papers included in the review. The development of these methods 
was supported by a library specialist and an expert in evaluation of literature. Prior to 
conducting the review, an informal, systematic review of reviews was conducted to establish 
whether any review was previously published. This originally looked for reviews on 
determinants of uptake and use of HIV prevention interventions among women in sub-Saharan 
Africa, but was expanded to search for qualitative reviews as well. The databases searched 
were Health-evidence.ca, Cochrane, Medline, Systematic Review Journal, Database of 
Abstracts of Reviews of Effects (DARE), and International Prospective Register of Systematic 
Reviews (PROSPERO). The search strategy used in this effort were adapted from validated 
search strategies by combining concepts from published systematic review searches and 
disease specific searches (1,2). Out of a total of 1515 hits from the six different databases, 
there were no papers that matched the topic. Concepts for building a search strategy for the 
eventual meta-ethnography were collected through this review and further developed through 
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reviewing key qualitative literature and the handful of other meta-ethnographies previously 
conducted, which are referenced in more detail in the papers included in this chapter.  
 
The results of these methods are presented in the meta-ethnography paper in this chapter 
which explores women’s perceptions of use of a limited array of HIV prevention products. 
These results provided the basis of thinking for developing the research tools and direction of 
inquiry employed throughout the rest of the PhD. This results paper was accepted for 
publication, pending final review of revisions, in BMC Public Health in September 2017, 
following a year-long process of review.  
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2.3.1 Abstract 
Background 
Women in sub-Saharan Africa are disproportionately affected by high rates of HIV, yet 
relatively few products exist for female-initiated HIV prevention. New ARV-based prevention 
options could present opportunities for women to expand their HIV prevention choices, 
however acceptability and adherence plays a key role in the effectiveness of these products 
and implementation is still in early stages. To better understand which HIV prevention options 
might best serve women in sub-Saharan Africa, how and why, this review will explore 
qualitative evidence from clinical trials and implementation studies alike using a meta-
ethnographic approach to synthesize data and interpret results.  
 
Methods 
This systematic review will use a meta-ethnographic approach to analyse qualitative data 
extracted from multiple studies featuring actual use of female-initiated technologies for HIV 
prevention. The search strategy will be applied in seven databases and papers will be selected 
using strict inclusion and exclusion criteria. The review will closely follow the guidance set 
forth by PRISMA and CRD where the guidance applies to qualitative data. Two reviewers will 
review all papers during the paper selection phase, with consultation from a third reviewer to 
confirm consensus. All papers included in the review will be read and analysed by two 
reviewers. The final analysis will be conducted by three primary reviewers with additional 
input from all other authors.  
 
Discussion 
With new HIV prevention technologies currently in early implementation phases and still more 
on the horizon, there is much to learn about how best these products may be delivered. A 
review such as this could help to inform the real-world implementation of the next wave of 
new HIV prevention technologies such as ARV-based oral pre-exposure prophylaxis (PrEP). 
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2.3.2 Background 
New HIV infections in sub-Saharan Africa persist at high rates where women, in particular, are 
disproportionately affected (4). In South Africa, a survey published by the Human Sciences 
Research Council in 2012 estimated the national prevalence rates among women between the 
ages of 20 and 49, to be between 17.4% to 31.6% (5). Current methods for HIV prevention 
have taken the field only so far, but to further reduce new infections, new options for 
prevention are needed.   
 
There are several approaches men and women can take to prevent the acquisition or 
transmission of HIV. Currently, these include: the use of male or female condoms; medical 
male circumcision; or the use of post-exposure prophylaxis (PEP), an anti-retroviral (ARV) drug 
based regimen given after suspected exposure to HIV. The majority of these prevention 
options, aside from PEP, are either entirely or partially controlled by men, or their use is 
dependent upon male acceptance. Male condoms require mutual agreement for use, and 
while the female condom can be initiated by women, it difficult for them to do so covertly. 
Additionally, research has suggested that female condoms are often difficult to access, and not 
always acceptable or easy to use (6). PEP has typically only been available or accessible for 
specific circumstances, such as post-rape care (7), and the limited implementation suggests 
there may be significant intervention capacity issues relating to the training and education of 
healthcare providers (7,8). The diaphragm has been tested as an option for preventing HIV 
infection, and shown to have no effect (9), although efforts have been renewed to revive it as 
an option by redesigning the product and adding a microbicide. Studies published in the last 5 
years (10,11) indicate that ARV-based HIV treatment has also been shown to have a powerful 
secondary prevention effect by the suppression of an infected individual’s viral load, however, 
the population-level impact of this will take time and is unlikely to  control the epidemic on its 
own (12).  
 
A new primary prevention option utilising ARV-based medication has shown significant 
promise. Development of a variety of products (including pills, intravaginal microbicide gels, 
films and intravaginal rings) has yielded a new first-generation option in the form of a daily pill-
based regimen, called pre-exposure prophylaxis (PrEP). Six recent clinical trials testing oral 
PrEP have shown varying levels of overall efficacy (13–16), from 44% to 75%. At present, 
however, the indication is currently only registered in the United States. The varying degrees 
of efficacy from the oral PrEP trials can mostly be attributed to adherence, or consistent and 
correct use of the products (17). The FEMPrEP trial, consisting only of women, was stopped for 
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futility, while the VOICE trial was partially stopped for futility, with the final arm continuing to 
a flat result (18,19). These findings have caused researchers and implementers alike to 
question whether adherence dependent ARV-based prevention options would actually be 
effectively taken up by women and make a significant contribution to HIV prevention. Analyses 
of qualitative and mixed method research from these trials are underway, along with 
additional follow-up studies to better understand why women did not use the products. Two 
papers already published on this area have revealed important insights as to the reasons 
women did not use the products, including: misaligned incentives for participating in the trials 
(money and access to better services); ambivalence about the research resulting in non-use of 
the products; a lack of understanding of the need to accurately report actual product use; and 
misperceptions of personal risk of HIV (20,21). This has shown that non-use of the products 
often had little to do with the products themselves and more to do with contextual issues, 
which may mean that oral PrEP could still be a viable prevention option if offered to suitably 
motivated users. This perspective is reinforced by recent results from the FACTS001 trial, 
which evaluated the efficacy of tenofovir-based intravaginal microbicide gel and established 
the gel not to be efficacious in preventing HIV acquisition, largely as a result of complex 
behavioural/social factors, as well as possible biological ones (22).  
 
Given the complexities highlighted in the PrEP efficacy trials about delivering and 
implementing new prevention options, it is important to understand women’s perspectives 
and what factors determine the use of emerging biomedical technologies. This is essential not 
only to understand how existing HIV prevention options may be better implemented, but also 
to inform the delivery of the next wave of technologies, such as oral PrEP, as well as other new 
products further upstream in the development pipeline, such as vaginal rings containing 
microbicides and injectables. To date, a number of studies have explored the acceptability of 
HIV prevention technologies, including those already licensed for widespread use and those in 
development or clinical trial phases, as well as other contextual factors that function as 
motivators or barriers to their use. Studies producing qualitative data, like those stemming 
from the failed oral PrEP trials, are imperative for understanding what people think, as well as 
how and why they make decisions regarding uptake of HIV prevention options.  
 
This systematic literature review will explore, synthesize, interpret and present the key factors 
that motivate or deter uptake and use of prevention technologies for women in sub-Saharan 
Africa. Such a review can help to inform the development and roll-out of new technologies as 
they become available. This review will focus on female-initiated technologies, which are those 
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women administer themselves, and can be technologies already available in the market or in 
the development phase. Data included in the review will be drawn from studies of actual 
product use, rather than hypothetical investigations. Technologies included in the review will 
include: PEP, PrEP, vaginal microbicides, the diaphragm and the female condom. While the 
diaphragm is not currently an accepted, efficacious method for preventing HIV, the research 
conducted around experiences with use will be included in this review as these may provide 
transferable insights into other product use.  Qualitative research is best suited to the 
exploration of personal experience and decision making. Given its focus on the motivations 
and barriers to the uptake and use of technologies, the review will focus on the synthesis and 
analysis of qualitative data only, utilising a meta-ethnographic approach.  
 
2.3.3 Methods and Design 
This is a systematic review using a meta-ethnographic approach to analysis. As such, the 
review will include only qualitative data extracted from studies identified through intensive, 
systematic searches, and will closely follow the guidance set forth by the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement and the Centre for 
Reviews and Dissemination (CRD). This review has not been registered on PROSPERO as since it 
is a review of qualitative evidence it does not qualify. As a result, there is no PROSPERO 
number associated with this review.    
 
The primary objective of this review is to identify and understand the motivations and barriers 
affecting uptake and use of female-initiated, primary biomedical HIV prevention technologies 
for women in sub-Saharan Africa. The review will incorporate the following secondary 
objectives: 
 
 To identify types of studies from which data are extracted (e.g. stand-alone 
qualitative/social science, implementation or service delivery evaluation, or clinical 
trials); 
 To describe elements of uptake and use of specified technologies by sub-population 
(e.g. female sex workers, victims of rape, or young women); 
 To describe factors that influence uptake and use by intervention; 
 And to identify priorities for future research. 
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Search Strategy 
The search strategy incorporates four primary concepts: HIV; uptake and use; qualitative 
research; and sub-Saharan Africa. Search strategy concepts have been constructed using an 
iterative process. Search terms will be adapted across databases to account for variations in 
subject headings. The following databases will be included in the search: Africa-wide Info, 
CINAHL, Embase, Global Health, Medline, Psychinfo, and Web of Science. The Medline search 
strategy was developed as the primary search strategy template and will be adapted for the 
other databases. 
 
Inclusion and Exclusion criteria 
Papers will be selected during the screening process using the following inclusion criteria: 
 
 Population: Adult women, age 18 and above 
 Intervention: Female-controlled, biomedical – PrEP/microbicides, PEP, female 
condom, and diaphragms 
 Comparator: Not relevant 
 Outcome: Narrative on the motivations or barriers to HIV prevention uptake and 
use 
 Study Design: Qualitative studies – interviews or focus groups 
 Study type: Studies must be based on primary research where products have been 
made available for actual use  
 Location: sub-Saharan Africa 
 
Exclusion criteria are as follows:  
 
 Any papers published on research occurring before 2003 
 Reviews 
 Any studies based on hypothetical or potential use of products not made 
immediately available at the time of the research 
 Any data not from the women’s point of view as the user 
 Any research from the perspective of HIV-positive women 
 Any research based on secondary prevention technologies or interventions (e.g. 
PMTCT) 
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Papers will be excluded from the review if they do not meet all of the criteria above. Papers 
will not be excluded according to a quality assessment, per se, but will be evaluated according 
to principles and practices as outlined below. There will be no limitation by language, and grey 
literature will be included if identified through the database searches or through consultation 
with relevant experts.  
 
The concept of experience of actual use is central to this review. As such, we will include data 
from studies conducted in both trial and implementation settings. It may be argued that 
incentives could be quite different in a trial setting where participants are paid to come to a 
clinic as compared to a ‘real-world’ setting where patients come when they feel they need to. 
From this perspective, trial participants could be more incentivised to attend the clinic. 
However, in the case where new prevention options proven to protect against HIV are 
available, the accessibility of the product or intervention may be the incentive to come to the 
clinic. Clearly, there are a variety of motivators for engaging in health related behaviour, which 
we hope to explore in the context of female-initiated HIV prevention. In this review we 
hypothesize that some of the experiences of actually using the products should be similar 
regardless of initial motivation. Additionally, some HIV prevention trials were stopped early or 
ended with a flat result because of non-use. In this paper, we aim to elucidate the issues 
leading to non-use across both the trial and the clinic settings, and hypothesize that reasons 
for non-use are likely to be similar. We will also compare between the two setting types to 
highlight any differences. 
 
The year 2003 was chosen as the cut off point for selecting papers as it marks the 
establishment of PEPFAR and the wide-scale introduction of antiretroviral therapy (ART) for 
HIV treatment in Africa. With the introduction of effective medication regimens, general 
population views of HIV and the means by which its transmission could be managed began to 
change (23).The rollout of ART in Africa significantly changed the approach to the epidemic in 
sub-Saharan Africa which, until this time, largely consisted of efforts to promote condom use 
and HIV testing with the aim of preventing new infections; this had limited success as people 
testing HIV-positive could not access life-saving medication. Although treatment was not 
uniformly rolled out simultaneously in all countries in 2003, the launch of PEPFAR and 
increased access to ART renewed hope and motivation to prevention efforts and is attributed 
to the turn of the epidemic in Africa (24).  
 
 
63 
 
Screening Process 
All references will be uploaded into a reference manager database and duplicates removed 
before starting the paper selection process. After de-duplication, all papers will be reviewed by 
title and abstract according to the inclusion and exclusion criteria by two reviewers. Any 
discrepancies between reviewers will be discussed and mediated by a third researcher. Once 
papers have been selected by title and abstract, three reviewers will review papers by full-text 
according to the inclusion criteria. Decisions regarding inclusion of papers from the same study 
will occur through discussion with all three reviewers on a case by case basis. All papers 
selected by the reviewers will be discussed by all three reviewers to reach consensus and 
confirm inclusion.  
 
Data Extraction, Analysis and Synthesis 
This review will be conducted as a meta-ethnography. This process of analysis will follow the 
principles set out in Noblit and Hare (25), but will use a form of this method as adapted more 
recently by several researchers (26–28). Specifically, this adapted form of meta-ethnographic 
synthesis allows for qualitative data collected through methods beyond ethnography, such as 
interviews and focus groups, to be combined and interpreted to derive meaning and 
understanding of data across different types of studies.  
 
Once papers for inclusion have been finalized after full-text review, reviewers will be assigned 
papers for data extraction according to the data extraction tool developed for the review. A 
thematic framework will also be constructed through the data extraction phase in an iterative 
fashion, with input from all reviewers. A minimum of two reviewers will extract data from each 
paper; consensus will be reached with input from the third reviewer on any differences in 
extracted data. The thematic framework will be used to build the meta-ethnographic 
constructs which comprise three layers: the perspective of the participants, the perspective of 
the authors, and the perspectives of the researchers conducting this review. These layers are 
often fluid and may overlap where the perspectives of the authors cannot always be divided 
from those of the participants, but eventually, these two initial layers lead into the 
construction of the final layer in which new understanding can be developed by looking across 
all of the data at once. 
 
Quality Assessment  
In contrast to quantitative research, there has been considerable debate over how to assess 
the quality of qualitative research (29–32). Inherent to qualitative research is a flexible, 
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iterative, and pluralistic process which is guided by the context in which it is conducted and by 
the research subjects themselves. Several authors have argued that it is not typically an 
undertaking easily standardized by checklists, which could actually hinder the creative nature 
of the work. Instead, there are accepted practices, or fundamental principles, by which one 
can analyse the research (30,33). An approach often adopted is the ‘The weight of evidence 
review’, which first establishes elements of good research and those elements are then taken 
into account when looking across all of the papers included in a review (34). This enables an 
assessment of the quality of the literature so that the review can be judged as a whole, rather 
than evaluating individual elements of each paper. In this review, a combination of the 
fundamental principles and weight of evidence review may be employed to judge the overall 
level of quality of papers included.  
 
Anticipating Limitations and Bias 
As with any research study, the authors recognise that there will be limitations to this 
particular review.  
 
Some components of the qualitative research included in individual studies may have been 
excluded from publication due to limits enforced by the publisher. Often, in-depth descriptions 
of methods, and development of the research and process through which it was undertaken, 
are left out of the publications, making it difficult to assess quality of the research process and 
the awareness of the researchers’ positions within their own research (reflexivity). Inevitably, 
these exclusions would affect the potential scope of qualitative evidence available for this 
review. 
 
It is possible that some research may be absent altogether from the searchable and published 
literature. Research has shown that around 44% of conference abstracts on qualitative 
research are translated into papers published in journals - which is about the same rate as for 
quantitative research (35). Additionally, while this review will not exclude grey literature, the 
constraints of web-based searching and the lack of systematic, online grey literature indexing 
means it is difficult to determine whether our search has successfully captured all relevant 
grey literature.  
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2.3.4 Discussion 
This systematic review, using a meta-ethnographic approach for analysis, is the first of its kind 
to synthesize qualitative data across a wide and complex body of literature in this subject area. 
The ultimate aim of this study is to learn from research already conducted on women’s 
experiences of HIV prevention technologies and their motivations to take up and use them 
(and barriers to doing so), in order to inform the real-world implementation of the next wave 
of new technologies such as oral PrEP. Ultimately, these findings can help with future 
programming design, decisions, and research to optimize delivery of existing and new HIV 
prevention interventions for women across sub-Saharan Africa.  
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2.4.1 Abstract 
Background 
Women bear a disproportionate burden of HIV throughout the world prompting extensive 
research into HIV prevention products for women which has met with varied success. With an 
aim of informing future policy and programming, this review examines the barriers and 
motivations to the uptake and use of female initiated products in sub-Saharan countries. 
 
Methods 
We conducted a systematic review as an adapted meta-ethnography of qualitative data 
focused on actual use of products. After deduplication, 10,581 and 3,861 papers in the first 
and second round respectively were screened. Following the PRISMA guidance, 22 papers 
were selected and synthesized using Malpass’s definitions of first, second, and third order 
constructs. First order constructs, consisting of participant data published in the selected 
papers, were extracted and categorised by second and third order constructs for analysis. A 
weight of evidence review was conducted to compare and assess quality across the papers.  
 
Results 
The 22 papers selected span 11 studies in 13 countries. We derived 23 second order constructs 
that were translated into seven overarching third order constructs: Sexual Satisfaction, Trust, 
Empowerment and Control, Personal Well-being, Product use in the social-cultural 
environment, Practical Considerations, Risk Reduction, and Perceptions of Efficacy. 
Relationships and trust were seen to be as or more important for product use as efficacy. 
These constructs reveal an inherent inter-relationality where decision making around HIV 
prevention uptake and use cannot be binary or mono-faceted, but rather conducted on 
multiple levels. We developed a framework illustrating the central and proximal natures of 
constructs as they relate to the decision-making process surrounding the use of prevention 
products.  
 
Conclusions 
Health systems, structural, and individual level HIV prevention interventions for women should 
adopt a holistic approach. Interventions should attend to the ways in which HIV prevention 
products can serve to reduce the likelihood of HIV transmission, as well as help to protect 
partnerships, enhance sexual pleasure, and take into account woman’s roles in the social 
environment. Stigma, as well as sexuality, is likely to continue to influence product uptake and 
use and should be prominently taken into account in large-scale interventions. 
72 
 
2.4.2 Introduction 
Women bear a disproportionate burden of HIV infection across the world, and in particular in 
sub-Saharan Africa (1). Until recently, the only readily available HIV prevention options for 
women have been male condoms. Female condoms were at one time a promising new option, 
however lack of support from international agencies and funders translated into challenges in 
delivery and access (2–4). This meant that male condoms have remained the dominant form of 
HIV prevention for decades. Additionally, post-exposure prophylaxis (PEP), while proven to be 
efficacious in preventing HIV acquisition (5,6), has generally only been available for health 
workers and rape victims (7,8).  
 
Advances in HIV prevention research have yielded a new approach: pre-exposure prophylaxis 
(PrEP). PrEP is the use of antiretroviral drugs taken orally by people who do not have HIV to 
prevent acquisition of the virus. A recent systematic review of oral PrEP including 18 studies 
found that “ PrEP use with greater than 70% adherence demonstrated the highest PrEP 
effectiveness (RR=0.30, 95% CI: 0.21-0.45, p<0.001) compared to placebo”,  confirming 
that oral PrEP will prevent HIV with high rates of efficacy when taken consistently (9). This 
review did not include one study completed with people who inject drugs (10), which 
found a moderate but significant level of efficacy, nor did it include two microbicide gel3 
studies (CAPRISA004 and FACTS001), the results of which together did not prove product 
efficacy (11,12). The non-significant levels of efficacy in the two microbicide trials, as well as 
the similar results of the VOICE (comparing oral PrEP and microbicide gel)  and FEMPrEP (oral 
PrEP only) trials were either partially or largely due to poor adherence (13,14), opening up 
questions around the ability to take oral PrEP effectively. 
 
Qualitative research conducted as part of these clinical trials has explored reasons for poor 
adherence. Reasons range from apathy towards the research itself, dislike of product side 
effects, lack of privacy in which to use the products, low risk perception, and access to better 
healthcare offered in studies as primary motivation for study participation (15,16). The insights 
arising from these studies, conducted primarily in sub-Saharan Africa and India, combined with 
lessons learned from past research of other HIV prevention products will provide the field with 
further understanding of why and how women take up and use HIV prevention products, 
which can inform better implementation.  
 
                                                          
3 Microbicide gel can also be referred to in the literature as topical PrEP, however, in this review we have kept is as 
microbicide gel, or just gel.  
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This is a systematic literature review conducted in the form of a meta-ethnography to 
synthesize qualitative findings from research on the practical use of HIV prevention products 
among populations of women across sub-Saharan Africa. Broadly, our aim is to inform future 
policy and programming for HIV prevention products for women going forward, by drawing on 
the wealth of information already published from the research conducted in sub-Saharan 
Africa. As such, the primary objective of this review is to identify and understand the 
motivations and barriers affecting uptake and use of female-initiated, primary biomedical HIV 
prevention products for women in sub-Saharan Africa. 
 
2.4.3 Methods 
We conducted a systematic review using a meta-ethnographic approach following the 
principles set out by Noblit and Hare (17). This approach allows for a sophisticated and robust 
manner of synthesis as compared to a typical literature review of qualitative data, and focuses 
on interpretation through analysis of constructs rather than summarization of themes (18). For 
this review, we conducted an adapted meta-ethnography as defined more recently by several 
researchers (19–21), which allows for qualitative data collected through a variety of methods, 
such as interviews and focus groups, as well as ethnographies, to be combined and 
interpreted. Qualitative data are best placed to answer the questions around how and why 
products are utilised effectively, rather than measuring only their uptake or adherence. 
Throughout this process, we also employed the guidance set forth by the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement and the Centre for 
Reviews and Dissemination (CRD) (22,23). The protocol for this review has been published and 
the methods described in more detail (24). 
 
This review was not registered on PROSPERO since reviews of qualitative evidence are not 
currently included on the PROSPERO database. Additionally, the original protocol articulated 
“female-initiated HIV prevention technologies” in the title, however we chose to change 
technologies to products in the final paper.  
 
Search Strategy and Inclusion Criteria 
We searched seven databases: Africa-wide Info, CINAHL, Embase, Global Health, Medline, 
Psychinfo, and Web of Science. The search strategy comprised four primary concepts: HIV 
prevention; uptake and use; qualitative research; and sub-Saharan Africa, which were first 
confirmed through iterative pilot searching in Medline, and then adapted for the other 
74 
 
databases. The first set of searches was conducted in July of 2013, and then again in July of 
2015.  
 
Papers were included in the review if they met the following criteria: women aged 18 and 
above; data focused on female-initiated products (oral PrEP, microbicide gel, PEP, female 
condom, vaginal ring, and diaphragms); included narrative on motivations and/or barriers to 
uptake and use of products; qualitative research; located in sub-Saharan Africa; and, research 
conducted from 2003 or later. Note that female-initiated product refers to any HIV prevention 
product that can be initiated and used exclusively by women without requiring the 
involvement or permission of a partner. 
 
Actual experience of product use was central to this review, rather than hypothetical 
acceptability studies (e.g. where study participants did not actually have access to products). 
Since few studies have been published in ‘real-world’ programme settings, we also included 
data from across research settings, both randomized control trial and implementation. While 
incentives to participate in research could be quite different to clinic attendance, in this review 
we hypothesized that experiences of actual product use should be similar regardless of initial 
motivation. Additionally, we have included women’s perspectives on use of the diaphragm and 
vaginal microbicide gels, despite the limited efficacy of these products to prevent HIV. At the 
time of those studies, efficacy was unknown, and importantly, women’s experiences and 
perceptions of use extend beyond efficacy. The interest of this review is to examine the 
elements that would make a product feasible and relevant for a woman to use it, and what 
those salient elements are across products.   
 
We did not limit our search by language, and we allowed for grey literature to be included, 
however none was identified through our searches or through consultation with relevant 
subject matter experts. Studies were excluded if they focused only on hypothetical use of 
products or represented perspectives from the male point of view, HIV-positive women only, 
or secondary prevention products (e.g. Prevention of Mother to Child Transmission). 
 
Screening and Selection Process 
All 25,861 references identified through searching were uploaded into the reference software 
manager Mendeley. After de-duplication, two reviewers screened all 10,580 papers by title 
and abstract according to the inclusion and exclusion criteria. Any discrepancies between 
reviewers were discussed and mediated by a third researcher. The papers were identified first 
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by title and then by abstract, and were then reviewed in duplicate by three reviewers. There 
were several cases of papers published from the same study, however we determined no 
overlap of data therefore these papers were all included. The 39 papers identified for 
possibility for inclusion were discussed by the three primary reviewers during which some 
were eliminated mainly due to inability to isolate female-centred data from male, or due to 
the research being conducted before 2003. Finally, 22 papers were selected for analysis.  This 
process is illustrated in Figure 1.  
 
Analysis and Synthesis 
Data were extracted from the papers by two reviewers, then sorted by themes and 
incorporated into a construct worksheet. To generate the concepts for our constructs, we 
employed Malpass’s definition of the first, second, and third order constructs (25) used 
previously by authors of other similar reviews (19,20). First order constructs consist of 
participant data published in the selected papers, and were extracted and categorised by 
second and third order constructs for analysis. Second order constructs consist of author 
perspectives of their manuscript data extracted from the papers, and third order constructs 
are thematic categories developed through our analysis. In this regard, our construct 
worksheet comprised three meta-ethnographic layers: the perspective of the participants, the 
perspective of the paper authors, and the perspectives of the researchers conducting this 
review. We then used the process of concept translation, as described by Musheke et al (20), 
to arrive at our synthesized third order constructs.  
 
Weight of Evidence Review 
We employed a weight of evidence (WoE) review to assess the relative strength of the papers 
included in the review. A WoE review, as defined by Gough et al (26), is a process by which 
standard elements of research are identified in each paper included in the review, and then 
assessed in comparison with one another to judge the overall strength or quality of the papers 
(26). The results of our WoE are listed in Table 1. This process uses a systematic approach 
similar to the GRADE process used by the World Health Organization (WHO) in assessing the 
quality of quantitative studies included in systematic reviews in support of guidelines. Each 
paper was assessed in terms of relevance (how directly the paper answered the aim of the 
review), appropriateness of study design, and soundness (which equates to the inclusion 
criteria for this review). 
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Figure 1. PRISMA chart of review process 
 
Figure 2. Map indicating HIV prevention products for women and sub-Saharan countries featured in the 
review papers 
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2.4.4 Results 
The 22 papers included in the review represent 11 studies (including ancillary research as part 
of larger studies) across 13 countries in sub-Saharan Africa, as shown in Figure 2. Since the 
review covers studies conducted between 2003 and 2015, more papers describe experiences 
using products such as diaphragms and microbicide gels, as compared to more recent products 
such as oral PrEP for which few papers have yet been published.  
 
We derived 23 second order constructs that we translated into seven overarching third order 
constructs, mapped in Table 2. The results presented here are organised by third order 
construct labels. The findings are organised in this way to best illustrate and organise the fluid 
and inter-relational nature of the themes, which are illustrated in Figure 3. This is instead of a 
more binary presentation which has been characteristic of other such reviews (19,20). It is also 
important to note that while this review offers a synthesis of the findings and an overview of 
the primary themes present in this diverse literature, it was not possible to capture every 
nuance in all of the selected papers.  
 
Weight of Evidence Review     
The WoE review found a relatively high level of quality across the body of evidence included in 
this adapted meta-ethnography. No one category scored lower than medium. Rather we found 
many medium-high and high ratings. Some papers came from ancillary or imbedded trial 
research which may not be considered ‘real-world’, and many did not explicitly focus on 
answering the overall aim articulated in this review. However, these papers were still included 
because they contained data directly responding to the review aim. All of the studies were 
conducted with strong, clear methodologies which led us to give the evidence overall a high 
rating.  
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Table 1. List of papers and Weight of Evidence Review 
 
Authors Title 
Pub 
Year 
Product 
Data 
Type 
Study 
Context 
Location Pop N 
Study 
Dates 
Theory Soundness 
Appropriaten
ess of study 
design  
Relevance 
Overall 
Rating 
Abrahams; et 
al 
Barriers to post 
exposure 
prophylaxis [PEP] 
completion after 
rape: a South 
African 
qualitative study 
2010 PEP IDIs   
Stand-
alone 
qualitative 
South Africa 
Victims 
of sexual 
assault 
29 
2005-
2006 
Not 
specified 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
High: 
standalone 
qualitative 
research 
High: though an 
outlier, 
specifically 
discusses 
barriers to PEP 
use 
High 
Behets, Frieda 
M T F; et al 
Evidence-based 
planning of a 
randomized 
controlled trial 
on diaphragm 
use for 
prevention of 
sexually 
transmitted 
infections 
2008 
Diaphrag
m 
FGDs 
Formative, 
qualitative 
Madagascar 
Female 
sex 
workers 
266 2004 
Not 
specified 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a 
formative 
research 
activity, mixed 
methods  
Medium-High: 
qualitative 
research 
focusing on 
acceptability, 
data on 
motivations and 
barriers come 
through  
Medium
-High 
Gafos, Mitzy; 
et al 
Intravaginal 
insertion in 
KwaZulu-Natal: 
sexual practices 
and preferences 
in the context of 
microbicide gel 
use 
2010 
Pro2000 
gel 
IDIs and 
FGDs 
MDP 301 
Phase III 
RCT 
South Africa 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
136 
March 
2006 - 
August 
2008 
Not 
specified 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
Medium-High: 
qualitative 
research on 
vaginal 
practices 
Medium
-High 
Greene, 
Elizabeth; et al 
Acceptability and 
adherence of a 
candidate 
microbicide gel 
among high-risk 
women in Africa 
and India 
2010 
Celulose 
Sulfate 
IDIs 
Phase III 
RCT 
Uganda, 
Benin 
High risk 
women/t
rial 
participa
nts 
30 
Feb-
Aug 
2007 
A variation 
of the 
socio-
ecological 
model 
(Mcleroy et 
al. 1988) 
High - all 
details 
included 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
High - 
specifically 
evaluates 
barriers to use 
of gel among 
users 
High 
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Guest, Greg; 
et al  
Changes in sexual 
behaviour during 
a safety and 
feasibility trial of 
a 
microbicide/diap
hragm 
combination: an 
integrated 
qualitative and 
quantitative 
analysis 
2008 
ACIDFOR
M Gel 
and 
Diaphrag
m 
IDIs and 
FGDs 
Safety and 
Feasibility 
study 
South Africa 
Sexually 
active 
adult 
women 
120 
April 
2004 - 
Nov 
2005 
 Data 
analysis 
conducted 
within a 
positivist 
framework 
(Bernard & 
Ryan, 
1998), no 
specific 
theory for 
study 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
Medium: paper 
is focused on 
changes in 
sexual 
behaviour and 
not 
motivators/barr
iers to use, 
although these 
come out in the 
data 
Medium
-High 
Guest, G; et al 
Acceptability of 
PrEP for HIV 
prevention 
among women at 
high risk for HIV 
2010 
Oral TDF 
PrEP 
IDIs 
Phase III 
RCT 
Nigeria, 
Cameroon, 
Ghana 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
24 
June 
2004-
March 
2006 
Not 
specified 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
Medium-High: 
qualitative 
research 
focusing on 
acceptability, 
data on 
motivations and 
barriers come 
through  
Medium
-High 
Kacanek, 
Deborah; et al 
A qualitative 
study of 
obstacles to 
diaphragm and 
condom use in an 
HIV prevention 
trial in sub-
Saharan Africa 
2012 
Diaphrag
m 
FGDs 
MIRA Trial 
phase III 
RCT 
South Africa 
and 
Zimbabwe 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
206 
Aug 
2006 - 
Jan 
2007 
Modified 
grounded 
theory 
(Glaser & 
Strauss, 
1967) for 
analysis, no 
specific 
theory for 
study 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
Medium-High: 
data focused on 
ability to use 
condoms with 
diaphragm, 
though barriers 
to use of 
diaphragm 
came through 
Medium
-High 
Mathenjwa, T 
& Maharaj, P 
Female condoms 
give women 
greater control': 
A qualitative 
assessment of 
the experiences 
of commercial 
sex workers in 
Swaziland 
2012 
Female 
condom 
IDIs and 
FGDs 
Stand-
alone 
qualitative 
Swaziland 
Female 
sex 
workers 
25 
Jan - 
May 
2010 
Not 
specified 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
High: 
standalone 
qualitative 
research 
High: 
specifically 
looks at 
experiences, 
motivations and 
barriers to use 
of female 
condom 
High 
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Montgomery, 
C M; et al 
The role of 
partnership 
dynamics in 
determining the 
acceptability of 
condoms and 
microbicides 
2008 
Pro2000 
gel 
IDIs 
Component 
of pilot 
study for 
MDP 301 
phase III 
randomize
d trial 
South Africa, 
Tanzania, 
Uganda and 
Zambia 
general 
populatio
n women 
in 
couples 
45 
Not 
specifi
ed  
none 
specified 
(though 
used 
relationship 
based 
questions 
and 
anthropolo
gical 
approaches
) 
Medium: study 
dates not 
specified, 
though can 
assess date of 
data collection 
knowing this 
was connected 
with larger 
MDP301 study; 
no theoretical 
approach 
articulated for 
the study 
Medium-High: 
qualitative 
research 
within a pilot 
for a larger 
trial  
High: 
specifically 
evaluates 
experiences of 
gel use 
Medium
-High 
Montgomery, 
Catherine M; 
et al 
Re-framing 
microbicide 
acceptability: 
findings from the 
MDP301 trial 
2010 
Pro2000 
gel 
Semi-
structure
d, serial 
IDIs 
Component 
of MDP 301 
phase III 
randomize
d trial 
South Africa, 
Zambia, 
Uganda and 
Tanzania 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
464 
The 
trial 
started 
in 
Octobe
r 2005 
and 
comple
ted 
follow-
up in 
August 
2009 
emic 
approach 
to 
acceptabilit
y 
High:  all 
details 
included 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
High: specific to 
women's 
experiences of 
gel, and their 
interpretations 
of use 
High 
van der 
Straten, A; et 
al 
High 
Acceptability of a 
Vaginal Ring 
Intended as a 
Microbicide 
Delivery Method 
for HIV 
Prevention in 
African Women 
2012 
Placebo 
vaginal 
ring 
FGDs 
randomize
d safety 
and 
acceptabilit
y study 
(mixed 
methods) 
South Africa 
and Tanzania 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
48 
April 
2007 
to 
March 
2010 
Not 
specified Medium-High: 
no theoretical 
approach 
articulated for 
study 
High: 
qualitative 
research 
within a 
pilot/acceptab
ility study  
High: 
specifically 
aimed at 
understanding 
possible 
motivations and 
barriers to use 
of the ring 
High 
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Montgomery, 
Elizabeth T; et 
al 
Sharing the 
trousers: gender 
roles and 
relationships in 
an HIV-
prevention trial 
in Zimbabwe 
2012 
MIRA 
diaphrag
m and 
replens 
lubricant 
FGDs and 
IDIs 
MIRA Male 
Involvemen
t Study 
(ancillary to 
MIRA trial) 
Zimbabwe 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
85 
August 
2006 
to June 
2007 
Not 
specified Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
Medium: 
specifically 
looks at gender 
roles around 
decision making 
in the house 
and around sex, 
but experiences 
with diaphragm 
come through 
Medium
-High 
Okal, Jerry; et 
al 
Secrecy, 
disclosure and 
accidental 
discovery: 
perspectives of 
diaphragm users 
in Mombasa, 
Kenya 
2008 
Diaphrag
m 
IDIs and 
FGDs 
prospective 
study 
investigatin
g 
diaphragm 
continuatio
n rates 
Kenya 
Sexually 
active 
adult 
women 
39 
Januar
y 2004 
- July 
2005 
None 
specified 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
High: 
standalone 
qualitative 
research 
High: 
specifically 
aimed at 
understanding 
possible 
motivations and 
barriers to use 
of the 
diaphragm 
High 
Sahin-
Hodoglugil, 
Nuriye; et al  
User experiences 
and acceptability 
attributes of the 
diaphragm and 
lubricant gel in an 
HIV prevention 
trial in southern 
Africa 
2011 
MIRA 
diaphrag
m and 
replens 
lubricant 
FGDs 
MIRA Trial 
phase III 
RCT 
Zimbabwe 
and South 
Africa 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
105 
August 
2006 
to 
Januar
y 2007 
None 
specified 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
High: 
specifically 
evaluates 
experiences of 
diaphragm and 
gel use 
Medium
-High 
Stadler, 
Jonathan & 
Saethre, Eirik 
Blockage and 
flow: intimate 
experiences of 
condoms and 
microbicides in a 
South African 
clinical trial 
2011 
Pro2000 
gel 
IDIs, 
FGDs, 
and 
participa
nt 
observati
on 
Qualitative 
research 
conducted 
during 
MDP301  
phase III 
efficacy 
trial  
South Africa 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
179 
wom
en in 
401 
IDIs,  
42 
FGDs 
Trial 
was 
comple
ted in 
August 
2008 
and 
follow 
up 
comple
ted in 
August 
2009 
Not 
specified 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
Medium-High: 
examined 
women's 
interpretation 
and meanings 
of condom and 
gel use; leads to 
motivations and 
barriers but not 
explicitly 
examining 
Medium
-High 
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van der 
Straten A; et 
al  
Women's 
Experiences with 
Oral and Vaginal 
Pre-Exposure 
Prophylaxis: The 
VOICE-C 
Qualitative Study 
in Johannesburg, 
South Africa. 
2014 
TDF gel 
and Oral 
TDF and 
Truvada 
IDIs, 
serial 
ethnogra
phic 
interview
s, FGDs, 
observati
ons 
Qualitative 
sub-study 
in VOICE 
phase III 
randomize
d clinical 
trial 
South Africa 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
102 
July 
2010 
and 
August 
2012 
social-
ecological 
model 
High: all details 
included 
High: 
qualitative 
sub-study for 
larger trial  
High: 
specifically 
examines user 
experiences of 
gel and pill use 
High 
Gafos, Mitzy; 
et al  
The implications 
of post-coital 
intravaginal 
cleansing for the 
introduction of 
vaginal 
microbicides in 
South Africa 
2014 
Pro2000 
gel 
serial 
ethnogra
phic 
interview
s 
Qualitative 
research 
conducted 
during 
MDP301  
phase III 
efficacy 
trial  
South Africa 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
84 
March 
2006 
to 
August 
2008 
with 
follow-
up 
visits 
contin
uing 
until 
August 
2009 
Not 
specified 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
Medium - 
explores vaginal 
hygiene 
practices within 
context of gel 
use 
Medium
-High 
Lees, S 
Emergent HIV 
technology: 
urban Tanzanian 
women's 
narratives of 
medical research, 
microbicides and 
sexuality 
2015 
Pro2000 
gel 
IDIs and 
observati
ons 
Qualitative 
research 
conducted 
during 
MDP301  
phase III 
efficacy 
trial  
Tanzania 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
99 
Novem
ber 
2005 
to 
August 
2009 
None 
specified 
(though 
used 
anthropolo
gical 
approach) 
Medium-High: 
no theoretical 
approach 
articulated for 
study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
Medium-High: 
specifically 
explores 
motivations for 
participating in 
research, but 
also includes 
experiences and 
interpretations 
of gel use 
Medium
-High 
Magazi, 
Busisiwe; et al  
Influences on 
visit retention in 
clinical trials: 
insights from 
qualitative 
research during 
the VOICE trial in 
Johannesburg, 
South Africa 
2014 
TDF gel 
and Oral 
TDF and 
Truvada 
IDIs and 
FGDs 
Qualitative 
sub-study 
in VOICE 
phase III 
randomize
d clinical 
trial 
South Africa 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
102 
July 
2010 
to 
August 
2012 
social-
ecological 
model 
High: all details 
included 
High: 
qualitative 
sub-study for 
larger trial  
High: 
specifically 
examines user 
experiences of 
gel and pill use 
High 
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Montgomery, 
Elizabeth T; et 
al 
Male partner 
influence on 
women's HIV 
prevention trial 
participation and 
use of pre-
exposure 
prophylaxis: The 
importance of 
understanding 
2015 
TDF gel 
and Oral 
TDF and 
Truvada 
IDIs and 
FGDs 
Qualitative 
sub-study 
in VOICE 
phase III 
randomize
d clinical 
trial 
South Africa 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
102 
July 
2010 
to 
August 
2012 
social-
ecological 
model 
High: all details 
included 
High: 
qualitative 
sub-study for 
larger trial  
Medium-High: 
looked more at 
partnership 
dynamics than 
experiences of 
product use, 
but influences 
of dynamics on 
use is explored 
High 
Stadler, J; et al 
Hidden harms: 
women's 
narratives of 
intimate partner 
violence in a 
microbicide trial, 
South Africa 
2014 
Pro2000 
gel 
serial IDIs 
Qualitative 
research 
conducted 
during 
MDP301  
phase III 
efficacy 
trial  
South Africa 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
401 
IDIs 
with 
150 
wom
en 
Not 
actuall
y 
specifi
ed 
except 
"up to 
2010" ( 
see 
other 
MDP 
papers) 
None 
specified 
Medium: study 
dates not 
specified, 
though can 
assess date of 
data collection 
knowing this 
was connected 
with larger 
MDP301 study; 
no theoretical 
approach 
articulated for 
the study 
Medium-High: 
qualitative 
research 
within a larger 
trial setting 
Medium-High: 
looked more at 
partnership 
dynamics than 
experiences of 
product use, 
but influences 
of dynamics on 
use is explored 
Medium
-High 
Van Der 
Straten, A; et 
al  
Perspectives on 
use of oral and 
vaginal 
antiretrovirals for 
HIV prevention: 
The VOICE-C 
qualitative study 
in Johannesburg, 
South Africa 
2014 
TDF gel 
and Oral 
TDF and 
Truvada 
IDIs and 
FGDs 
Qualitative 
sub-study 
in VOICE 
phase III 
randomize
d clinical 
trial 
South Africa 
Sexually 
active 
adult 
women/t
rial 
participa
nts 
102 
July 
2010 
to 
August 
2012 
social-
ecological 
model 
High: all details 
included 
High: 
qualitative 
sub-study for 
larger trial  
High: 
specifically 
examines user 
experiences of 
gel and pill use, 
and in 
particular how 
meanings of 
ARVs for 
prevention can 
become 
conflated with 
treatment and 
being HIV + 
High 
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Table 2. Second and Third order constructs 
Third Order Labels Second Order Constructs Summary definition (translation) of the 1st and 2nd order constructs  Sources 
  
Sexual Satisfaction 
General Sexual Satisfaction 
The use of HIV prevention products like the microbicide gel can 
improve sexual satisfaction within the individual, partner, client, and 
couple combined.  
Gafos et al, 2010; Greene et al, 
2010; Montgomery et al, 2010;  van 
der Straten et al, 2012; Okal 2008 
Sexual Performance and 
Play 
Product use can improve performance allowing the user or individual to 
perform better, be hotter, for her partner, and partners or clients can 
last longer. There is also the added foreplay of initiating product use 
(ex. applying the gel).  
Guest et al, 2008; Stadler & 
Saethre, 2011; Montgomery et al, 
2010; Stadler et al, 2014; Gafos et 
al, 2010 
Implications of enhanced 
satisfaction 
Enhanced sexual satisfaction increases trust among some couples, can 
promote security in the relationship if male partners find their main 
partners more attractive because of improved sex, and the sense of 
additional safety from the protection conferred adds to the sexual 
satisfaction.  
Montgomery et al, 2010; van der 
Straten, et al 2014 
Lubrication and traditional 
vaginal practices 
Previous intravaginal cleansing and insertion practices can be replaced 
by product use (ex. microbicide), and can improve feeling of sex and 
feeling of vaginal, making sex more smooth. This more often improves 
sexual satisfaction, but added wetness can also imply promiscuity in 
some instances.  
Gafos et al, 2010; Greene et al, 
2010; Guest 2008; Lees, 2015; 
Montgomery et al, 2008; Stadler & 
Saethre, 2011; Montgomery et al,  
2010; Sahin-Hodoglugil et al, 2011 
  
Trust 
Trust or lack of trust in 
partner 
Product use could be motivated by fear of an unfaithful partner, where 
they had been and whether they would use a condom. General trust 
that a partner would use a condom properly was also often missing. In 
these cases, other HIV prevention products (gel, PrEP, or diaphragm) 
could confer added protection and peace of mind.  
Sahin-Hodoglugil et al, 2011; 
Kacenek et al, 2012; van der straten 
et al, 2014; Guest et al, 2008; 
Kacenek et al, 2010; Sahin-
Hodoglugil et al, 2011; Mathenjwa 
et al, 2012; Lees 1015 
Implications of product use 
for development and 
maintenance of trust  
Intimacy and creating and maintaining trust are important in 
relationships where other HIV prevention product use could reaffirm 
the relationship while condoms carried negative connotations of 
distrust, denoting infidelity. However, there was sometimes a worry 
that gels or oral PrEP could promote promiscuity, or at least suggest it.  
Okal et al, 2008; van der Straten et 
al, 2014 
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Communication and 
Enabling Environments  
Partner trust of a product was critical, because the trust in the product 
would translate to trust in a partner as well. Communication and 
disclosure of product use would improve use of the product, as well as 
overall communication in the relationship. If not discussed, or if the 
male partner did not trust the product, there was possibility for arguing 
and violence.  
Montgomery et al, 2008; Stadler & 
Saethre, 2011; Montgomery et al, 
2010, Greene et al, 2010; 
Montgomery et al, 2012; 
Montgomery et al, 2014; 
Montgomery et al, 2008; Kacanek 
et al, 2012; van der straten et al, 
2014; Magazi et al, 2014; 
Montgomery et al, 2015; Sahin-
Hodoglugil et al, 2011; Stadler et al, 
2014 
  
Empowerment and 
Control 
Self-esteem and personal 
agency 
Product use had positive effects on personal agency and self-esteem 
leading women to feel empowered by the ability to decide to use a 
particular product and that there was something they could use 
without necessarily needing a male partner's consent. However, in 
some cases the product could reduce the sense of personal power if it 
reminded the user of previous trauma.  
Sahin-Hodoglugil et al, 2011; Okal 
et al, 2008; van der Straten et al, 
2012; Mathenjwa et al, 2012; 
Abrahams et al, 2010; van der 
Straten 2014; Lees 2015; Stadler & 
Saethre, 2011; Kacanek et al, 2012; 
Guest et al, 2008; Greene et al, 
2010 
Power positioning 
(Negotiation and control, 
Product use and 
engagement in services 
affects power dynamic)  
Male partners could react negatively to women having decision making 
power over product use, clinic attendance, or even knowledge that 
they did not possess. This could result in anger or violence in the 
household.  
Stadler et al, 2014; Montgomery et 
al, 2015; Montgomery et al, 2012 
  
Personal Well-
being 
Product use promotes 
health and well-being  
The use of HIV prevention products was seen as a deliberate action to 
promote one's own health and sense of well-being. Products could 
strengthen the sense of self and empowerment, as well as prevent 
multiple diseases and improve health issues. The physical experience of 
side effects could also contribute to the sense of protection from the 
products. The engagement in health services in connection with HIV 
prevention product use was also a part of seeing oneself as being 
healthy and promoting that image to others.  
Stadler & Saethre 2011: 
Montgomery et al, 2010; Magazi et 
al, 2014; van der straten et al, 2014  
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Quality of care as 
motivation for engaging in 
healthcare 
The quality of care could motivate or demotivate use of HIV prevention 
products, negative or positive attitudes from health worker staff would 
transfer to the individual and promote either their sense of good health 
or negative feelings towards health.  Van der Straten 2014, Magazi 2014 
  
Social Well-being 
Perceived implications of 
use (how I'm seen by 
others) 
People using products can fear what others will think of them as 
someone who uses HIV prevention products, largely because of an 
association with promiscuous sexual activity  Okal et al, 2008; Gafos et al, 2010 
Social construction of 
medication and product 
use 
The use of a medication can symbolise illness for some women and can 
challenge their understanding of what it means to be healthy. 
van der Straten et al, 2014; van der 
Straten et al, 2014; Montgomery et 
al, 2015 
Conflation of ARVs for 
treatment and prevention 
Family members, partners or wider community members can mistake 
use of ART based PrEP, for ART used to treat HIV infection. This can 
lead to stigmatisation of people believed to be HIV positive 
van der Straten et al, 2014; Magazi 
et al, 2014; Montgomery et al, 2015 
Interaction with normative 
vaginal practices and 
beliefs 
The use of vaginal microbicides in some settings compliments locally 
normative vaginal practices in helping to cleanse the vagina prior to, or 
after, sex. However, the converse was also observed and vaginal 
microbicides can be rendered less effectiveness by virtue of cultural 
norms relating to vaginal cleansing immediately after sex.  
Gafos et al, 2014; Greene et al, 
2014; Behets et al, 2008, Stadler & 
Saethre, 2011 
  The role of outsiders 
Many of the product trials or demonstration projects have been led 
and/or delivered by people perceived as 'outsiders', largely relating to a 
perception that originate in the Northern Hemisphere. 
van der Straten, 2014; Guest et al, 
2010; Montgomery et al, 2010; 
Lees, 2015; Montgomery et al, 2014 
  
Practical 
Considerations 
Accessing and storing 
medication 
Physically getting to the clinic to pick up medication or product refills 
could prove difficult and was an issue in terms of consistent access. 
Storing medications was sometimes problematic due to stigma within 
the household or among friends, where personal privacy was minimal.  
Greene et al, 2010; Magazi et al, 
2014; Montgomery et al, 2010; van 
der Straten et al, 2014; Abrahams 
et al, 2010; Mathenjwa et al, 2012 
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Taking and adhering to 
medication 
Strategies for using products, such as gel within a certain time period or 
pills on a daily regimen, could be interrupted by changes in routines or 
boredom with use. Perceived or actual side effects were also barriers, 
as was the need to use multiple products such as condoms and gel 
when wanting to also prevent other STIs or pregnancy. If product use or 
associated clinic attendance got in the way of livelihood then product 
use was also demotivated. 
Guest et al, 2010, van der Straten et 
al, 2014; van der Straten et al, 
2014; Montgomery et al, 2012,  
Health service level issues 
The health service itself, including waiting times at the clinic, required 
frequency of visits in relation to livelihoods, and transport and ability to 
get to the clinic could also cause problems in consistent and continued 
product use.  Magazi et al, 2014 
Product attributes and 
acceptability 
The ease or difficulty in using a product would directly affect whether a 
product could be taken up and used. These included need for privacy or 
washing facilities, whether the product stayed where it was supposed 
to, ability to transport it inconspicuously, and flexibility around when 
sex occurred. Pain or irritation with use was also a demotivator. Ability 
to use covertly was positively regarded, even if rarely done. 
Okal et al, 2008; Sahin-Hodoglugil 
et al, 2011; Montgomery et al, 
2012; Greene et al, 2010; Kacanek 
et al, 2012; van der Straten et al, 
2014; Guest et al, 2010; Behets et 
al, 2008; Gafos et al, 2014; Stadler 
& Saethre 2011; Guest et al, 2008; 
Mathenjwa et al, 2012; van der 
Straten et al, 2012 
  
Efficacy and Risk 
Reduction 
Efficacy for HIV prevention 
central concern 
Whether or not the product can effectively protect them from 
acquiring HIV was a key concern of women engaged with the products 
via trials or demonstration projects. Recognition that condoms are not 
always sufficient drives interest in new product efficacy.  
Lees, 2015; Greene et al, 2010; 
Stadler & Saethre 2011; 2014; van 
der Straten et al, 2014; 
Montgomery et al, 2010 
Other (non-HIV) protective 
effects 
While not necessarily accurate in all instances, some female 
participants expressed beliefs that products could protect them from 
other STIs or from unwanted pregnancy.  
Montgomery et al, 2012; Okal et al, 
2008; Mathenjwa et al, 2012; Guest 
et al, 2008; Behets et al, 2008 
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Perceptions around 
combination prevention 
While women may not always be using new technologies in isolation, 
sometimes a result of concerns for their effectiveness, they were 
comforted by a feeling that products could provide an additional layer 
of protection should their primary prevention mechanism (usually 
condoms) fail. 
Sahin-Hodoglugil et al, 2011; Okal, 
et al, 2008; Guest et al, 2008; 
Kacenek et al, 2012 
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Meta-ethnography  
Sexual Satisfaction 
Constructs of “Sexual Satisfaction” arose in thirteen of the papers we reviewed (27–39). These 
second-order constructs included: 1) general sexual satisfaction; 2) sexual performance and 
play; 3) implications of enhanced satisfaction; and 4) effects of vaginal lubrication and 
traditional vaginal practices. Particularly strong positive feelings were voiced in relation to 
vaginal microbicide gels (27,28,32), as a result of the “heat”, or kusisha in isiZulu, created 
through use (27). This also occurred in relation to diaphragms where many women reported 
increased vaginal tightness (35), or enhanced stimulation when a partner’s penis made contact 
with the vaginal ring (33). At the same time, women also reported negative reactions from 
some male partners who found the ring to be obstructive during sex (34).  
 
Particularly striking in its primacy was discussion of how product use could form part of sexual 
performance and play between couples. Several papers describe how the use of microbicide 
gels and diaphragms was integrated into sexual foreplay, such as the product insertion 
performed by the male partner (29,37). Vaginal microbicide use was also associated with 
increased libido among some women (32,37) and viewed as a means of overcoming sexual 
problems, particularly in limiting premature ejaculation by male partners (32,36). A perception 
that the microbicide gel could lead to tightening of the vagina meant that, as described in two 
papers, male partners would actively request their female partners to use the product to 
improve the sexual sensation (27,37). In a similar vein, the potential for product use was often 
seen as facilitating discussion and greater sexual intimacy between partners. Sexual pleasure 
itself had positive impacts on relationships, improving the performance and play among 
couples, but also improving the security of the relationship for some women when their 
husbands stopped seeing other women as a result of improved sexual encounters within the 
primary relationship (32).  
 
Lubrication played a key role in shaping women’s perceptions of microbicide gel use with the 
majority of papers reporting a positive impact that helped to make sex feel more smooth or 
comfortable (27–29,31,37,38). Inserting the vaginal microbicide gel mirrored the use of other 
substances inserted into the vagina to create a pleasing environment for both themselves and 
their male partner (32). 
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There are others who insert traditional medicines for her to be enjoyable (during sex) . . 
. I used to love things that are inserted that make you enjoyable. . . . Now that I am old 
I don’t have that time of going to buy such things. I get help from the gel. (32)  
The multiple dimensions of Trust 
We found “Trust” to be a particularly strong, complex, and crosscutting construct, either 
positively or negatively influencing product uptake and use. From various perspectives, trust 
was either built up or broken down by interactions with partners in relation to product use. 
Three second-order constructs emerged under this theme including: 1) trust in one’s partner; 
2) implications of product use for development and maintenance of trust; and 3) 
communication and enabling environments for trust building. These constructs were identified 
in 16 of the papers (15,27–38,40–43).  
 
Women’s lack of trust in their partners was a strong motivator for use of PrEP, female 
condoms, microbicide gel, and gel with diaphragm (15,29,30,35). Product use helped ease the 
fear of possible infections a man might bring home with him, HIV or otherwise, especially 
when it was difficult to insist upon the use of male condoms within the context of a regular 
partnership (29,30,35).  
 
Product use also had direct implications for the development and/or maintenance of trust 
within the couple. In several instances, women reported that bringing an HIV prevention 
product into the home was negatively seen by partners who felt it implied infidelity on their 
part or could encourage the woman’s promiscuity, thereby impacting their ability to use the 
products (15,34). 
  
Conversely, for many couples, the microbicide gel did not convey the same level of mistrust 
that the condom had, making use easier to negotiate (37,38). Communication improved 
product use, and product use in turn could improve sexual and relationship communication, 
allowing for new dialogues and trust around sex and intimacy. Disclosure of product use, or 
lack thereof, also had the potential to influence a woman’s standing in her home and her 
relationship, where use could result in violence or dissolution of the relationship, or help to 
improve sexual satisfaction and dynamics within a couple (28,32,38,41,43).  
 
Partner support of product use was also a critical factor. Some partners plainly refused to use 
any prevention products citing mood, general disapproval, or dislike of added wetness from 
microbicide gel use (15,28,30). However, in many instances, men could also be supportive and 
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feel they were protected by the product, as well as become involved in supporting their female 
partner in use, such as providing transport to clinic appointments (28,35,42,43). 
 
Finally, there was an aspect of trust in the product itself, either negative or positive. Negative 
perceptions often manifested from male partner’s disapproval and mistrust in outsiders having 
influence on sexual relationships or in the efficacy of the product. On the other hand, some 
couples found that a new product with greater efficacy could actually improve trust and 
feelings of safety that would motivate use, particularly when they had previously found 
effective condom use problematic.  
 
I like using the diaphragm a lot.  My partner likes condoms, but he says they are weak.  
I also think they are weak [...] [Condoms] burst just like D said.  It burst while we were 
busy [having sex]...So I sometimes use [the condom], but I trust the diaphragm more. 
(35) 
 
Empowerment and Control 
The interrelated constructs of “Empowerment and Control” were central to women’s 
narratives about how they perceived and used HIV prevention products. Two second-order 
constructs were identified under this theme: 1) self-esteem and personal agency; and 2) power 
positioning. These constructs emerged from 14 of the review papers (15,28–30,30,31,33–
37,40,41,44).  
 
Some women expressed how products, in particular microbicide gel, vaginal ring, and 
diaphragm, gave them a sense of ownership and agency over preventing HIV, but also their 
own bodies and health (33–35). They were able to make the decision to use a product, without 
a man’s consent or involvement. This was especially valuable when women felt that their 
partners would not necessarily agree or were untrustworthy. Participants suggested that 
women were responsible for their own health, as this quote notes in relation to the female 
condom:  
 
Men cannot be trusted to act in our best interests. He can wear the condom at the start 
of the act and then remove it later or he will just tear it. … So we have to take care of 
ourselves by using condoms. (40)  
 
In less common contexts, product use can also affect agency, as described in one paper about 
PEP use within the context of post-rape care. In this paper, successful PEP use after cases of 
sexual assault was directly related to how the rape was perceived and how the use of PEP 
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affected the victim on an emotional level (44). Several women reported that the use of PEP 
reminded them of the rape or made them feel like they were HIV positive, leading to negative 
associations with the product and demotivated use.  
 
In direct contrast to the generally improved self-agency from product use is the construct of 
power positioning which emerged as a barrier to product uptake and use. A key concern in this 
regard was a fear of violence should male partners’ discover covert use of the product.  
 
‘I was scared of the conflict it would cause’; ‘if he finds out he is going to be angry’; ‘I 
had seen that he didn’t like the gel and I thought if I told him he would fight with me’; ‘I 
think he will fight with me for using the gel with him in secret...’ (multiple 
respondents)(36) 
 
Women had conflicting feelings about product use. Some felt product use could improve their 
ability to make choices and negotiate protection, however, this could also pose a threat to 
men’s authority and potentially destabilize the relationship (43).  
 
Personal Well-being 
“Personal Well-being” arose as an important construct in how women used and engaged with 
products. We identified three distinct constructs comprising this theme: 1) product use 
promoted health and well-being; 2) attributes of product use indicated the power of 
medication and good health; and 3) quality of care was a motivator for engaging in services 
and product use.  These constructs emerged to varying degrees in five of the review papers 
(15,32,37,39,42).  
 
Two of the papers (32,37) explored how a microbicide gel gave women a sense of well-being, 
solved multiple health issues, and prevented other diseases or infections. Indeed the power of 
the prevention product was seen to have the ability to promote fertility and vaginal 
cleanliness, clean the blood, and cure ailments (32).  
 
As a result of continuous use, my pores are now open. My body is no longer stiff and I 
don’t get tired any more. I am not unsure about my health anymore. Since I started 
using the gel, I am always energetic like somebody who is using drugs. It has even 
opened the veins to my kidneys. (37)  
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Another paper found that the experience of side effects from ARV-based prevention products 
encouraged perceptions of the power of the ARVs working in the body to protect the user 
(15,39). 
 
[T]he tablets are also working because they have some reaction on us like some of us 
have headaches and become nauseous and stuff like that, so you would believe that 
means that these tablets have a certain possibility of reducing the risk of contracting 
HIV, you know. (15)  
 
Interaction with a health service, whether within a trial or actual clinic setting, driven by 
product use promoted an additional sense of personal well-being in which women could 
actively look after their own health and be seen by others as ‘healthy’ (15). Knowledge of one’s 
HIV status with regular check-ups could promote a negative status, leading to continued 
product use (42).  
 
Additionally, the quality of care during clinic attendance was directly related to motivation for 
use in two of the papers (15,42). Women noted the importance of staff demonstrating their 
concern and care for their study participants or clinic clients through educational or one-on-
one counselling sessions, in contrast to previous experiences in government public health 
clinics where staff were often quick to dismiss interests in new products and/or the feelings of 
their patients (42).  
 
Product use in the social-cultural environment  
The construct of “Product use in the social-cultural environment” incorporates four second-
order constructs which, combined, represent a significant and sizeable component of the 
published evidence on the uptake and use of female controlled HIV prevention products 
(15,27,31,34,35,37–39,42,43,45,46). The four constructs include: 1) perceived implications of 
use; 2) dominant, setting-specific social construction of medication and product use; 3) 
conflation of ARVs for prevention and for treatment; and 4) interaction of products with 
normative vaginal practices and beliefs. Cutting across these constructs is the notion of how 
women use products within the social-cultural environment and interactions which point to 
their need or desire to protect their ‘social well-being’, including their observation of social 
norms and values.  
 
Many women were concerned that use of vaginal microbicides, the diaphragm, or oral PrEP 
might suggest to others that they are either promiscuous or identified them as a sex worker 
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(27,34). Clinic attendance and use of an ARV based technology also caused confusion for the 
family and friends of some female participants who struggled to distinguish between ARVs for 
treatment and for prevention (15,42,43). The use of ARVs has become synonymous with HIV 
infection and, in some instances, sickness (39) and those using ARV-based prevention products 
were considered to be ill. As such, the social construction of medication and product use 
encapsulates particular beliefs regarding use of medications.  Therefore, a woman’s own view 
of how she sees herself, and how she is seen by others, may be threatened by the use of a 
technology such as PrEP coming in the form of a tablet (42). 
 
Like my family, I explained that I am attending a [PrEP] study but they don’t [believe] 
that I am attending a study, they just thinking I am HIV positive and I am hiding it. (15) 
 
The impact of beliefs on uptake and use of new products also extend beyond those that relate 
to HIV stigma. Culturally appropriate or common hygiene practices as they relate to use of 
prevention products are the focus of several papers within this review (28,37,45,46) and 
authors highlight the ways in which cleansing practices, in particular, are an important 
dimension of the social self. Hygiene practices, such as using cleansing products, were 
reported both as a barrier and an enabler to the effective use and acceptability of vaginal 
microbicides. Some women found vaginal microbicides highly acceptable given the existing 
cultural norms around intravaginal insertions for cleansing and preparation for sex (28,32). 
Partner and social preferences for “dry sex” motivated microbicide use which was seen to have 
cleansing effects on the vagina, translating into a reduction of STIs and foul-odours previously 
caused by traditional vaginal cleansing products (37). Interestingly, at least in the South African 
context, preferences for dry sex seem to actually refer to cleanliness or tightness rather than 
the desire for a dry vaginal environment, as presented by Stadler and Saethre (37).  
 
The perception and extent of engagement with a biomedical product was also influenced by 
who was delivering the product and whether they were seen as part of the community. Four 
studies (15,31,32,47) cite concerns relating to the fact that vaginal microbicides, PrEP or the 
diaphragm were delivered by muzungu (white people in Swahili) or people from the northern 
hemisphere, and a generic mistrust of foreign medications not common in the local setting.  
 
So I sometimes think what if what my friends are saying is true, as they say ‘what if 
they are infecting you with AIDS using that gel? (15)  
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In several instances it was male partner mistrust of ‘outsiders’ in their social setting that stood 
as a significant barrier to uptake and use of the product as they sought to prevent their female 
partners from engaging  in use (43). 
 
 
Efficacy and Risk Reduction 
Constructs of perceived and actual efficacy of prevention products, or the potential for risk 
reduction, were a significant feature of nine papers (28–30,34,37,40,41,45) and an implicit 
dimension of three (31,32,39). Three constructs identified among these papers were 1) 
efficacy for HIV prevention as a central concern; 2) other (non-HIV) protective effects; and 3) 
perceptions around combination prevention. 
 
The fear of infection was a dominant feature in participants’ narratives (28,31) as was the hope 
that new products may succeed in stemming the epidemic where condoms have been 
insufficient (37). In several studies, women said that sex was more enjoyable when they felt 
protected from HIV, as described in Guest et al:  
 
It is the diaphragm and gel that made us enjoy sex more because there is no virus that 
goes inside me or penetrates me.  I don't know what he is doing in my absence, and he 
doesn't know what I am doing in his absence so we are safe when we are using the 
diaphragm. (29)  
 
Female participants were comforted by the additional protection that new prevention 
products offered. While they may maintain a desire to utilise male condoms for many sexual 
encounters (e.g. to prevent pregnancy or other STIs), it was felt that the diaphragm (34,35) or 
vaginal microbicides (29) could provide an additional layer of protection from acquiring HIV.  
 
I feel free when the diaphragm inside me in this 6 hours I do simply know that even if it 
has happened that a condom burst, no HIV will be passed on to me.  It will go back. 
(35)  
 
The preference for use of more than one product at a time affording multiple layers of 
protection was not uniform. Kacanek et al (2010) highlight the reluctance of women in their 
study to use both the diaphragm and condoms simultaneously. However, women did 
acknowledge that this was partly born from a desire to understand the effectiveness of the 
diaphragm as a preventative HIV transmission method in isolation. 
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For female condoms and the diaphragm, women articulated their belief, and feelings of 
comfort, that these methods could also protect them from other STIs and unwanted 
pregnancy  (29,34,40,41,45). The female condom was particularly favoured by women who 
had experienced problems with hormonal contraceptive methods (40). 
 
Practical Considerations 
Four second-order constructs emerged within the third order construct of “Practical 
Considerations”. These included: 1) accessing and storing products, 2) product attributes and 
acceptability, 3) ability to effectively take or use the product, and 4) issues relating directly to 
health services. These constructs were identified in 17 of the papers (15,28–30,32–
35,37,39,40,42,44–47). 
 
While all of the studies included in this review report data on actual use of products in 
contexts where the products were provided for research purposes, either in trials or clinic 
settings, issues around access to the products still arose. This was directly related to women’s 
ability to get to the clinic for refills in between scheduled visits. In some cases women just 
waited for the their next appointment rather than making an extra trip, or were away from 
home due to family obligations (28,42).  
 
Storing the products could also pose problems in settings where there is little privacy in the 
home and women feared accidental discovery and potentially negative reactions from 
household members or partners (15,32). Some women used the discovery of a product as a 
means to establish health status and pride around use:  
 
At first I was putting [the tablets] inside my bag and then I took them out of it and put 
them inside my wardrobe but then one of my friends opened my wardrobe. Because 
she saw that I was taking the tablets and she didn’t understand why I was taking the 
tablets even my partner didn’t understand why I was taking the tablets. So I put the 
tablets in open field so that they could understand that I was taking the tablets for the 
study and it’s not that I was sick or anything like that. (15) 
 
Attributes of the products themselves could directly influence the ability to use them. With 
regard to the diaphragm, users found that it could be problematic to insert or remove it 
without privacy or clean facilities in which to wash themselves and the product. Some women 
found it painful at first to use, while others appreciated the small size and that it was 
inconspicuous enough to fit in a handbag or in a pocket (34,35). The long-acting attribute of 
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the vaginal ring contributed to a feeling of flexibility when sex occurred, as well as constant 
protection in case of rape (15).  
 
Vaginal lubrication practices also arose under this third order construct from the practical 
perspective. After using microbicide gel, women articulated that the use of traditional 
lubricants was less preferred owing to their ability to cause foul-smelling odours, whereas the 
microbicide gel or the female condom had built-in, clean lubrication which was a strong 
motivator for use (28). This built-in lubrication would also prevent pain and tearing of condoms 
or vaginal tissues, as well as dryness, which can occur during longer sexual encounters and as 
such was preferable to male condoms (29,32,37). The vaginal ring could bring added pleasure 
to sex as well where the ring itself would add stimulation to the male partner (40). 
 
Other papers presented discussions of traditional or conventional vaginal practices and how 
they might affect the practical and effective use of products (37,45,46). Women spoke of the 
“dirt” (or pollution resulting from perceived accumulation of semen, menstrual blood, and 
lubricants), either their partner’s or their own, which could get trapped in their vaginas after 
sex because of product use (37,46). However, the rinsing of a vaginal microbicide gel or 
diaphragm within an hour after vaginal intercourse could significantly negate its effectiveness. 
This issue was amplified for female sex workers who felt a need to cleanse their vagina 
between clients (45,46). Interestingly, some women felt that using the newer products actually 
made them feel cleaner, thus reducing cleansing practices and motivating use.  
 
Side effects, whether real or perceived, were a critical influence on continued use of a product. 
Women stated they would use products providing there were no visible side effects which 
could alert friends, family, or partners to their use and potentially stigmatise them as being HIV 
positive (15). Women expressed fear of using products due to potential or experienced side 
effects (15,33,39), while others were able to quickly overcome the side effects and felt happy 
to use the product (28). Lack of side effects as experienced with the female condom was a big 
motivator for use, especially for those women who had experienced them with other products. 
 
An additional practical consideration centres on the consciousness required for consistent and 
correct pill taking, in particular related to oral PrEP. Some women had difficulty remembering 
to use the product, such as in the case of oral PrEP, when they were intoxicated, “feeling bored 
or lazy, on the go”, or just not used to having to take a pill every day (15,28).  
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Finally, issues with health services, even in trial settings, were also factors influencing product 
use. Waiting times at the clinic would cause women not to attend and pick up their products, 
as did availability of and ability to get transport, and family, community, or work obligations 
which disrupted clinic attendance (42).  
 
2.4.5 Discussion 
The analysis and synthesis of the data included in this review reveal nuanced personal, 
relational, social and cultural factors that women perceive and attempt to manage as they 
consider the uptake and use of biomedical HIV prevention products. The factors are far from 
binary, in that a given factor can act as either a motivator or deterrent to uptake and use 
depending on the individual context. Our analysis led us to identify seven third-order 
constructs. Figure 3 illustrates how the third order constructs tend to be situated in terms of 
primacy to the decision making process to take up and use HIV prevention products, and how 
they can influence each other in this process.  
 
In this manner, the centrality of “Sexual Satisfaction”, “Trust” and “Empowerment & Control” 
are emphasised among those constructs that appear more proximal or those that are 
functional or pragmatic, but which still play a role in product uptake and use. The inter-
relationality of these constructs, illustrated by the overlapping circles in the centre of the 
framework which also connect with the other shapes in Figure 3, is as important as the 
individual constructs themselves, as no one construct can be isolated and addressed without 
acknowledging the others. In the remainder of this section we use this framework as the basis 
for discussing the broader context of the constructs, their meaning and potential impact for 
policy and programming.  
Figure 3. Conceptual framework of third order constructs influencing HIV prevention product decision-
making for uptake and use among women in SSA. 
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Core influencing constructs 
Improved sexual satisfaction emerged as one of the strongest motivators for using a particular 
product, especially in relation to vaginal microbicides and the diaphragm. However, this 
construct was typically positioned within a partnership where trust and empowerment 
mediated (or were mediated by) enhanced sexual pleasure.  Several authors highlighted how 
the mere fact that sexual satisfaction for both partners plays such a key role in broader 
relationship satisfaction, and that in many respects vaginal microbicides or diaphragm use help 
to enhance sexual pleasure, means that this dimension of the product is central to their uptake 
and use (29,32).  
 
Improved sexual satisfaction in a relationship can directly lead to improved security between a 
couple, where a husband may stop seeing other women and the main partnership therefore 
becomes strengthened (32). Product attributes themselves can also contribute to trust, or lack 
thereof, in a given product. For instance, the added wetness from a microbicide gel could 
denote infidelity in the eyes of a male partner (28,36), especially in contexts where traditional 
preferences derived from social norms are for dryer sex. This connotation of lack of fidelity 
generates a lack of trust and ultimately demotivated use of the product.  
 
We found that many authors approached their research from the perspective of 
empowerment, or control over prevention choices. Women across the research expressed 
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how having something that was theirs and/or their choice was important and empowering, but 
it was not necessarily the primary motivation for use. This is significant to note in the context 
of a global PrEP and vaginal microbicides discourse that often emphasises empowerment of 
women as a key component of such products (48–50). While this review demonstrates that 
empowerment and control issues still play an important role in the decision to use a new 
technology, they do not necessarily feature as the primary factor in women’s’ thinking and 
must be considered within individual contexts.  
 
Empowerment could actually be diminished if a partner discovered covert use of a product and 
became angry or violent, and fear of these reactions led women either to openly disclose or 
discuss use with a partner, or stop use altogether. Some women found that empowerment 
through building trust with their partner and strengthening the relationship through open 
communication was a positive by-product of introducing new prevention options into the mix.  
 
 
Proximal influencing constructs 
Product use in the social-cultural environment consists of multiple factors pertaining to 
interactions between women and their communities, and the social norms generated around 
traditional practices and beliefs, denoting women’s sense of ‘social well-being’.  
 
Our analysis revealed  the importance to women of meeting both cultural norms and 
expectations of vaginal dryness (31) as well as vaginal cleansing (32). This is where women 
carefully consider how vaginal microbicide use might impact on good health and the “vaginal 
environment” (32), which directly relates to perceptions of well-being in the social-cultural 
environment as well as sexual satisfaction within the relationship. Several authors suggest that 
in countries or areas where intravaginal insertion prior to sex (e.g. to tighten or dry the vagina) 
is commonplace, acceptability of vaginal microbicides – and, therefore, uptake and use – may 
be higher than in areas where such practices are less common (28,32). 
 
The construct of personal well-being speaks to the feelings women had about the impact of 
products on their health more broadly. Use of products meant not only a continuous process 
of engagement with healthcare services, but also a general sense of health and cleanliness. A 
further key dimension of this construct was how others might see women as ‘healthy’ by virtue 
of their on-going healthcare engagement. This observation actually sits in contrast with other 
findings described in some results that suggest women may be the victims of stigma or 
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discrimination if others come to believe they are accessing HIV services because they are sick, 
conflating services for prevention with those for (HIV positive) treatment.  
 
Functional & pragmatic influencing constructs 
Inherent to the construct of efficacy and risk reduction is the process of decision-making. 
Women will engage in balancing the potential risk of HIV with the risk to trust her partner, or 
the risk to intimacy within a partnership that could be threatened by use of HIV prevention 
products. Products that pose added benefits from product attributes, such as clean lubrication 
from the female condom or microbicide gel, could outweigh potential issues around distrust or 
scepticism around product use.  
 
Several authors stressed that the efficacy of the technology in preventing the transmission of 
HIV was absolutely central to its perceived acceptability (28,29,32), as well as its uptake and 
use. However, we found that sometimes beliefs about a certain product was as, or more 
powerful than the reality. For example, the belief that a product could prevent more than HIV, 
that it could ‘cleanse the blood’ or prevent other diseases because of how it made the person 
feel when using or taking it, was a strong motivation for use. Similarly, belief that a product 
was extremely efficacious as a result of experiencing side effects or a feeling of empowerment 
promoted continued use.   
 
In order to make effective use of the products women need to be able to store, be able to 
confidently use, and have barrier-free access to healthcare services. Products must also be 
developed or formulated in such a way as to be acceptable to women wanting to use them in 
the medium or longer term. Vaginal microbicides and the diaphragm, in particular, can be 
difficult for women to insert in adequate time prior to sex and concern was also expressed that 
their use may interfere with traditional vaginal hygiene practices.  
 
Further reflections on these findings  
Since the time that this review was conducted, additional qualitative evidence on perceptions 
of female-initiated and controlled HIV prevention products or interventions has emerged, 
particularly from trial research around oral PrEP. The HPTN/ADAPT study (51), which 
compared daily to intermittent dosing of oral PrEP in a phase II clinical trial setting, has 
recently published qualitative research which further supports and develops the findings in 
this paper. In this study, they found nuanced motivations and barriers linked to perceptions of 
safety taking PrEP, trust in what PrEP really was and whether it really worked, whether its 
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providers were worthy of trust, and a sense of community commitment and dedication with 
regards to adopting (or not) the PrEP intervention. The insights related to trust, or lack thereof, 
in oral PrEP have been further supported by findings from the VOICE D study (a sub-study of 
the main VOICE study on preferences and adherence) where women expressed concerns 
around safety and efficacy of PrEP as well as similar community perceptions which affected 
their own thinking (52,53). As more data continue to emerge from ongoing trial research as 
well as the early PrEP implementation studies which will start to publish results, perceptions 
which might create product-specific stigma, distrust, and aversion will be important to 
consider when designing messaging and education campaigns. Additionally, it will be 
important to ‘arm’ health workers and clinicians providing PrEP will accurate information and 
careful training to be able to address rumours head on.  
 
In this review, oral PrEP was discussed less than other products (such as microbicide gels or the 
ring) with regard to sexual satisfaction, largely because it lacked tangible attributes that could 
contribute to improved pleasure. However, social marketing campaigns have evolved since this 
review was conducted that capitalise on the ability of PrEP to remove some of the fear around 
sex which can then lead to improve satisfaction or pleasure (54). PrEP and other HIV 
prevention products may present a new opportunity to develop discourse around sexual 
pleasure even in places traditionally closed to these notions.  
 
Vaginal practices played a key role in much of the research surrounding vaginal products such 
as the gel and the ring with regards to traditions and habits of women. Interestingly, the 
notion of “dry sex” was revealed in some of the literature to be less about having a dry vaginal 
environment, but rather more about the cleanliness of the vagina and “hotness” of the sex. 
Regular clinic visits allowed women to be more consistently free of STIs, and use of the gel 
provided clean lubrication, which most women and their male partners enjoyed. If there is to 
be continued pursuit of vaginal HIV prevention products, this line of enquiry may benefit from 
further investigation.  
 
Adherence, or the burden of adhering to a specific HIV prevention product regimen, was not a 
theme that emerged as prominently as others in this review. However more evidence has 
emerged recently about levels of adherence required to ensure efficacy, and findings from 
qualitative research may help to shed light on where issues lie in maintaining consistent use. 
Oral PrEP in particular requires high levels of adherence to confer adequate protection, 
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particularly among women (55,56). This will also be an important consideration for large-scale 
PrEP implementation as well as for development of new HIV prevention products.  
 
Finally, as the research included in this review comes from studies where participants received 
some form of financial reimbursement for participation, and the products were provided free 
of charge, it is not possible to determine how perceptions of use may differ in a context where 
this was not the case. Future research could examine this further, and potentially use the 
findings from this paper to develop surveys to also quantitatively assess motivations and 
barriers to use in more ‘real-world’ settings.  
 
Strengths & Limitations 
This is the first review paper of its kind to aggregate data from across a large population of 
women, from multiple sub-Saharan African countries, relating to a range of female controlled 
HIV prevention products. In doing so we have documented the key themes or issues that can 
influence their uptake and use and how these overlap according to context and the specific 
technology. The systematic review involved searches in all languages, double screening and 
double extraction of relevant data from each paper. Our explicit focus on studies where the 
product of interest was available, rather than simply the object of theoretical discussion with 
women, helps to ensure the findings are grounded in personal experience. 
 
The papers in this review, however, included mostly data gathered in the context of clinical 
trials where products were freely given and participants were usually reimbursed for costs 
associated with participation (such as transport to and from clinics). The unique environment 
and provision of wrap-around counselling and treatment services does not often mirror the 
real-world implementation of new products. Nevertheless, regardless of this, the themes that 
emerged were common across a wide range of countries, implementation contexts (including 
clinical trial and implementation studies), and cultural settings, as well as across the products 
themselves, suggesting a relatively robust body of evidence. One crucial consideration, 
however, relates to the construct of product use in the social cultural-environment, where 
social norms are seen to influence uptake and use of products. As those products found to be 
efficacious are rolled out into countries and communities, the extent to which their use is 
‘normative’ will also change. This would certainly have affected the data included in this 
review as none of the products had been in the field long enough for use to have been 
normalised. It is also important to note that while this review of evidence only included 
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perspectives from women, it is clear that the perspectives of men influence women’s choices, 
decision making, and effective use. 
 
A further limitation of this analysis is the limited nature of published qualitative research. 
Often it is required, for word length purposes, to condense detailed findings to a few 
sentences that capture their essence. Understandably, the papers included in this review will 
have focused on certain viewpoints, whereas there may be many more data providing 
additional nuance, which could contribute valuable insight.  
 
Finally, while it is a strength of this review that we have synthesized qualitative data from 
across research contexts, it is also somewhat of a limitation that the contexts were not more 
diverse and include more pure implementation research studies. The body of evidence for 
understanding the motivations and barriers to uptake and use of female-initiated HIV 
prevention products can be further strengthened by more lessons learned and documented 
from the field.  
 
2.4.6 Conclusions  
This is an exciting time in HIV prevention as new biomedical products are developed and 
systems put in place to ensure their effective rollout. Health systems, structural and direct 
contact level interventions relating to new products need to take into account more than just 
superficial notions of acceptability. Instead, they should focus on a holistic approach including: 
aspects of how a product can protect a partnership ( in terms of physical and emotional 
health); an awareness of the significance of sexual satisfaction and enjoyment; an 
understanding of the social and cultural norms influencing product use; and include efforts to 
tackle the continuing stigma associated with HIV. Structural and individual level interventions 
aiming to improve uptake and use of those products already available have tended to focus on 
practical issues (e.g. access to products and services, ability to use and store products safely, 
access to hygienic facilities). These may be perceived as the ‘low hanging fruit’ as issues that 
lend themselves to immediate intervention, but they do not necessarily reflect those concerns 
that are most central to effective uptake and sustained use of the product from the 
perspective of the user. While the reduction of transmission risk is essential for the use of any 
of these products, and has justifiably been the focus of international scientific attention, this is 
not often the key determining feature of use. Formative research conducted in each setting 
prior to the roll out of new product-based interventions will help to ensure that 
communications and educational materials are aligned to the local cultural and social norms, 
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and take account of both personal concerns and personal values in safer, and enjoyable, sexual 
practice.  
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3.0  Chapter 3: Methods employed and lessons learned from designing a 
PrEP intervention for FSWs in South Africa 
 
3.1. Introduction 
Chapter 3 addresses the research question associated with PhD Objective 2: What are the 
practical and contextual factors which might affect the uptake and use of PrEP among FSWs in 
South Africa? This question was addressed through the experience of conducting formative 
research to develop interventions to be implemented and evaluated in the TAPS 
Demonstration Project. While this PhD focuses on PrEP, the TAPS project included both PrEP 
for HIV-negative women and early ART for HIV-positive women. As discussed in the paper, this 
is a direct result of demand voiced during consultations and discussions with sex worker 
organizations and sex workers themselves. Since these two interventions were combined and 
this paper was written both for sharing learning from the project with a broader audience as 
well as for this PhD, it was not possible to separate the two interventions into different papers. 
In addition, PrEP cannot be implemented in a vacuum, separate from other clinical and 
behavioural interventions, therefore it was important to take into account the wider delivery 
environment as well as the sex work context. Indeed, the learning related to the design of both 
interventions overlapped and pointed to many synergies which could be capitalised upon in 
the project. One in particular, which develops throughout this PhD, is the notion of social 
support among HIV-negative and positive women who are all taking pills and often motivated 
by similar reasoning. This will be explored in more depth in Chapters 4 and 6. 
 
The paper contained in this chapter describes the method of employing an inductive approach 
based on the principles of grounded theory (1) to choose methods and make decisions 
concerning intervention design due to the broad original scope of PrEP and early ART 
implementation considerations. This methodological approach was used given the many 
unknowns regarding PrEP implementation in general, and for FSWs in particular. A range of 
methods were considered at the outset (formal surveys, focus group discussions, interviews, 
site assessments, consultations), however, it was more appropriate to let the findings elicited 
after each step dictate the subsequent methods rather than employ a fixed plan from the 
outset. This grounded approach allowed for broad exploration of factors which might either 
support or detract from the interventions. These factors are situated within the spheres of the 
MSEM pertaining to the interactions with HIV prevention across individual, social, community, 
policy and epidemic contexts. This work addresses issues around applicability of PrEP for FSWs, 
where relevance and responsiveness are critical in designing the intervention. 
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The approach and decisions made relied heavily on systematic and extensive engagement with 
stakeholders and experiences during outreach in the field accompanying the existing Sex 
Worker Programme staff during health promotion and clinical services. Working through the 
existing programme was essential in order to build the TAPS interventions into relevant, or 
applicable, options for FSWs to take up and use. This formative research focused primarily on 
the applicable or practical components of intervention design and delivery – namely where, in 
which contexts, how, and when the interventions should be offered. The final piece of the 
formative research took the form of focus group discussions with potential end-users which 
will be described in the following chapter. The strength of this research is the systematic way 
in which it was undertaken, at the same time relying on a grounded approach to allow for the 
data to drive the decisions. Formative research is almost always undertaken before 
programme implementation, but rarely reported in detail.  
 
This paper was submitted for publication to BMJ Open in July 2017 and is awaiting an editorial 
decision.  
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3.3.1. Abstract 
Objectives 
This paper examines how an inductive approach, based on the principles of grounded theory, 
to formative research influenced the design and execution of oral pre-exposure prophylaxis 
(PrEP) and early antiretroviral (ART) interventions for female sex workers (FSWs) in South 
Africa. 
 
Setting 
The formative research was carried out in a variety of locations as dictated by the inductive 
approach. These included five sites in and around sex worker clinics, and at stakeholder 
offices.  
 
Participants 
Participants in this research included stakeholders, experts in the field, and FSWs. Since this 
was an evolving, inductive approach to research, numbers of participants were not always 
tabulated except in the case of focus group discussions (FGDs).  
 
Results 
Results consisted of methods chosen and subsequent data. Five chosen methods were: 1) 
stakeholder consultations launching and evolving the research; 2) engagement with FSW 
communities and working environments including hotspot mapping and clinic interactions; 3) 
site feasibility assessments for site selection; 4) supportive structures development for 
retention and adherence; 5) FGDs conducted with FSWs to explore specifics of acceptability. 
This process identified implementation barriers, opportunities, and research gaps critical to 
intervention design. Two sites were selected in Johannesburg and Pretoria, out of five 
considered. The contexts of the two urban sites varied, necessitating adjustments to 
intervention implementation. 
 
Conclusions 
Using an inductive approach allowed for a wide range of perspectives, defining population 
needs and how to best reach them. This research illustrated how similar sex work 
environments can vary and how implementation of interventions may not be uniform across 
contexts. Lessons learned in details could assist in future project designs and implementation 
of new interventions where feasibility, social and cultural factors affecting acceptability must 
be considered. 
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Strengths and Limitations 
 This formative research process drew on principles of grounded theory allowing for an 
inductive, iterative approach to drive the selection of the most appropriate methods 
for gathering a broad spectrum of data aimed at intervention design.  
 Five components were selected through the research process, providing an array of 
data for decision making and intervention design. 
 This was a systematic approach in five known sex worker sites and final sites were 
chosen for their nearer uniformity than for diversity; results may not translate beyond 
this study, however lessons learned will be applicable.  
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3.3.2. Introduction 
Several guidance documents highlight the need for formative research both when preparing 
for larger studies and to design the implementation of new public health HIV interventions 
(1,2). Formative research includes the assessment of feasibility, reach, acceptability, and need 
of populations to strengthen planned uptake and use of interventions. In particular, formative 
research aims to ensure the capacity for physical implementation and responsiveness to 
cultural, social, economic and physical environments (3–5). However, this phase of work is 
frequently not reported and important lessons learned may be lost. This paper describes the 
detailed decision making and conduct of formative research undertaken to design two new 
HIV prevention and treatment interventions delivered to female sex workers in a 
demonstration project in South Africa. 
 
Oral pre-exposure prophylaxis (PrEP) using antiretroviral (ARV) drugs given to an HIV-negative 
individual to prevent HIV infection, has been shown to be efficacious in multiple clinical trials 
(6). In additional, HIV treatment can be given to HIV-positive people as soon as they are 
diagnosed, and together with oral PrEP, is now the standard of care recommended in 2015 by 
the World Health Organization (WHO) (7).  
 
Demonstration projects were recommended by the WHO in 2013 to generate evidence to 
answer implementation questions around feasibility and acceptability of oral PrEP (8). The call 
prioritised research for key populations such as sex workers, who have been shown by 
modelling to be ideal candidates for PrEP, especially in combination with early antiretroviral 
(ART) treatment for HIV-positive people (9–11). In the previous decade, HIV prevalence among 
female sex workers in South Africa was found to be between 46% and 69% (12–14), with 
recent research estimating a prevalence of 72% in the greater Johannesburg area (15).  
 
This paper examines and illustrates how a comprehensive and inductive approach to formative 
research based on grounded theory (16) informed the design and execution of oral PrEP and 
early antiretroviral (ART) interventions for female sex workers in South Africa as part of the 
TAPS (Treatment And Prevention for Sex workers) Demonstration Project. The purpose of TAPS 
was to demonstrate how these two interventions could be implemented among female sex 
workers, and inform national rollout. We explore the approach and process undertaken to 
define and carry out the formative research, describe how the results informed the overall 
design of the oral PrEP and early ART interventions for TAPS, and reflect on challenges and 
successes encountered during the process. 
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3.3.3. Methods 
Formative research can include an array of methods depending on the final desired outcomes. 
For the design of interventions, formative research will include exploring feasibility of 
supportive structures and logistics for physical delivery of the intervention, as well as exploring 
the acceptability among populations  in different contexts (2).  
 
The overall aims of the larger TAPS Demonstration Project were to explore whether FSWs will 
take up early ART or PrEP, whether the service delivery mechanism is capable of handling the 
increase in resource needs that might be required, and what the implications of the 
implementation of these interventions might be, including overall costs should the 
interventions be scaled up (17). TAPS is part of the Wits RHI Sex Worker Programme (SWP), a 
comprehensive health and well-being programme for sex workers running for over 20 years in 
Johannesburg and other provinces in South Africa (18).  
 
While TAPS itself aimed to answer questions of feasibility and acceptability in the actual 
delivery of PrEP and early ART for female sex workers, the formative research began with 
foundational concepts of feasibility and acceptability in order to design interventions which 
could then be evaluated. These concepts addressed questions including: whether there was 
initial support from stakeholders to test the implementation of PrEP and early ART; where 
could the interventions be delivered, how, and by whom; how to engage with female sex 
workers; what was needed to generate demand; what structures should be included to 
support delivery; and how did women conceive of acceptability as users of the interventions?  
 
The formative research was conducted between August 2013 and March 2015. An inductive 
approach was employed based on the principles of grounded theory (16), where lessons 
emerging from the data at each step in the research process dictated decisions and 
subsequent steps. A grounded approach was chosen given the wide original scope required to 
consider a large range of logistical possibilities (e.g. site locations, adherence support 
structures) for the design and implementation of the interventions.  
 
Decision making about which methods, sites, and stakeholders with whom to engage at each 
step was guided by feedback from consultations and discussions. Principles from the Good 
Participatory Practice Guidelines (GPP) developed by UNAIDS and AVAC were also followed, 
promoting multi-level stakeholder engagement as a core component of research (1). In line 
with these guidelines, a range of stakeholders were engaged, including sex workers, sex work 
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related organizations, and the Department of Health (DoH). Community mobilization and 
outreach served to develop awareness around the interventions and generate demand led by 
peer educators who were current sex workers. Site assessments were conducted as part of 
feasibility which included site visits, and took into account findings from the community 
engagement and ‘hot spot’ mapping activities (identifying areas in which multiple sex workers 
operate). Additionally, focus group discussions (FGDs) were held with female sex workers at 
the final selected sites. Since the development of the methods for this process represents 
results in and of themselves, the specifics of how activities were chosen, why, and what was 
learned, are detailed as part of the results.  
 
These activities eventually fell into five core methods: consultations, community engagement 
and mapping in the field, site assessments, participatory development of supportive structures 
and messaging, and FDGs. These methods generated three primary sources of data which 
informed the design of the interventions: 1) recorded minutes and reports of meetings with 
stakeholders; 2) field notes from engaging with sex worker communities and the environments 
within which they work, the process of hotspot mapping, experiences at potential clinic sites, 
and through the development of supportive structures; and, 3) transcripts of FGDs. Outcomes 
included the final design of the intervention incorporating perspectives of stakeholders 
gathered from the data, as well as relevant data collection and monitoring tools and 
supportive structures. These data were collected by a combination of researchers, peer 
educators, and clinical staff.  
 
Data analysis   
Data were continuously collected and analysed based on the inductive approach over 18 
months. Field notes, meeting notes, written reports, and FGD transcripts, were reviewed as 
activities occurred to identify key themes for further exploration and to define next steps, such 
as whether to disqualify a site due to low accessibility of the population or where to spend 
more time on community mobilization, education, and hotspot mapping. Site selection and 
staff recruitment represented the end of the first major phase of formative research. 
Community mobilization was then focused at the selected sites where testing of messaging, 
development of supportive systems, and development and testing of potential data collection 
tools continued led by clinic staff, peer educators, and potential end users.  
 
FGDs were conducted at each of the final selected sites in multiple languages to suit the 
participants and analysed following principles of thematic analysis (19), concentrating on 
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themes originating from the FGD guides and those emerging from the discussions. Further 
details of the methods and results from the FGDs are presented in a companion paper (20). 
 
3.3.4. Results 
Results are presented in five sections according to the chosen methods as products of the 
grounded approach. Sections include how and why methods were chosen and undertaken, and 
lessons learned influencing the design and execution of the interventions.  
 
The five methods were: 1) stakeholder consultations both launching and iteratively 
progressing the research with stakeholder perspectives; 2) community engagement in the field 
with sex workers and the environments within which they work including hotspot mapping 
and experiences at potential clinic sites; 3) site assessments to determine feasibility of 
delivering the interventions in given sites; 4) development of supportive structures to 
encourage retention and intervention adherence; 5) FGDs conducted with potential end-users 
to explore specifics of acceptability. A diagram of the five methods and the timeline during 
which they occurred is shown in Figure 1, illustrating how some activities were continuous and 
others discrete.  
 
Figure 1. The formative research process and timeline to design the PrEP and early ART interventions for 
TAPS. 
 
Abbreviations: ppts = participants; SMS = Short Message System; FGDs = Focus Group Discussions 
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Stakeholder Consultations 
Research began with this activity in order to ascertain stakeholder knowledge of and attitudes 
towards PrEP and early ART, as well as attitudes towards sex workers, which denoted initial 
levels of acceptability for the interventions in this population. We conducted three community 
consultations in 2013 with a total of 81 attendees from sex worker communities and partner 
organizations in Hillbrow and Ngodwana, where a new sex worker clinic was in the initiation 
phase. Additionally, an international consultation of 38 attendees was held in Hillbrow in 2013 
and included representatives from sex work communities and organizations, funders, UNAIDS 
and WHO (21). These consultations allowed for mapping of organizations and individuals to be 
included in future consultations and phases of formative research.  
 
Smaller meetings were held with local DoH representatives in Johannesburg, Mpumalanga, 
Phongolo, and Pretoria to develop partnerships and support agreements for the TAPS project. 
Updates on, and engagement with, the plans for the TAPS interventions continued at quarterly 
and other scheduled meetings with local DoH and partners. Parallel meetings were also held 
with National DoH and the South African National AIDS Council (SANAC).  
 
Feedback from the consultations pointed to varying degrees of support depending on local 
capacity to take on new interventions and scepticism towards the interventions, and 
particularly PrEP. Stakeholders affirmed that implementing PrEP and early ART together would 
promote synergistic delivery, as well as potentially normalise the use of ARVs in providing 
options to both HIV-negative and positive sex workers. However, concerns were voiced about 
adherence to PrEP (and sometimes early ART), as well as the potential for reduction in condom 
use, increases in risk of resistance to ARVs, and burden on scarce resources. These concerns 
indicated where special attention should be focused, such as providing evidence about 
possible resistance to PrEP and strategies for and the philosophy around supporting adherence 
and condom use, both in early messaging and education for sex workers, implementing and 
policy partners, as well as where to focus messaging and monitoring when implementing the 
interventions in TAPS.  
 
Sex workers at each potential site, driven largely by peer educators, helped to identify 
community organizations to engage for additional perspectives. Stakeholder engagement, 
both formal and informal, was tracked using an engagement tracking tool (22) developed by 
the HIV prevention advocacy group, AVAC. According to the data recorded in the tool, at least 
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20 meetings occurred during this time; however it is not possible to definitively quantify all of 
the contact points given that many interactions occurred on an ad hoc basis. 
 
Finally, consultations were also used to identify potential community advisory board (CAB) 
members. Meetings were held with individuals expressing interest in participation to inform 
them about the study and the CAB.  These discussions continued until a CAB with up to 12 
members was established. The CAB incorporated representatives from the local police force, 
sex worker advocacy organizations, sex workers themselves, and religious organizations. The 
CAB became both a result of the formative research and another source of consultation. The 
CAB was also a supportive structure for the interventions as members took it upon themselves 
to help spread knowledge of the interventions and the TAPS project, as well as lobby for 
expansion of the interventions to more sites, populations, and organizations.  
 
Community Engagement and Mapping  
Data were also collected through community mobilization activities, accruing organically in 
scope and number, as discussions and interactions within the communities pointed to 
additional contacts for engagement. Each point of contact presented opportunities for new 
consultations and/or locations to conduct outreach. Feedback from the community about 
potentially adding PrEP and early treatment as new HIV prevention and treatment options was 
collected during peer and clinical staff outreach and workshops, which also aimed to generate 
demand for the interventions in the potential demonstration project site communities. 
 
Outreach is a specific set of activities in the sex worker service delivery field undertaken to 
educate clients about health, promote condom use, and provide a spectrum of services from 
HIV testing and counselling to full clinical services in mobile units in locations accessible to the 
population (23). Staff and peer educators from the SWP, in collaboration with TAPS staff and 
researchers, conducted outreach as a team to probe the local sex worker populations for any 
knowledge or perceptions of PrEP and early ART, as well as start to introduce related 
information. This outreach occurred as part of existing programming consisting of health talks, 
condom distribution, and mobile clinic services, through which we progressively integrated 
education and awareness of PrEP and early ART. As a core feature of the SWP, interventions 
were designed around outreach which was identified as a central aspect critical to generating 
demand and recruiting participants for TAPS. Through this activity, we noted working hours 
and environmental contexts, created hot spot maps to focus recruitment efforts, and learned 
about community perspectives of PrEP and early ART.  
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Feedback collected during outreach  in the form of field notes provided contextual information 
as to where and how sex workers operated and how they interacted with health services, 
informing viability of given sites. Cursory understanding of the interventions and how they 
might be taken up and used, determined which supportive structures would be needed and 
how messages would have to define the differences between PrEP and early ART. These 
outcomes are described in further sections.   
 
Site assessments and selection 
Assessments were conducted in five sites, after eliminating other sites spanning multiple 
provinces in the Wits RHI SWP. The five sites featured existing SWP clinics already delivering 
ARVs per national guidelines or sites with plans to implement new clinics, interest and support 
from the local communities, and potential access to a large group of FSWs in areas where HIV 
prevalence was high. This information came from the initial consultations and community 
engagement and mapping, as well as internal programme data. The five sites were: Ngodwana 
(rural village in Mpumalanga province), Phongolo (rural trucking site in KwaZulu Natal 
province), Hillbrow (central, inner-city Johannesburg), City Deep (peri-urban trucking site 
immediately south of Johannesburg), and the Pretoria central business district (CBD), the latter 
three of which were located in Gauteng province. 
 
Narrowing the site selection was a critical step in moving forward with the design of the 
interventions. We aimed to select 2-3 sites (according to funding and capacity for oversight) 
with the following population criteria: access to a large number of FSWs (>200 according to 
early sample size calculations (17)), populations with a relatively balanced proportion of HIV-
negative and HIV-positive women, and accessibility of clinics. Physical feasibility of the clinics 
to implement the interventions was assessed through reviews of space, clinical and laboratory 
infrastructure, required site permissions and approvals, and supply chain mechanisms. Support 
for the interventions was explored with local DoH and sex worker communities, as well as 
identification of logistical gaps. Site visits, hot spot mapping, and site assessments were 
conducted to determine the feasibility of delivering PrEP and early ART in each of the five sites.  
 
Hot spot mapping was conducted to determine the number of FSWs working near the 
potential study sites as well as their working hours. The methods utilized and built on the 
results produced by the South African Health Monitoring Study (SAHMS), which drew on 
multiple mapping methods including time-location and the “wisdom-of-crowds” (15). This 
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activity in combination with prior experience derived through the SWP, revealed that time and 
location of sex work is driven by client availability. Peak working hours were recorded in each 
site as critical data dictating when women could be free to attend the clinics. Local languages 
at each site were also documented so that study materials could be translated and appropriate 
staff hired.   
 
Following the site assessments, three sites were eliminated. Ngodwana was eliminated due to 
lack of infrastructure and building delays, as well as lack of local support. Although there was 
initial interest, the implementation of the interventions potentially conflicted with limited 
resources and competing priorities in the area. The rural sex worker community in that 
location do not self-identify as sex workers which would have created challenges in being able 
to compare formal sex workers who self-identify and those who do not as part of project 
evaluation. The prevalence of HIV in Ngodwana was estimated locally to be around 75-80% in a 
relatively small village of <300 people mostly made up of sex workers, which also would have 
made it difficult to implement PrEP.  
 
City Deep was eliminated due to low clinic attendance, as well as the highly transient nature of 
the sex worker populations. Most of the women attending that clinic in arrived in the trucks 
coming from all over South Africa as well as neighbouring countries, which would have made 
commitment to regular, repeat clinic visits difficult. The Phongolo site, located next to the 
Swaziland border, was also eliminated as women tended to move in and out of the town and 
were away for as many as three to four months at a time.  
 
Two sites were finally selected: Hillbrow and Pretoria. Hillbrow was chosen because of the 
long-standing Wits RHI sex worker clinic which maintains strong ties to a large community of 
sex workers and their managers (brothel owners, ‘pimps’). At the time, HIV prevalence was 
estimated locally at around 50%. The clinic is situated in an area with a high concentration of 
brothels and street based locations within walking distance, but also with a number of 
surrounding outreach areas in the Johannesburg CBD, Yeoville, Jeppe, and Rosettenville. For 
these reasons, this site was considered “low-hanging fruit” for new intervention 
implementation, due to the substantial population of women at risk of HIV infection and as a 
location with solid community support.  
 
In Pretoria, tailored sex worker services and relationships with the community were new at the 
Sediba Hope clinic in the heart of the CBD, however there was strong support from the local 
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DoH and expressed need from the sex workers themselves. The newness of such interventions 
in the area posed a challenge as to whether PrEP and early ART could be implemented within a 
new sex worker clinic in a new setting, and what it would take to do so. 
 
After final site selection, further identifying and understanding the contexts in which the 
women worked and lived, as well as their perspectives of those environments, was explored 
through more intensive outreach and community engagement to determine, on a granular 
level, how the interventions could fit into their lives. Through the existing, long-term work of 
the SWP, there was awareness of different types of sex work locales, however the formative 
research allowed for a deeper understanding of how these locales affected women’s lives, and 
how they might affect their ability to take up and use the interventions.  
 
We assumed three general categories of sex work locales within the two urban settings. 
Brothels or hotels usually offer alcohol and entertainment, including combinations of music, 
dancing, and bar games. Many are former or existing hotels while others are simply bars with 
backrooms. Security protecting sex workers from violent clients is common in these 
establishments. Secondly, street-based sex work occurs in high traffic areas where sex workers 
pick up clients, and either join them in vehicles or have sex in a nearby location such as an 
alley. The third category comprises the “dark places” (IsiZulu: mnyamandawo), informal 
locations in empty lots or other uninhabited/unoccupied buildings or areas where sex workers 
build rudimentary structures in which to work.  
 
In both cities there is also a fourth, more hidden sex work market found online. Awareness of 
the online market was generated through conversations with sex workers during outreach and 
through peer educators, some of whom had online pages and knew of others with similar 
arrangements. Sex work conducted online usually involves regular clients met through a web-
based connection, where business is conducted out of private spaces (personal homes, private 
spaces run by an owner, upscale hotels or clubs). This population was engaged later in the 
process as they are less visible to implementers and researchers, and difficult to build 
relationships with given their desire for anonymity.  
 
The different types of locales dictated how outreach needed to be conducted in order to 
generate demand for the interventions. In brothels it was possible to hold group health talks in 
spaces lent by women or brothel managers, but engaging with women on the street or dark 
places required time to build trust and a certain level of discretion to avoid unwanted 
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attention. Careful planning around space needs (setting up a rented or borrowed space for sex 
workers based on the street, or bringing a mobile clinic) was also necessary in these locales. 
Similarly, it was not possible to go to a place of work to conduct health talks and recruitment 
for participants identified online, rather relationships were developed with one or two women 
who could act as advocates for the interventions within their community.  
 
The different risks and benefits for sex workers in each locale type were important to take into 
account. In brothels, women are protected by managers, staff, and security. On the street and 
“dark places” there is little or no security, unless organised by a pimp or a gang. Stories of 
violence and rape were commonly recorded throughout the formative work. Women reported 
violent interactions with clients, managers, community members, and often the police. These 
interactions highlighted the need for supportive referral structures, including for mental 
health, serious injuries, and criminal issues.  
 
Earning ability, directly associated with the type of sex work locale, was identified as an 
important aspect of being able to take time off to come to the clinic even for short periods of 
time. Sex workers operating in brothels tend to be able to charge higher rates for sex, usually 
between R50 and R150 (about 3-10 USD), depending on the status of the brothel and the cost 
of room rental incurred by the sex workers. On the street, rates are around R50, and in a dark 
place sex can be R20-30 (about 1.30-2 USD). Making less money meant more difficulty in 
taking time away from work to attend the clinic for regular PrEP or treatment related 
appointments.  
 
Development of supportive structures and messaging 
During consultations, a number of stakeholders provided views on possible components to be 
incorporated in the intervention design, in particular supportive structures. Mechanisms for 
supporting intervention adherence and retention in care were explored, however we decided 
only to consider those which could also be incorporated into a national programme. Among 
the possibilities were the use of MEMS caps (electronic bottle caps which would count bottle 
openings as a proxy for pill withdrawals and thus, adherence), pill counts (as conducted in 
clinical trials), and mHealth solutions in the form of short message service (SMS) messages. 
After discussing options with DoH partners, it was concluded that SMS as demonstrated by the 
ongoing MAMA Connect project (24), could be scaled up in a national programme, whereas 
other options would not be feasible.  
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A participatory process led by representatives of RHI’s mHealth and Mental Health teams was 
undertaken through a series of workshops where themes around healthy living were 
developed followed by relevant SMS messages by peer educators. Both male and female sex 
worker peer educators worked in groups to create the messages which aimed to encourage 
healthy choices and wellness. These messages took into account the importance of avoiding 
inadvertent disclosure of HIV status to non-participants, and could still be used by the SWP 
after TAPS concluded. This process produced 110 SMS messages which would be sent once a 
week in succession to all participants who signed up for the service. 
 
Experiences from early outreach activities directly influenced the messaging employed in each 
location, as well as educational materials used as part of supportive structures for generating 
demand and promoting awareness of the interventions. Messages focused on defining the 
interventions, addressing common myths and concerns around side effects, and providing 
information on efficacy and access.  
 
Peer educator and potential user feedback indicated that personal testimonies are highly 
valued by women in both locations, so these were included on the informational pamphlets. 
Trained peer educators also enrolled in the study were invited to become ambassadors for the 
interventions so that they could directly relate their experiences and dispel rumours about side 
effects. 
 
Finally, additional supportive structures for the interventions and the women using them 
included the CAB, as well as tried and tested referral systems where we could ensure women 
would get additional support beyond the scope of our clinics as needed. One result of the 
consultations, as well, was the need for holistic sensitivity training around sex work which was 
conducted with every staff member, from cleaner to clinician, at both sites. Although a more 
passive support mechanism provided by a local community partner organisation, this was 
important in ensuring women felt welcome at the clinics. 
 
Focus Group Discussions 
FGDs were conducted in the Hillbrow and Pretoria CBD sites following site selection as the final 
set of activities in the formative research process. The FGDs aimed to test the core 
intervention design components for acceptability among potential users within the target 
communities. Four FGDs were held in each site with a total of 69 participants. The FGDs 
comprised important final steps in informing design as they explored a more focused 
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community perspective of intervention acceptability on two main levels. One level consisted of 
data concerning logistics and preferences around physical delivery (location, preferred clinic 
times, frequency of visits and HIV testing), while the other level included social and structural 
level data where elements of stigma and socioeconomic norms (e.g. where the need for 
income might supersede health) that might affect uptake and use of PrEP and early ART were 
explored. Since this paper is focused on feasibility and early stages of acceptability, the end-
stage formative data from the FGDs are presented in a companion paper (25).  
 
3.3.5. Discussion 
In this paper, we have described in detail the formative research process and findings used to 
inform the design of the PrEP and early ART interventions implemented in TAPS. The inductive 
approach afforded a breadth of information around potential site locations, community and 
stakeholder perspectives, including potential barriers to successful implementation, and 
nuanced aspects of the urban sex work settings for considering how to ensure the 
interventions accomplished reach, accessibility, acceptability, and filled the needs of potential 
end-users. This process allowed for rapid and relevant consolidation of lessons learned to 
inform adaptations to the planned interventions.   
 
Feasibility played a significant role in early decision making as to whether PrEP and early ART 
could be implemented, and acceptability from stakeholders ran in parallel. Questions of 
feasibility addressed site capacity, experience in delivering ARVs, experience with and access 
to FSWs, site locations related to FSW populations, and existing supply chains. Early 
acceptability was determined through consultations and engagement with potential end users 
in the community during outreach. Factors influencing feasibility and acceptability would not 
have been as comprehensively understood, such as the day to day clinic operation and the 
physical contexts and locales of sex work, without repeated site visits and time spent in the 
field. Continuous, in-depth interactions with the women themselves allowed the TAPS team to 
better understand sex workers’ needs in addition to how interventions reach could be 
maximized. Additionally, identifying and addressing potential biases from providers and other 
stakeholders in the provision of the interventions was essential to avoid issues with 
maintaining permissions and supply chains as well as supportive services.  
 
Generally, it would be expected that sex work populations and industries, with similar urban 
contexts and in relative geographical proximity, would be the same in both places and that 
interventions could be implemented uniformly in both locations. However, the formative 
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research demonstrated just the opposite. While there were some similarities in how women 
live and work in terms of the types of locales and spaces, there were also significant 
differences. Sex work locales can be similarly categorised in the two cities, but the organization 
of these spaces and the make-up of them within Hillbrow and Pretoria is quite different in 
terms of women’s personal safety and earning capability, for example. This translates into 
different sex worker populations and market dynamics and the need for adaptations to 
intervention design. Outreach strategies (groups versus one on one discussions) and 
messaging channels (word of mouth, top down through brothel owners and pimps, or 
developing online contacts) were dictated directly by context and the expressed needs of the 
FSWs.  
 
The formative research created awareness for the TAPS team around which stakeholders 
needed to be involved and engaged throughout the duration of the project, either through the 
CAB or in regular consultations, as well as the contexts in which women worked and lived and 
the need to be sensitive around FSW engagement to generate demand for PrEP and early 
treatment. Without the formative research, we would not have understood the importance of 
some messages over others from the perspectives of sex workers, the dynamics of sex work 
locales and their effects on risk and income, nor how flexibility around clinic visit scheduling 
would need to be taken into account. 
 
3.3.6. Conclusions 
The lessons learned from this formative research process were directly applied to the design 
and implementation of the PrEP and early ART interventions delivered through the TAPS 
project. The inductive approach afforded the opportunity to adapt and include voices and 
perspectives, which might have otherwise been missed, and clarified the needs of the 
population as well as how to reach them appropriately. This research illustrated how sex work 
environments can vary, even when the settings are very similar, and therefore implementation 
of interventions is unlikely to be uniform across contexts. Formative research is critical in 
designing interventions, especially in new environments but also in well-known contexts. 
Including intensive stakeholder engagement in formative research will help to ensure that 
interventions are designed with feasibility and relevance for populations in mind.  
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4.0  Chapter 4: FSW community perspectives on the impending 
implementation of PrEP in their local sex worker clinics 
 
4.1. Introduction 
Chapter 4 addresses the research question associated with PhD Objective 3: What are the 
community-level perceptions of PrEP in terms of acceptability within the context of imminent 
implementation among FSWs in South Africa? Following the practical learning and decision 
making around intervention design during the formative research presented in Chapter 3, in-
depth focus group discussions (FGDs) were undertaken to gain insight into the perspectives of 
women on the uptake and use of both PrEP and early ART immediately before the launch of 
implementation through the TAPS Demonstration Project. The paper in this chapter focuses 
only on the FSW perspectives on PrEP, however, given that it was relatively unknown in this 
context as compared with early ART. Perspectives of both HIV-negative and HIV-positive 
women, who were combined in the groups, were included to illustrate some of the overlap in 
thinking and how inclusive research, implementation and related messaging may better 
support delivery of new interventions.  
 
Overall, there was significant positivity around PrEP among the women in the groups, and 
excitement about both PrEP and early ART led them to leave their names on waiting lists to be 
called when TAPS officially launched. In this way, these groups served as an additional means 
for early community engagement and education around both interventions where the women 
who participated in the FGDs could take information back to their friends and colleagues to 
help spark interest in the interventions.  
 
This work builds on the previous chapter’s research which focused heavily on ensuring the 
applicability of the PrEP intervention was aligned with the needs of FSWs in the chosen sites 
and contexts. The FGDs then allowed for a narrower focus on the concentrated community 
perceptions of applicability and acceptability of PrEP (and early ART) as it was to be delivered 
to them through these local sex worker clinics. These insights helped to situate the impending 
implementation within the spheres illustrated in the MSEM framework from the community 
perspective, which is inherently made up of individuals and their experiences, as well as 
interactions across the social, community, policy, and epidemic domains.  
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This paper is under review at the Journal of the International AIDS Society, and is one of the 
first to report FSW perspectives of impending PrEP implementation. It is important to note 
that these FGDs produced an incredibly rich set of data and at least one further paper is 
planned to combine FSW views on PrEP and early ART within the context of health service 
delivery.  
 
The information and consent forms as well as the FGD guide are attached in Appendices vii and 
viii. 
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4.2.1. Abstract 
Background 
Female sex workers (FSWs) are at high-risk for HIV acquisition in South Africa, where the 
advent of new HIV prevention and treatment interventions represent the potential to 
significantly impact the epidemic. This paper focuses on aspects of PrEP acceptability as a new 
intervention within the context of a larger service delivery programme including the 
simultaneous roll-out of early ART. This paper explores PrEP acceptability among the FGD 
participants as future potential users. 
 
Methods 
FGDs were conducted in two clinic-based sites in Johannesburg and Pretoria. They aimed to 
explore community-level, multi-dimensional acceptability of PrEP within the context of 
imminent implementation alongside early ART in the TAPS Demonstration Project. Sex worker 
peer educators recruited participants from varying sex work locales. Facilitation was in English 
with adaptation by facilitators into local languages as needed. Transcripts were translated and 
transcribed into English. Thematic analysis was used to analyse the data.   
 
Results 
Four FGDs were conducted in each site for a total of eight FDGs and 69 participants. 
Demographics were largely similar across the sites. Overall, there was strong acceptability of 
PrEP among participants and positive anticipation for the imminent delivery of PrEP in the local 
sex worker clinics. Themes arising from the discussions exploring aspects of PrEP acceptability 
included: awareness and understanding of PrEP; PrEP motivations including choice, control, 
and vulnerability, managing PrEP risks and worries; and, de-stigmatising and empowering PrEP 
delivery. Participant discussions and recommendations highlighted the importance of 
developing clear education and messaging to accurately convey the concept of PrEP, and 
intervention integration into supportive and tailored services. 
 
Conclusions 
Through the course of these FGDs, PrEP became a positive and highly anticipated prevention 
option among the FSWs participants who endorsed implementation in their communities. 
Effective integration of PrEP into existing services will include comprehensive health 
programming where ART is also available, appropriate messaging, and support.   
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4.2.2. Introduction 
Female sex workers (FSWs) are at high-risk for HIV acquisition in South Africa, with a recent 
study reporting a prevalence of 72% in the greater Johannesburg area, and 40% and 54% in 
Cape Town and Durban respectively (1). The advent and success in clinical trials of oral pre-
exposure prophylaxis (PrEP) for HIV prevention (2), and test and treat (also ‘early ART’) for HIV 
treatment (3,4), represent the potential to significantly impact the epidemic. As a result, these 
two interventions have become part of the standard of care set out by the World Health 
Organization (WHO) in 2015 (5). 
 
As countries move towards implementation and scale-up, formative research on the feasibility 
and acceptability of integrating PrEP and test and treat into local and national programmes is 
progressing, in particular for target populations (6). However, little has yet been published in 
low and middle-income country settings about community perspectives on the acceptability 
these interventions in a context where they are soon to be implemented. The acceptability of, 
and willingness to engage with, an intervention is central to its development, roll-out and 
scale-up, and understanding how it is may be perceived by target populations can help counter 
or mitigate unintended consequences or potential barriers (7,8).  
 
Dimensions of acceptability contributing to successful uptake and use can include personal 
preferences around ease of use and product attributes; social factors including stigma from 
partners, family, and friends, and social norms; interactions with medical facilities and service 
delivery mechanisms; the policy and regulatory landscape; and the context of the HIV epidemic 
itself (9,10). Some of these elements were explored in previous PrEP and vaginal microbicide 
efficacy trials, though they more often focused on product attributes (11). Following these 
qualitative findings, however, a holistic, multi-dimensional approach to acceptability was 
considered to be critical to promote effective use during scale-up (12).   
 
Given that the transition to PrEP implementation is recent, the multiple dimensions of 
acceptability are yet to be fully understood as drug-based prevention is unfamiliar to the wider 
public. Additionally, service providers’ experience with rolling out ART programmes, and the 
delivery of contraception to prevent unwanted pregnancies, could provide a basis for 
understanding PrEP where services would be similar, but motivations to take the medication 
would differ in prevention versus treatment. 
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In this paper, we present findings from focus group discussions (FGDs) that sought to inform 
the design of oral PrEP and (then called) early ART interventions for FSWs in Johannesburg and 
Pretoria for implementation in the Treatment And Prevention for Sex workers (TAPS) 
Demonstration Project. The findings presented here arose in the context of impending PrEP 
provision, where at the time of data collection, the role and potential of PrEP had not yet been 
normalised by government guidelines and national regulatory approval. This paper focuses on 
aspects of PrEP acceptability as a new intervention within the context of a larger service 
delivery programme including the simultaneous roll-out of early ART. The aim of this paper is 
to explore PrEP acceptability among the FGD participants as future potential users.  
 
4.2.3. Methods 
FGDs were conducted in two clinic-based settings in Johannesburg and Pretoria between July 
and December 2014. They aimed to explore community-level acceptability of PrEP and early 
ART interventions with a view to learn how this could influence uptake and use in TAPS. A 
holistic, multi-dimensional approach to acceptability was employed, including perspectives 
from both HIV-negative and HIV-positive women on both interventions.  
 
Initial topics for discussion were developed based on the results of an adapted meta-
ethnography of women’s experiences of uptake and use of biomedical HIV prevention 
products across sub-Saharan Africa (9,13), as well as the Modified Social Ecological Model 
(MSEM) designed by Baral et al (14). Discussions encouraged community-level narratives of 
women’s lives and experiences with their work and health services; perceptions of optimal 
prevention and treatment delivery; knowledge, attitudes, and perceptions of health and well-
being, and of PrEP and early ART specifically; acceptability of and commitment to increased, 
frequent clinical monitoring and HIV testing; and identifying overall motivations and barriers to 
accessing services, and in particular, PrEP as the newest intervention.  
 
Sex worker peer educators recruited women through their work/social networks from varying 
sex work locales (brothels, streets, and other informal areas) aiming to gather diverse 
perspectives from different working and living environments. Discussions were facilitated 
primarily in English with adaptation by facilitators and staff note takers into local languages as 
needed. FGDs lasted between one and a half and two hours. 
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Analysis 
Transcripts for each of the FGDs were translated and transcribed into English, then uploaded 
into NVIVO (version 10.0, Burlington MA). Analysis followed principles of Braun and Clarke’s 
thematic analysis (15) beginning with a set of questions building from themes derived from the 
discussion guide based on the MSEM but we remained open to new lines of enquiry as they 
emerged from the data in an inductive manner. The coding framework was devised by the 
primary author with support from two other researchers, and all transcripts were coded in 
duplicate by two researchers. Inter-coder reliability was not a focus of the analysis, rather 
coding choices were discussed throughout and at the end of the coding process to resolve any 
differences. 
 
Ethical Considerations 
All participants provided their informed consent and pseudonyms to protect identities, 
indicated in this paper as colours. This study was reviewed and approved by the Wits Human 
Research Ethics Committee (reference number: M131009).  
 
4.2.4. Results 
Participant Demographics 
Four FGDs were conducted in each site for a total of eight FDGs and 69 participants. Key 
demographic characteristics are displayed in Table 1.  
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Table 1. Demographic characteristics of FGD participants.  
 
 
Participants were not asked to disclose their HIV status, however most participants did so of 
their own volition during the discussions. From their disclosures we estimate about 50-75% of 
the participants were HIV-positive, which is similar to the estimated prevalence in the greater 
Johannesburg area (1), and to what was observed in Pretoria during outreach and HIV testing 
during formative work.  
 
While there was relative diversity among the FGD participants, themes arising from the 
discussions did not differ across the groups. To qualitatively assess overall aspects of PrEP 
acceptability, we review the thematic findings here in terms of: awareness and understanding 
of PrEP; PrEP motivations including choice, control, and vulnerability, managing PrEP risks and 
worries; and, de-stigmatising and empowering PrEP delivery. Quotes from participants are 
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labelled with their chosen colour pseudonyms, abbreviation of site location 
(JHB=Johannesburg; PTA= Pretoria), and FGD number.  
Awareness and understanding of PrEP 
Prior awareness of PrEP was explored within the context of existing or known HIV prevention 
options. Most of the discussion centred on male and female condoms, however some women 
acknowledged male circumcision and prevention of mother to child transmission (PMTCT), and 
some had heard of, or participated in, studies involving the vaginal gel and ring. Aside from 
condoms, post-exposure prophylaxis (PEP) was most often discussed, along with STI 
treatments and/or the morning after pill for unwanted pregnancies. “If you do sleep with a 
client and a condom gets broken …. everybody decides to drink that pill. But it’s just for 
cleaning, we know it doesn’t prevent HIV” (Brown, PTA 3). Considering PrEP within the context 
of other previously known options, or lack thereof, allowed women to recognise and interpret 
PrEP as a potential choice for prevention. 
 
Prior to a detailed description of PrEP within the FGDs, awareness was low. Initial 
understanding of PrEP was usually reached by equating it with contraception. “Okay meaning 
that people who are going to take this tablet they must be very careful because a pill for 
preventing, it’s very risky, because once you forget …. like on birth control pills, it’s very risky 
….” (Red, PTA 4). Alternatively, the concept of PrEP was further assimilated through prior 
knowledge and experience with HIV testing and ART. 
 
Questions relating to awareness and understanding of PrEP frequently resulted in discussions 
about what type of woman could and should use PrEP, or who would make a “good PrEP 
taker”. There was universal understanding of motivations to take PrEP for HIV-negative 
women, however it was the need for a certain degree of commitment which the participants 
focused on: 
 
“She has to take care for herself …., so she must behave like a person who prevents 
when she is avoiding to fall pregnant. But she shouldn’t be like when someone prevents 
and they skip a pill and they would say ‘aggh even if I forgot to take my pill nothing will 
happen to me’. So with PrEP she must continue using it every day” (Green, PTA 4).  
 
PrEP motivations: choice, control, and vulnerability 
An awareness of the high prevalence of HIV among FSWs in their communities underscored 
the need for more prevention options to safeguard those who were still HIV-negative. “The 
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methods are very limited. …. The only method that we know so far is to use a condom, and.... it 
can burst anytime” (Brown, JHB 1). 
 
These sentiments laid the groundwork for seemingly universal approval and anticipation of 
PrEP, which FGD facilitators indicated would be imminently offered in the clinics in their 
locality:  
“People are dying outside of HIV. And HIV is spreading so fast …. At least people who 
are still negative will have a chance to stay negative…. So the spreading of HIV will get 
limited. Then as time goes by the HIV rate will go down …. I don’t want my daughter to 
go through what I am going through now.” (Brown, JHB 1).  
 
All of the women immediately saw the benefit of having PrEP in the body, especially given that 
condoms often burst or were removed. “PrEP is good because it’s good because it stays in your 
blood” (Red, PTA 3). As sex workers, participants reported how they frequently found 
themselves in vulnerable positions with clients, which could be hard to anticipate or plan for. 
In such circumstances, PrEP could be invaluable in protecting women from HIV where they 
would have personal control over one method of protection. “Even with a client in your own 
house, they can throw away the condom, strangle you and leave you helpless because you do 
not want to use a condom. And do as they please with you” (Purple, JHB1). 
 
Experiences of sexual violence were frequently reported (unprompted) within groups, and 
were seen as particularly motivating for PrEP uptake and use. “Another thing, as a sex worker, 
there is no one here who say they not been gilwa (treated badly). Maybe they even, some of us 
we have even been ganged raped. So I believe we have to test continuously, time and again” 
(Brown, JHB 1).  
 
Finally, in their own recognition that the primary HIV risk for FSWs came from their main 
partners rather than clients, many participants reflected on the utility of PrEP in protecting 
them in the likely event that their partner was also having sex with other women:  
 
“Even if she says, that boyfriend, she loves him, there are many hotels. He doesn’t have 
her only. The other hotels there are many he’s got another girlfriend, the other hotel, 
he’s got another. And he’s been sleeping with them without that condom” (Red, JHB1).  
 
Such sentiment informed a belief expressed by many that PrEP should be made available to all 
women, rather than just FSWs. “Yes I also agree with them that the entire woman should use 
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PrEP who are HIV-negative because again they also don’t know who their husbands are 
sleeping with” (Brown, PTA, 4). 
 
 
Managing PrEP risks and worries 
While the potential to reduce HIV transmission was keenly recognised and appreciated, 
women were also acutely aware of a range of other risks in their sexual, social and personal 
environments that might influence their willingness to use PrEP. These would, they felt, 
require careful consideration and management. 
 
A primary concern related to the potential discontinuation of condom use in the context of 
PrEP, and the implications of this for acquisition of other sexually transmitted infections (STIs) 
or unwanted pregnancies:  
 
“But what I think, neh, if they are going to use these PrEP pills they have to teach 
people well, that they must use condoms. Make them to be aware of what is going to 
happen because of, if they say ok you can keep on drinking these pills they will start 
forgetting to use condoms and start to sleep around without. That’s why they’re 
scared, that many teenagers of South Africa, they will have plenty of babies” (Red, JHB 
1).  
 
All of the women agreed that PrEP could not take the place of condoms, and that the two 
should go together in order to prevent other STIs and unwanted pregnancies, especially since 
most of the women acknowledged not using other modes of contraception. This perception 
reflected a general sense that PrEP would serve as useful backup when condoms failed, rather 
than being seen as the primary prevention strategy. 
 
The risk of potential non-adherence, and thus diminished PrEP effectiveness, was commonly 
expressed. Many participants felt that some women may not be sufficiently motivated to take 
a pill every day, especially when they were not feeling unwell. This experience was reflected by 
some in the group who disclosed their HIV-positive status:  
 
“It’s difficult to support somebody who’s not sick and say she must take medication 
especially every day. At the clinic they will always check and tell you that your viral load 
is high, but you will tell yourself that there is no need to take that medication, rather 
take drugs and you will be ok” (Brown,  PTA 3).  
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Additional worries around adherence included substance use (alcohol and illicit drugs) and the 
potential for forgetting to take a daily pill. “…. those who are using drugs, they won’t be able to 
take PrEP every day because they will forget under the influence of drugs” (Brown, PTA, 3). 
However, there was also discussion about how lessons learned in ART adherence among HIV-
positive women could help improve adherence among those taking PrEP, such as aligning pill 
taking with television shows, using phone alarms, and coming up with strategies to keep pills 
on hand such as in secret bra compartments.  
 
Importantly, the discussion of substance use raised questions about whether PrEP could be 
taken even when someone knew they would be drinking or using other substances during the 
course of the day. “So this PrEP it’s not for HIV-positive, so I want to ask something, is there 
somewhere where it says don’t smoke, don’t drink ….?” (Grey, PTA 4). Explaining that using 
alcohol or other drugs would not diminish the preventive effects of PrEP was met with 
approval from the participants.  
 
The perception of potential side effects, especially given knowledge of ART side effects from 
existing drugs on the market, was seen as a likely major barrier to uptake: 
 
“Yes, maybe they will come for counselling first before they take the PrEP right, and 
then they tell them about the side effects and then a person gets scared of it and say, 
my goodness no, you know what these side effects are going to do to me, ‘they will 
make me sick, they will make me throw up, I will die’ you see that kind of thing, or you 
will be paining” (Red, JHB 4).  
 
Interestingly, as a result, participants felt it would be important to ensure clear messaging 
around potential side effects and their duration was central to in the promotion of PrEP. 
 
Perhaps less common were concerns that focused more on logistical and social aspects outside 
of the women’s control, such as the pills being stolen outside clinics:  
 
“They know that this one has come to fetch her pills, they steal them from you, you get 
hurt. They know that they are going to use the pills as drugs. You know that you will be 
mugged, they hold you up they stab you, what do you do? You are now not killed 
because of your AIDS but for your pills” (Purple, JHB 1).  
 
De-stigmatising and empowering PrEP delivery 
The need for supportive, non-judgmental services tailored to sex workers was universally 
stated. “It is right that such a clinic is there. …. having such a clinic will make people not shy to 
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go to the clinic. They can speak freely, because the clinic is ours” (Black, JHB 4). Indeed, positive 
interactions in the clinic would motivate women to return: “….when a clinic treats you well, 
you return to it, but if they don’t treat you properly you don’t return” (Red, JHB 2). Including 
PrEP as part of this type of service delivery environment was considered paramount to 
successful implementation.  
 
Additionally, having PrEP offered alongside early ART was considered important in 
destigmatizing interventions. Stress and panic, especially in environments where HIV 
prevalence was so high, was widespread, therefore many of the women felt that PrEP 
presented an opportunity to “de-stress”. HIV-negative women felt that with PrEP becoming 
positive wasn’t necessarily inevitable, and HIV-positives felt that having additional protection 
in the community might result in fewer infections.  
 
The need for social support, often initially voiced by women with ART experiences, was 
identified universally as a valued component of pill-taking and a way to help ensure 
commitment:  
 
“If you get somebody who supports you in what you are doing it’s much more easier for 
you to continue than when they don’t have anybody next to you. Like a person like my 
sister is my biggest supporter. Immediately when I found out I am positive that’s the 
first person I told.” (Purple, JHB 1).  
 
Finally, flexibility in service delivery was underscored as critical for a successful PrEP 
intervention. This stemmed from not having much time to go to the clinic due to having to 
work long hours to pay rent, as well as having become habituated to mobile services in the 
case of the Johannesburg groups:  
 
“I don’t pay rent. I do business to feed myself. The other’s on the streets they are 
staying in flats .… they need [money] for rent that’s why they work the whole night. So 
we are different in that, you who is staying in a hotel, you don’t have time to come to 
clinic, you are waiting for a mobile clinic to come, you understand?” (Green, JHB 1). 
 
4.2.5. Discussion 
Our findings indicate strong acceptability of PrEP among FSWs in the two communities and 
positive anticipation for the imminent delivery of PrEP in the local sex worker clinics. FGD 
participants in turn provided useful insights into how uptake and use could be ensured by this 
most-at-risk population in South Africa. These centred on developing clear education and 
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messaging to accurately convey the concept of PrEP, and intervention integration into 
supportive and tailored services.  
 
Fitting PrEP within existing knowledge of ART and PEP, while equating it with contraception as 
a prevention modality, was an effective and naturally developed education strategy among 
participants. Indeed, this has also been true among researchers (16). In addition, experiences 
with early ART or PEP can translate to PrEP, such as taking medication every day even while 
feeling well. Discussions in these FGDs suggested that HIV-negative and positive women could 
represent valuable support systems, a strategy which was successfully used in another study in 
Zimbabwe (17), and may prove useful for normalizing and implementing the two interventions 
in scale-up. 
 
There is limited previously published qualitative research regarding PrEP acceptability 
specifically among FSWs in sub-Saharan Africa. Most microbicide trials targeted women at high 
risk, which included but did not focus on sex workers (18–22), aside from some of the 
nonoxynol-9 vaginal gel studies (23,24). One study on intermittent PrEP in Kenya included men 
who have sex with men (MSM) and FSWs (25), however, only five FSWs were included and 
results were not disaggregated. Lenses into PrEP acceptability among sex workers have been 
made available through research with people who use drugs, such as one Canadian study 
which found that engaging in sex work was in itself a motivation to take up PrEP (26). While 
limited in scope, findings from these studies, have pointed to values and perspectives around 
PrEP particular to FSWs’ work and roles as women. This also manifested in this study where 
the key motivation for use was having an additional layer of protection, and personal control, 
to safeguard against the unpredictable, such as sexual violence at work or lack of condom use 
with main partners having an unknown status with whom condom use was seen as untrusting 
or unloving. These dimensions are different than what has been articulated by MSM who have 
been more concerned with (lack of) accurate risk perception and stigma within their social 
circles (27), suggesting the need to carefully consider differences in population perspectives 
when planning to rollout PrEP.  
 
Of particular note were the participants’ worries and concerns in our study about the broader 
effects of PrEP and potential for misuse and misinterpretation. Their recognition, combined 
with the same awareness among other current and existing users in other parts of the world 
(27–29), should come as a reassurance to those with apprehensions that the introduction of 
PrEP could be mismanaged leading to declines in condom use (30).  
152 
 
 
Finally, data from our study suggest that normalisation may be an important factor when 
considering PrEP roll-out. There was overall agreement that all women, and even men, should 
have access to PrEP, and that PrEP should be combined with early ART in the same clinic. The 
notion of stress around HIV infection was a strong recurring theme, relating to individual 
disease burden as well as stigma, where a strategy around normalization of both PrEP and 
early ART could play an important role. The articulation of the stress of HIV and stigmatization 
of pill taking, points as well to the need to include HIV-positive individuals in the discussion, to 
garner their perspectives and longer-term commitment to pill taking.  
 
The main limitation in this research is the snowball sampling used to recruit participants which 
may have resulted in enrolment of more informed or vocal women and/or women who have 
been continuously involved in sex worker programme outreach activities. However, this was 
less the case in Pretoria where services had not previously existed. Additionally, the FGDs 
included only FSWs and took place only in two urban areas, which may limit generalizability to 
other populations and contexts. The theoretical nature of the FGDs, where actual use was 
imminent but not yet in place, may not translate into subsequent uptake of PrEP.  
 
4.2.6. Conclusion 
Through the course of these FGDs, PrEP became a positive and highly anticipated prevention 
option among the FSWs participants who endorsed implementation in their communities. 
Participants shared important insights and interpretations of acceptability for consideration in 
implementation. Integrating PrEP into existing services as part of a comprehensive health 
programme where ART is also available, was seen as a best practice, as long as attention is 
paid to ensuring the appropriate messaging and support are included.   
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5.0  Chapter 5: Who used PrEP in the TAPS Demonstration Project?  
 
5.1. Introduction 
Chapter 5 addresses the research question associated with PhD Objective 4: What are key 
characteristics of FSWs who take up and use PrEP? This was an important question to address 
in order to develop a picture of the women taking up PrEP, beyond their personal stories and 
qualitative perspectives which will be presented in Chapter 6. The aim of examining 
characteristics was to describe women who wanted, and were clearly motivated, to take up 
PrEP. These data are relevant both to the applicability and acceptability of PrEP as they 
illustrate the more profiles of women who took up PrEP when offered, without any other 
motivation aside from access to PrEP and the clinic.  
 
Each HIV-negative participant enrolled in TAPS, and therefore taking up PrEP, completed an 
extensive baseline demographic and behaviour questionnaire, however it was not possible to 
report on every variable in the primary analysis paper upon which this chapter is based. 
Instead, key characteristics were identified from the literature, including: age, relationship 
status, country of origin, level of education, and workplace. Several other papers have 
provided evidence on the importance of these variables in understanding risk profiles of FSWs 
(1–5). The one variable not as prevalent in this referenced research is the country of origin. 
This was important to include in the analysis of key characteristics due to the high volumes of 
women from neighbouring southern African countries who are often even more marginalised 
than their South African counterparts as targets of xenophobia. These variables illustrate 
individual characteristics which interact mostly with the social and sexual networks sphere of 
the MSEM framework.  
 
At the risk of repetition, the results presented in this chapter which are salient to this PhD are 
highlighted here.  
 
 The majority of FSW participants were between ages 21-30, married, had or lived with 
a steady partner, completed some or all secondary education, worked in brothels, and 
were born in Zimbabwe. 
 Women consistently reported high condom use with clients and low condom use with 
main partners.  
 Women had higher rates of STIs at baseline than during the rest of the study. 
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Interestingly, the descriptive analysis of these variables combined with the analysis of 
behavioural characteristics, including condom use with different partners and STI rates, 
suggest that FSWs who were at a self-recognised high risk of HIV infection took up PrEP. These 
findings, combined with the perspectives on PrEP use collected from a selection of the women 
in the study presented in Chapter 6, make for a compelling story of self-selection and risk 
perception which may be, key in driving interest in PrEP.  
 
A more in-depth regression analysis is planned using the larger demographic and behaviour 
data set and linked to the self-reported adherence data as well as the results of PrEP drug level 
analyses which are currently pending. This analysis will aim to look at correlates of PrEP use 
over time, as well as correlates of uptake as compared to those who screened but did not 
enrol in TAPS. Depending on the availability and comparability of the data sets, we may also 
conduct comparative analyses with Wits RHI’s larger Sex Worker Programme clinic data. There 
is also a mathematical modelling activity underway which will examine in more detail the 
potential impact and cost-effectiveness of PrEP in this population. These additional 
components, however, are beyond the scope of this PhD.  
 
The information and consent forms for the main TAPS research which are included in Appendix 
ix. The baseline demographic and behaviour survey for TAPS from which the key characteristics 
were derived is attached in Appendix x. STI data were aggregated from the clinical records. 
Note that supplemental material was only included as it relates to this PhD and will be 
included after the paper references.  
 
This paper has been submitted to PLoS Medicine and is pending editorial review of final 
revisions.  
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5.3.1. Abstract 
Background 
Operational research is required to design delivery of pre-exposure prophylaxis (PrEP) and 
early antiretroviral treatment (early ART). This paper presents the primary analysis of 
programmatic data, as well as demographic, behavioral, and clinical data from the TAPS 
Demonstration Project which offered both interventions to female sex workers (FSWs) in two 
urban clinic sites in South Africa. 
 
Methods and Findings 
The TAPS study was conducted between March 2015 and June 2017, with the enrolment 
period ending in July 2016. TAPS was a prospective, observational cohort study with two arms 
delivered in existing service settings: 1) PrEP as part of combination prevention for HIV-
negative FSWs, and 2) early ART for HIV-positive FSWs. The main outcome was programme 
retention at 12 months of follow up. Of the 947 FSWs initially seen in clinic, 692 were HIV 
tested. HIV prevalence was 49%. Among those returning to clinic after HIV testing and clinical 
screening, 93% were confirmed clinically eligible for PrEP (n=224/241), and 41% (n=110/270) 
had CD4 counts within NDoH initiation guidelines at assessment. 93% of those remaining were 
eligible for early ART (n=148/160). From those eligible, 98% (n=219/224) and 94% (n=139/148) 
took up PrEP and early ART, respectively. At baseline, the majority of women were married or 
had a stead partner, worked in brothels, and were born in Zimbabwe. Of those enrolled, 22% 
on PrEP (n=49/219) and 60% on early ART (n=83/139) were seen at 12 months, while we 
observed high rates of loss to follow up 71% (n=156/219) and 30% (n=42/139) in the PrEP and 
early ART arm, respectively. Little change over time was reported in consistent condom use or 
the number of sexual partners in the last seven days, with high levels of consistent condom use 
with clients and low use with main partners in both study arms. There were no 
seroconversions on PrEP and seven virological failures on early ART among women remaining 
in the study. Reported adherence to PrEP varied from 70 to 85%, whereas over 90% of 
participants reported taking pills daily while on early ART. Provider-side costs were also 
collected and analysed. The total cost of service delivery was approximately $126 for PrEP and 
$406 for early ART per person-year. The main limitations include lack of comparison arm not 
included due to ethical considerations, clinical trial requirements imposed when PrEP was not 
approved through the regulatory system which could have affected uptake, and the timing of 
implementation of the national sex worker programme which could have also affected uptake 
and retention.     
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Conclusion 
PrEP and early ART services can be implemented within FSWs routine services in high 
prevalence, urban settings. We observed good uptake for both PrEP and early ART, however 
retention rates for PrEP were low. Retention rates were standard for early ART compared to 
current standard of care. While the cost of the interventions is higher than previously 
published, there is potential for cost reduction at scale. The TAPS demonstration project 
results provided the basis for the first government PrEP and early ART guidelines and the roll 
out of a national sex worker plan in South Africa.  
 
 
Author summary 
Background 
 Nearly two million people still become infected with HIV every year, mostly through 
sexual transmission. These infections occur more often in vulnerable populations 
where people do not always have the access or option to use HIV prevention.  
 Antiretroviral-based drugs, normally used to treat HIV, have also been shown to 
prevent transmission both by giving the drugs to HIV-negative people to prevent them 
from getting HIV (called pre-exposure prophylaxis or PrEP) and treating HIV-positive 
people earlier (called early ART).  
 These interventions are now being piloted by national programmes to test whether 
(and how) they can be successfully delivered in clinics and the public sector. 
 
Why was this study done?  
 Female sex workers are a vulnerable population at risk of HIV, and in some areas of 
South Africa, nearly three out of four sex workers are already infected.  
 We conducted a study located in existing, sex worker-specific clinics to see if female 
sex workers would take up and use PrEP and early ART if these interventions were 
offered.  
 This was one of the first studies of its kind to be conducted in Africa. We partnered 
with the South African government so that they could see how the interventions 
worked and what it cost, to incorporate them into national HIV programming. 
 
What did we do and find?  
 We offered PrEP to HIV-negative and early ART to HIV-positive female sex workers in 
two clinics located in Johannesburg and Pretoria in South Africa. Over time, we 
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assessed how many women were contacted for the intervention within communities, 
how many came to the clinic for HIV testing, how many were HIV-negative and 
positive, and how many took up the interventions. We then monitored those who 
participated for at least 12 months to see whether they stayed in the programme and 
used PrEP or early ART.  
 The primary goal was to see how long women stayed in the project. We also looked at 
how well they took their medications, any safety or other clinical issues, and collected 
data on their demographic and behaviour characteristics. 
 We found a HIV prevalence of 49% among 692 women tested. Among those returning 
to clinic after HIV testing and clinical screening, 93% were confirmed eligible for PrEP, 
and 94% for early ART. From those eligible, 98% and 94% took up PrEP and early ART, 
respectively.  
 These women were mostly married or had a steady partner, worked in brothels rather 
than on streets, and came from neighbouring Zimbabwe.  
 At the end of the 12 month assessment, 22% remained on PrEP, while 60% remained 
on early ART at our clinic sites. It is possible that some women moved to other sites 
without our knowledge, as other sites started offering PrEP and early ART. The drugs 
were safe to use with few side effects. We also found that women who stayed in the 
study reported taking their pills regularly. None of the women who remained in the 
study in the PrEP arm got HIV, and very few women taking early ART had issues 
supressing the virus. The overall cost of the programme came to approximately $126 
for PrEP and $406 for early ART per person-year. 
 
What do these findings mean?  
 These findings suggest that female sex workers may be interested in both PrEP and 
early ART and that the interventions work well when taken, but longer-term 
commitment may be a challenge.  
 These interventions have already been introduced by the South African government 
into sex worker programmes, including male, female, and transgender people.  
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5.3.2. Introduction  
Rates of new HIV infections remain high, especially in key populations in sub-Saharan Africa, 
necessitating new options for HIV prevention and treatment [1,2]. Mathematical and clinical 
studies suggest that a programme combining current HIV prevention options with oral pre-
exposure prophylaxis (PrEP), i.e. giving antiretrovirals (ARVs) to an uninfected individual, and 
early antiretroviral treatment (early ART), i.e. giving ARVs to an HIV-infected person 
irrespective of CD4 count, could make significant inroads on reducing new infections in key 
and general populations [3–7]. 
 
Following the transition of WHO treatment guidelines to recommend both PrEP and early ART, 
research has shifted focus to answering questions about implementation [5] including uptake, 
adherence and retention in existing programmes [8]. Demonstration projects, open-label 
extension studies and population-based implementation trials testing feasibility in ‘real-world’ 
settings, are ongoing or have been recently completed [9,10]. Most of the completed 
demonstration projects have focused on men who have sex with men (MSM) populations 
throughout the world (though primarily in the United States, South America, and Europe) [10]. 
One or two other projects have been completed among serodiscordant couples [11], and only 
one randomized control trial implementation study had been completed among female sex 
workers (FSWs) at the time of writing [12].  
 
In South Africa, although sex work is still criminalised, female sex workers (FSWs) have been 
prioritised for focused, tailored services in the previous and new National Department of 
Health (NDoH) National Strategic Plans (NSPs), as well as a specialized plan for sex workers, as 
a population with the highest incidence and prevalence of HIV, especially in urban areas [13–
15]. This included support for demonstration projects to further the development of 
specialized services including PrEP and early ART.  
 
The TAPS Demonstration Project (Treatment And Prevention for female Sex workers), nested 
within the long-standing Sex Worker Programme [16], was designed to support integration of 
oral PrEP as part of a combination prevention approach and early ART in two urban settings 
with specific aims to assess uptake, retention, and adherence among FSWs and to estimate the 
cost of this strategy. TAPS was the first demonstration project in South Africa to include PrEP 
and early ART for FSWs, and among the first few in sub-Saharan Africa as well. This paper 
presents the primary results. 
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5.3.3. Methods 
The TAPS Demonstration Project was a prospective, observational cohort designed as a ‘real-
world’ implementation study to integrate PrEP as part of a combination prevention approach 
and early ART into existing services for evaluation. The protocol has been described in detail in 
a previous publication [17].  
 
Setting and intervention 
TAPS was embedded within the Sex Worker Programme (SWP), operated by Wits Reproductive 
Health and HIV Institute (Wits RHI), which is integrated into the South African public health 
clinical service. The SWP has been in existence since 1996 and is run by nurses, community 
health workers, and peer educators [16]. Systematic formative research conducted to support 
the design and in preparation for TAPS is presented elsewhere [18]. 
 
The two clinic sites were situated in inner-city Johannesburg and Pretoria. These clinics cater 
to an urban population of sex workers working in hotel brothels, on streets and in other 
informal environments. The clinics provide standard of care primary healthcare including HIV 
testing services (HTS), male and female condoms distribution, nurse-initiated and managed 
ART, tuberculosis screening, contraceptive provision, cervical cancer screening, clinical services 
for STIs and minor ailments, psychosocial support, and referrals for pregnancy and other 
clinical and legal services.  
 
Recruitment of FSWs took place in the clinics and in surrounding brothels, bars, and streets, 
relying on existing peer educator outreach services. Screening for participation was conducted 
in two steps. First, women were tested for HIV using a standard of care rapid test. This step 
included obtaining NDoH HTS written consent and asking brief questions as to current 
pregnancy and whether they were a sex worker (e.g. they were asked to self-identify after 
peer recruitment in their places of work). Women were then either referred to other relevant 
care (if they were pregnant, not a sex worker, or decided not to proceed), or they continued 
onto clinical screening for the TAPS study. This process always occurred on the same day to 
ensure that HIV testing and clinical assessments were aligned. The next phase of the screening 
process began by obtaining study-specific written consent, then continued with the 
assessment of clinical history, administration of demographic and behavioural questionnaires, 
tuberculosis (TB) and pregnancy screening, blood draws for creatinine, hepatitis B screening, 
and syphilis testing. HIV status confirmation with ELISA was done for HIV-positive participants 
at a private laboratory where all the other samples were also analysed. Women were offered 
169 
 
contraception, as well as the need to use condoms to prevent HIV, STIs and unwanted 
pregnancies. 
 
After screening, participants were asked to return a week later, to allow for laboratory 
analyses to be completed, for potential enrolment into either PrEP for HIV-negative FSWs or 
early ART for HIV-positive FSWs. The definition of the latter has evolved in line with national 
guidelines. At the start of the study the CD4 threshold for treatment initiation was 350 
cells/mL, this changed to 500 cells/mL, and then independent of CD4 count during the course 
of the study. Since our purpose was to offer treatment to those outside of the guidelines, TAPS 
transitioned with the national treatment initiation definition. Project milestones are provided 
in supplementary material (Supplementary material, Figure S1). Women were eligible for the 
study if they were: age 18 or over, not pregnant at enrolment, did not have multi-drug 
resistant TB, not participating in another clinical study, and had finished their regimen for post-
exposure prophylaxis if they were taking it at the time of assessment. Those who became 
pregnant through the course of the study were given the option to remain in the study on 
current medication, discontinue use during the period of pregnancy and remain in the study, 
or transfer out completely to antenatal care (ANC). The first two options also included referrals 
to ANC. 
 
Once initiated on PrEP or early ART, participants were scheduled for an initial one-month 
check-in to assess safety and/or adherence issues, and then scheduled for quarterly clinical 
testing and safety monitoring visits thereafter. All clinical monitoring followed South African 
national guidelines throughout the study (also detailed in the published protocol) [17] and all 
services were provided free of charge as per the public health clinic standard, including PrEP 
and early ART. Participants were given refills of 1-3 months depending on ability to safely store 
the products and desire to come to the clinic for refills. The importance of consistent and high 
adherence was emphasized during PrEP use, however participants could cycle on and off 
medication during periods of lower risk as desired and remain in the study. Indeed, the PrEP 
intervention for HIV-negative women included not only the use of PrEP but also other available 
prevention options (such as condoms, continuous testing and counselling and STI screening). 
Participants were offered short message system (SMS) reminders around clinic visits and 
positive messaging around adherence, health and psychosocial issues.  
 
For both arms, participants were asked about pill taking habits with a motivational technique 
employed at each staff touch point: counseling, clinical, and pharmacy. Counselling followed 
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the current standard of care for ART provision. Blood samples were taken for analysis of drug 
levels in the PrEP participant, results of which will be presented at a later date as not currently 
available. Adverse events were recorded per Good Clinical Practice (GCP) guidelines and WHO 
recommended grading [19,20].  
 
Evaluation  
Programmatic data to describe eligibility and uptake was collected in activity reports including: 
number of outreach contacts and appointments booked. Routinely collected demographic, 
behavioural, and clinical data were also analysed. Retention in care at 12 months was the 
primary outcome. Participants exited the analysis if they withdrew from the study or were lost 
to follow-up, defined as no contact over two consecutive quarterly clinic visits. Participants 
were considered retained in the programme if they had not withdrawn or been lost to follow 
up during this period. We used an adapted cascade approach to measure uptake and retention 
through a series of “touch points” with participants. These points started during outreach 
through the enrolment process. Retention data is reported at each of the time points (3, 6, 9 
and 12 months). Women who missed visits and returned later were included in the analysis. 
Data for those women who completed more than 12 months of follow up have been included 
as part of the supplementary analysis.  
 
Data were analysed on self-reported adherence and sexual behaviour, sexually transmitted 
infections (STIs), and side effects. We also monitored any possible seroconversions on PrEP 
and virological failures on early ART. Qualitative research including in-depth interviews (with a 
selection of up to 10% of study participants), clinic observations, and group discussions with 
providers was also conducted and will be presented separately.  
 
Costs were estimated from a healthcare provider perspective for each clinic using an 
ingredient approach. We included capital costs (equipment, buildings, non-recurrent training), 
as well as recurrent costs (personnel, supplies, management, and maintenance of buildings). 
Capital costs were annualised. Data collection activities included measurement of clinics, 
weekly timesheets completed by staff involved in the programme detailing time per 
programme activity as opposed to research activities, observations of practice detailing all 
clinical activities during each participant visit, interviews with staff exploring time shared with 
other programmes as well as review of expenditure and utilization data with regards to the 
programme. Sources used in the valuation of all resources and methods for allocation of 
shared resources are detailed in the supplementary material (Supplementary material, Table 
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S1). We used both bottom-up and top-down approaches to calculate unit cost per visit. 
Economic costs were assigned to drugs as per procurement prices from NDoH for generics 
(USD 4.8/month of PrEP; USD 8.3/month of early ART); quantities of drugs dispensed per 
patient were sourced from clinical and pharmacy records. Services, activities and healthcare 
providers involved in each type of visit are listed in the supplementary material 
(Supplementary material, Table S2). We present unit costs for the different types of visits 
(outreach contact, testing session, enrolment, follow up and refill visits. Our unit costs per 
person-year for PrEP and early ART include enrolment, follow up and refill visits taking place 
during the first year of services and reflect the attendance patterns observed during the TAPS 
Demonstration project.  All prices were collected in local currency and are reported in USD 
2015. The average exchange rate used was USD 1 =  ZAR 11.6. All data were analysed in STATA 
12 (StataCorp, USA) and EXCEL 2016 (Microsoft, USA).  
 
A national programme including PrEP and early ART for FSWs was launched in June 2016, 
during the study, and may have influenced enrollment and retention. To test this, a stratified 
analysis of uptake and retention indicators is provided in supplementary material by 
comparing the cascade results along TAPS cohorts disaggregated by time of enrolment and 
follow up periods. We tested the null hypothesis that the two proportions are the same at 
each step of the cascade and report p values for this testing. This analysis was the only 
additional analysis not prospectively defined. 
 
Ethics approval 
The TAPS Demonstration Project protocol was approved by the University of Witwatersrand 
Human Research Ethics Committee (reference number: 140502), the South African Medicines 
Control Council (reference number: 20140740). All participants completed a written informed 
consent process for the study consisting of a comprehensive consent form for the main study, 
as well as additional forms for laboratory sample storage and the qualitative study 
components. Costing studies were also performed after securing consent from clinic staff.  
 
5.3.4. Results 
Outreach and uptake 
Enrolment for the TAPS study occurred between 31 May 2015 and 31 July 2016. At the end of 
this period, 219 HIV-negative and 139 HIV-positive FSWs were enrolled.  
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This process began with outreach and recruitment, where 7,140 FSWs were contacted of the 
10,548 names gathered across the two sites, after excluding duplicates and inaccurate phone 
numbers (Figure 1). This included women recorded on waiting lists leading up to the launch of 
the study which were compiled during pre-study outreach and community education activities. 
After making contact, a total of 947 FSWs were seen in the clinic, of which 692 were HIV tested 
(73%) as per standard of care. At this point, 21% (n=197) of the women were found to be 
already taking ART, pregnant, or not considered themselves to be sex workers, making them 
ineligible for enrolment. These women were referred to relevant care options, and therefore 
did not complete the next phase of study screening which occurred in the same visit as the HIV 
testing. Among those tested for HIV, there was a prevalence of 49% (n=341/692). Following 
HIV testing, 79% (n=241/351) and 69% (n=270/341) participants returned for enrolment for 
PrEP and early ART, respectively. Among the HIV-negative participants who returned for 
eligibility assessment, 93% were assessed as clinically eligible (n=224/241). Among HIV-positive 
participants who returned for eligibility assessment, 41% (n=110/270) had CD4 counts within 
NDoH initiation guidelines at assessment, and 93% of those remaining were eligible for early 
ART (n=148/160). Reasons for non-eligibility are presented in Figure 1. Uptake among those 
eligible was high, 98% (n=219/224) of FSWs offered PrEP accepted and 94% (n=139/148) 
accepted early ART. The detailed numbers of participants at each step of enrolment and follow 
up are presented in supplementary material (Supplementary material, Table S3). 
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Figure 1. Flowchart of participant enrolment and follow up 
 
Abbreviations: HepB+, positive result for hepatitis B; CD4 count<threshold, indicates a CD4 count results 
below the threshold for ART initiation at the time of assessment.  
 
The comparison of TAPS cohorts, both PrEP and early ART, disaggregated by time of enrolment 
(e.g. before or after the launch of the national pilot), revealed no statistically significant 
differences throughout the enrolment and retention cascade, aside from two points: number 
of appointments booked (20% of contacts made resulted in an appointment being booked in 
the cohort enrolled before the national pilot as opposed to 26% among those enrolled after 
the pilot) and number eligible for early ART (more HIV positive participants were eligible for 
early ART in the cohort recruited after the pilot, 95%, compared to the cohort enrolled before 
the pilot, 51%). In particular, the higher proportion of appointments booked from contacts 
made among those enrolled post launch of the pilot cohort compared to those enrolled before 
the pilot could be related to larger recruitment and education efforts at the sites. The higher 
proportion of participants eligible for early ART in the cohort recruited after the pilot started 
could be an indication of earlier presentation. The comparison of TAPS cohorts, both PrEP and 
early ART, disaggregated by completion of follow up period (e.g. 12-month follow up 
completed before or after the launch of the national pilot), revealed no statistically significant 
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differences throughout the enrolment and retention cascade. These results are presented in 
Table S4 in the supplementary material. Further details regarding enrolment statistics over 
time can be found in the supplementary material (Supplementary material, Figure S2). 
 
Baseline characteristics 
In Table 1, selected baseline characteristics of enrolled participants are presented. Women 
enrolled in the PrEP arm were significantly younger than those enrolled in the early ART arm. 
Both arms presented a majority of FSWs either married or living with a steady partner (50% on 
early ART and 56% on PrEP), born in Zimbabwe (48% on early ART, 67% on PrEP), and with 
secondary education (86% on early ART, and 87% on PrEP). A substantial majority of the 
participants work in brothels, with 62% in the early ART arm, and 77% in the PrEP arm.  
 
Table 1: Baseline characteristics of FSW participants enrolled (total n=358) 
Characteristic Detail  Early ART (n=139) PrEP (n=219) P 
value* 
Age n, mean (SD) 139 31.9 (6.4) 219 29.8 (5.9) 0.0016 
median (min-max)  31.7 (19.6-
40.0) 
 28.9 (18.0-
55.4) 
 
18-20 years 1 0.7% 2 0.9% 0.001 
21-30 years 53 38.1% 127 58.0%  
31-40 years 71 51.1% 77 35.2%  
41-50 years 14 10.1 10 4.6%  
51-60 years 0 - 3 1.4%  
Current 
partnership 
No current partner 70 50.4% 102 46.6% 0.599 
    Single, no partners at 
present 
64 46.7% 88 40.4%  
    Divorced or separated 5 3.6% 7 3.2%  
    Married and living apart 1 0.7% 7 3.2%  
Currently in a partnership 67 48.2% 116 53.0%  
    Steady partner, not 
married/not living together 
52 38.0% 85 39.0%  
    Not married but living 
together 
14 10.2% 24 11.0%  
    Married and living together 1 0.7% 7 3.2%  
Did not answer 2 - 1 -  
Country of 
origin 
Zimbabwe 67 48.2% 146 66.7% 0.009 
South Africa 60 43.2% 60 27.4%  
Lesotho 7 5.0% 10 4.6%  
Swaziland 3 2.2% 1 0.5%  
Mozambique 2 1.4% 2 0.9%  
Education No education 0 0.0% 1 0.5% 0.107 
Primary 15 10.8% 12 5.5%  
Secondary 120 86.3% 189 87.1%  
Tertiary 4 2.9% 15 6.9%  
Did not answer/does not know 0 - 2 -  
Place of work Hotel/brothel 86 61.9% 168 76.7% 0.008 
Street 37 26.6% 28 12.8%  
Home 4 2.9% 5 2.3%  
Other 12 8.6% 18 8.2%  
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Abbreviations: n, number; SD, standard deviation; min, minimum; max, maximum. *All p-values are two 
sided; differences in means were assessed using t-tests and categorical variables were assessed using chi 
square. 
Visit attendance and retention  
During the first 12 months of follow up, 156 and 42 participants (71% and 30%) were lost to 
follow-up (missing two clinical monitoring visits) or did not complete an exit interview at study 
closure from the PrEP and early ART arms, respectively. The prevention and care cascades are 
shown in Figure 2.  
 
 
Figure 2. HIV prevention and care cascades 
 
(A) HIV prevention cascade: PrEP cohort. (B) HIV treatment cascade: early ART cohort. 
Abbreviations: mo, month. 
 
 
The study follow-up period closed in June 2017. There were 22% and 60% of the enrolled PrEP 
and early ART cohorts attending the 12 months visit. Overall, programme adherence was 
higher in the early ART arm compared to the PrEP arm, where participants tended to be less 
regular in their attendance. This is illustrated graphically in Figure S3 of the supplementary 
material. Eight women withdrew, four from each arm. Reasons for withdrawal were either side 
effects or moving to another location. Extended cascade results for those women who 
attended the study for a period of time longer than 12 months are presented in the 
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supplementary material (Supplementary material, Table S5). When examining loss to follow up 
over time, as shown in Figure S4, we observed that most women drop off earlier in the 
schedule, in particular in the PrEP arm. Denominators for each point in the cascade are also 
shown in this table and should be taken into account with the loss to follow up over time 
shown in Figure S4. 
Secondary outcomes 
In Figure 3, self-reported consistent condom use by partner type and study arm is shown over 
time. Higher condom use was reported with clients than with partners, especially main 
partners. Women on early ART tended to use condoms slightly more with casual and main 
partners, than those on PrEP. Little change in reported condom use over time by type of 
partner was observed. Additionally, there was no increase in number of partners over time. 
Further details on these data are presented in Table S6 (Supplementary material, Table S6). 
Number of STI episodes at baseline and every three months are presented in Table S7 of 
supplementary material. FSWs had significantly less STI episodes while participating in the 
study on both arms. These data are presented with the caveat that drop out over time may 
contribute to bias in the numbers at later time points.  
 
Figure 3. Sexual behaviour over time by partner type: consistent condom use and number of partners in 
last seven days. 
 
(A) Consistent condom use: PrEP cohort. (B) Number of partners in the last seven days: PrEP cohort. (C) 
Consistent condom use: Early ART cohort. (D) Number of partners in the last seven days: Early ART 
cohort. 
Abbreviations: mo, month 
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The proportion of women reporting taking PrEP pills daily varied from 70 to 85%, whereas over 
90% of participants reported taking pills daily while on early ART during the first 12 months 
follow up (Supplementary material, Table S7).  
 
During the first 12 months of follow up, there were seven pregnancies in the PrEP arm. 
Although women were given the option to continue on PrEP while pregnant, three chose to 
terminate and continue on PrEP, two were lost to follow up, and only one chose to continue 
on PrEP in the study while pregnant. There were eight pregnancies in the early ART arm, and 
an additional four in the extended follow up period, two of which were found at study exit. 
Early ART participants chose to continue with the study and their pregnancies.  
 
One participant from the PrEP arm who had previously decided to leave the study returned 
when she had become HIV-positive and was referred for ART initiation. In the early ART arm, 
there were 12 confirmed cases of virological failure, 11 of which resulted in high level 
virological resistance to at least one drug (11 with resistance to efavirenz, five to emtricitabine, 
and two to TDF), among the women retained in the study. One patient had fully susceptible 
virus at resistance testing. 
 
Of all 692 women who completed the screening process, only one participant presented with 
serious complicating health issues, including suspected tuberculosis and a creatinine clearance 
of 50 mL/min. There were no other cases outside the creatinine clearance for initiation of TDF.  
 
PrEP and treatment drugs were well tolerated, with the majority of adverse events being 
reported as mild for both arms, and few moderate. Of the 306 total adverse events recorded, 
only 17 were assessed to be drug related: eight on PrEP reported mild headaches, nausea, 
drowsiness, dizziness, or diarrhea; and nine on early ART reported mild nausea, diarrhea, 
dizziness, or drowsiness. One participant developed abnormal liver function tests, presenting 
ill after taking early ART for four months. Liver function tests revealed severely deranged liver 
function tests, and she was referred to a specialist, where the diagnosis was HIV-induced 
sclerosing cholangitis.    
 
Finally, in Table 2, both unit costs per visit type and overall cost of a person-year on early ART 
and PrEP are shown. We found lower unit costs for the visit types involving either low 
overheads, drugs or tests (i.e. outreach visits) or staff time (i.e. refill visits). The distribution of 
costs by input is presented in supplementary material (Figure S5). 
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Table 2. Unit costs per visit and per person-year for PrEP and early ART among FSWs (USD 2015) 
 Unit cost Site   
  
 
Hillbrow Pretoria Mean 
Outreach contact 3.0 2.6 2.8 
VCT session 21.2 15.1 18.1 
    
PrEP enrolment visit 40.4 29.0 34.7 
PrEP monitoring visit 37.4 33.0 35.2 
PrEP refill visit 7.4 6.2 6.8 
PrEP (per person-year, y1) 146.6 106.6 126.6 
    
early ART enrolment visit 67.1 64.0 65.5 
early ART monitoring  visit 72.5 62.9 67.7 
early ART refill visit 13.4 9.8 11.6 
early ART (per person-year, y1) 380.5 432.3 406.4 
Abbreviations: VCT, voluntary counselling and testing, y1, initial year of services. 
 
5.3.5. Discussion 
In this prospective, observational demonstration project, we observed high uptake of the PrEP 
and early ART interventions among eligible FSWs. Retention in the early ART arm was 
consistent with the national programme [21], while retention in the PrEP arm was lower at the 
12-month assessment. There were also few virological failures in the early ART arm and no 
seroconversions in the PrEP arm. However, given the low rate of retention at the end of the 
study in the PrEP arm, it is possible that women who dropped out and were not tracked 
became HIV-positive. To our knowledge, this is the first demonstration project to present 
results following the integration of a combined PrEP/early ART intervention into an existing sex 
worker health programme. The results of this project supported the establishment of the first 
official combined guidelines for oral PrEP and early ART in Africa, as well as the first specialized 
national programming including these interventions for sex workers in Africa [22,23]. The 
South African PrEP and early ART (or test and treat) guidelines were launched initially for sex 
workers in June 2016, where PrEP and initiation of ART irrespective of CD4 count became 
standard of care for sex workers. Test and treat was then extended to all HIV-positive people 
in South Africa in September 2016. 
  
Additionally, TAPS has produced two important programmatic findings. Firstly, the high 
number of women informed about the study translated into a much smaller number actually 
presenting to take up the interventions. Since both PrEP and early ART are novel interventions, 
it is possible that as knowledge and use spreads in this community overall uptake might 
increase, as seen in the introduction of contraception [24]. Normalisation of new interventions 
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may be key to their successful implementation [25], and this will be explored further in the 
analysis of qualitative data. Secondly, among those who presented at the clinic, there were 
high levels of intervention uptake for both PrEP and early ART.  
 
Higher levels of retention were maintained in the early ART, than for the PrEP arm. It is 
important to note that retention in care refers to two constructs depending on whether 
participants are being retained in a prevention or treatment intervention. For the PrEP arm, 
we tried to present results on the continuous contact with healthcare services and access to 
prevention packages, even though the women were allowed to cycle in and out of PrEP 
medication use. For the early ART arm, we valued retention in care as an essential component 
of a successful treatment programme. Interestingly, women who enrolled on PrEP earlier in 
the study tended to be the ones who continued the longest, suggesting those most motivated, 
interested, and/or able to take up the interventions came earlier. It is important to note that 
participants were not reimbursed for their participation, suggesting dedicated sex worker 
services can result in high levels of engagement in care among FSWs.  
 
We observed a significant participant drop-off between screening and assessment for 
eligibility. Much of the loss may be directly related to the waiting period between screening 
and enrolment required for research purposes and to assess laboratory results. This may not 
reflect service delivery in future programmes where same-day initiation for both PrEP and 
early ART are being considered. We had only a single creatinine case at screening meriting 
concern, and immediate initiation with follow up and potential discontinuation for those with 
concerning results may be possible.  
 
Women who became pregnant in either arm of the study were given options regarding 
maintaining PrEP use, staying in the study, or transferring into other care. However, only one 
woman decided to stay on PrEP and continue in the study while three chose to terminate their 
pregnancies. It is possible that those who were lost to follow-up decided to see their 
pregnancies through, but this is unconfirmed. It is also possible that by excluding those who 
were pregnant at enrolment, women highly motivated to take PrEP were not given the 
opportunity. Given the heightened risk of HIV infection in women who become pregnant, 
being able to continue PrEP use during pregnancy may be a critical programming 
consideration.  
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At baseline, the TAPS cohorts had similar demographic characteristics (age, education, and 
place of origin) when compared to the recently described local FSW population in 
Johannesburg [26]. Yet, there was a higher rate of FSWs in stable relationships in our sample. 
This is likely a reflection of the group of FSWs accessing SWP clinics in general, as a similar 
profile was recently reported among SWP attendees not enrolled in the study [27].  
 
The patterns of visits to the clinic for PrEP combined with the reported adherence would 
suggest intermittent use of PrEP while maintaining an overall engagement with services. 
Although we have only analysed self-reported adherence data in this paper, the data were 
collected at every clinic and pill collection visit, and women did not report perfect adherence 
and usually reported when they took ‘PrEP breaks’ suggesting a low levels of social desirability 
bias. Additionally, with no seroconversions among the PrEP users this does not appear to be an 
issue in maintaining a negative HIV status noting also the high use of condoms with clients. 
Reassuringly, there was no observed change in reported consistent condom use or number of 
partners in the last seven days over time in the study. STI episodes were fewer in the duration 
of the study compared to baseline for both arms. This latter finding, combined with the results 
of rigorous and consistent data collection on condom use over time with all sexual partners, 
suggests that the women who remained in the study may have been improving their attention 
to prevention through engagement in the study. This finding makes for an interesting 
comparison with other completed demonstration project studies among MSM where 
moderate increases in STIs during the study suggest slight reductions in condom use [28].  
 
Finally, we estimated a total cost for both PrEP and early ART per person-year to be in the 
same order of magnitude as recently published estimates [29,30]. The higher TAPS costs for 
early ART compared to those included in the South African Investment Case for HIV and TB 
reflect the TAPS programme procedures, service utilization, and staff costs which are likely to 
be lower in routine services [30].  
 
Limitations 
Firstly, no comparison arm was included, limiting the ability to assess effectiveness of 
integrated services, as it would not have been ethical to maintain comparison groups with no 
or delayed access to interventions shown to be effective [31]. Secondly, efforts to replicate 
healthcare delivery through an integrated service were affected both by regulatory (dispensing 
from a pharmacy and medical officer assessment of adverse events) and ethics committee 
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(informed consent administration) requirements. However, we expect the removal of these 
requirements would improve rates of uptake and retention. 
 
In addition, the National PrEP and early ART pilot in South Africa started 1st June 2016. After its 
initiation, this pilot could have influenced the uptake of the interventions for those FSWs 
approached for enrolment in TAPS. Conversely, it could have influenced retention within the 
programme for those FSWs for whom the follow up period overlapped with the provision of 
the national pilot. The TAPS clinics were the only providers of PrEP free of charge to FSWs in 
the public setting and required informed consent to access the interventions as part of a 
research study before the national rollout, where all services were also provided at no cost to 
clients. Furthermore, the implementation of PrEP as part of the national programme meant 
that PrEP could be viewed as a standard of care and therefore more normalised from the 
population’s perspective. Since PrEP was no longer considered experimental after 31 May 
2016, we expected that women would think about PrEP differently, which could have affected 
uptake and retention in TAPS. For example, as the programme was scaled up in the initial 11 
sites (including in the two TAPS sites), we became aware that some of the TAPS participants 
opted to collect their PrEP from the mobile clinics in Pretoria, rather than coming to the fixed 
clinic where TAPS was located. 
 
Finally, we do not have data on the women who did not come back to the study, and the 
adherence and sexual behaviour data are self-reported, increasing the possibility of bias. 
Unfortunately, drug level analyses of use in the PrEP arm were not available at the time of 
writing. However this will be presented in a more in-depth analysis in a subsequent 
publication. Additionally, the data reported are based on populations of FSWs in two specific 
urban settings, possibly limiting generalisability.  
 
5.3.6. Conclusion 
The findings from TAPS informed the set-up of the national rollout of PrEP and test and treat 
for sex workers. This analysis shows that PrEP and early ART can be aligned with existing health 
service programming for FSWs safely, without significant behaviour change, and with high 
rates of uptake for both interventions, with expected cost reduction in routine settings at 
scale.   
182 
 
Acknowledgements 
The authors would like to thank the entire Wits RHI Sex Worker Programme team for making 
this project happen. Most importantly are the participants in both Hillbrow and Pretoria whose 
engagement with this project has made it a success, as well as the larger sex worker 
community who has supported this project in both cities. In particular, our colleagues at 
SWEAT, Sisonke, OASIS, The Treatment Action Campaign, Sonke Gender Justice, and the 
Gauteng Health Sector have supported us through their partnership by creating awareness 
around early ART and PrEP for female sex workers. Finally, we would like to thank Dr. Adam 
Bourne of Sigma Research Group at the London School of Hygiene and Tropical Medicine, as 
well as Matthew Chersich and Fiona Scorgie for their support in developing a number of the 
data collection tools used in this project.  
 
Declarations 
Dr. Michelle Moorhouse and Prof Francois Venter declares receiving honoraria from Gilead for 
giving talks, and for participating on a PrEP advisory board. The other authors declare no 
conflicts of interest with regards to this study or publication. Drug supply for Truvada was 
donated by Gilead, and Atroiza was donated for HIV treatment by Mylan.  
 
Funding 
Bill and Melinda Gates Foundation [OPP1084416] and the United States Agency for 
International Development [AID-674-A-12-00034]. GBG was partly funded by an AMC ASPASIA 
overseas grant financed by the Netherlands Organisation for Scientific Research (NWO) 
[reference number 015.009.042]. The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript. 
 
Author contributions 
RE, GBG, WDFV, and HR conceived of and designed the study. RE led the daily oversight of the 
study including data collection and the qualitative research component. GBG led the 
quantitative evaluation components, costing and modelling activities. WDFV is the lead senior 
clinician on the study; WDFV and MM provide clinical oversight and technical support. HR 
maintains oversight and support as Principal Investigator. NN, JM, RB manage daily activities in 
both clinics. NN manages data collection and cleaning processes. MACE and GBG designed and 
conducted all costing studies. GBG led statistical analysis of all data, with input from RE. RE and 
GBG drafted the manuscript with input and contributions from all authors.  
  
183 
 
 
5.3.7. References 
1.  GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence, 
prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. 
Lancet HIV. 2016; online first.  
2.  UNAIDS. Prevention gap report [Internet]. Geneva, Switzerland: UNAIDS; 2016 Jul. 
Available: http://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-
report_en.pdf 
3.  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. 
Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016;375: 
830–839. doi:10.1056/NEJMoa1600693 
4.  Iwuji C, Orne-Gliemann J, Balestre E, Larmarange J, Thiebaut R, Tanser F, et al. 
FRAC0105LB: The impact of universal test and treat on HIV incidence in a rural South 
African population: ANRS 12249 TasP trial, 2012-2016. Durban; 2016.  
5.  Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM, et al. 
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS 
Lond Engl. 2016;30: 1973–1983. doi:10.1097/QAD.0000000000001145 
6.  Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, et al. HIV 
Treatment as Prevention: Systematic Comparison of Mathematical Models of the 
Potential Impact of Antiretroviral Therapy on HIV Incidence in South Africa. PLoS Med. 
2012;9: e1001245. doi:10.1371/journal.pmed.1001245 
7.  Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, Cremin Í, et al. Optimal Uses of 
Antiretrovirals for Prevention in HIV-1 Serodiscordant Heterosexual Couples in South 
Africa: A Modelling Study. PLoS Med. 2011;8: e1001123. 
doi:10.1371/journal.pmed.1001123 
8.  Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan 
Africa: a systematic review. PLoS Med. 2011;8: e1001056. 
doi:10.1371/journal.pmed.1001056 
184 
 
 
9.  Reynolds LJ, Camlin CS, Ware NC, Seeley J. Exploring critical questions for the 
implementation of “universal test and treat” approaches to HIV prevention and care. 
AIDS Care. 2016;28 Suppl 3: 1–6. doi:10.1080/09540121.2016.1178960 
10.  AVAC. Ongoing and Planned PrEP Demonstration and Implementation Studies [Internet]. 
22 Jul 2016. Available: http://www.avac.org/resource/ongoing-and-planned-prep-
demonstration-and-implementation-studies 
11.  Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. Integrated 
Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–
Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. PLOS 
Med. 2016;13: e1002099. doi:10.1371/journal.pmed.1002099 
12.  Frances Cowan. Results of the SAPPH-IRe Trial: a cluster randomised trial of a 
combination intervention to empower female sex workers in Zimbabwe to link and 
adhere to antiretrovirals for treatment and prevention. 2016. Available: 
http://programme.aids2016.org/Abstract/Abstract/10619 
13.  South African National AIDS Council. Strategic Plan on HIV, STIs and TB 2012 – 2016. 
2012; Available: 
http://www.sanac.org.za/files/uploaded/NSP%2027Jan2012%20Full%20APPROVED%201
0Feb2012%20Web.pdf 
14.  South African National AIDS Programme. South Africa’s National Strategic Plan for HIV, 
TB, and STIs 2017-2022 [Internet]. 2017. Available: http://sanac.org.za/wp-
content/uploads/2017/05/NSP_FullDocument_FINAL.pdf 
15.  South African National AIDS Council. National Strategic Plan for HIV Prevention, Care, and 
Treatment for Sex Workers [Internet]. 2014. Available: 
http://www.sahivsoc.org/upload/documents/national%20sex%20Work%20Strategy%20s
mall.pdf 
16.  Sibanyoni M. Sex in the Cities: Comprehensive healthcare for sex workers. Durban, South 
Africa; 2015.  
185 
 
 
17.  Gomez GB, Eakle R, Mbogua J, Akpomiemie G, Venter WDF, Rees H. Treatment And 
Prevention for female Sex workers in South Africa: protocol for the TAPS Demonstration 
Project. BMJ Open. 2016;6: e011595. doi:10.1136/bmjopen-2016-011595 
18.  Eakle R, Manthata G, Stadler J, Mbogua J, Sibanyoni M, Venter WDF, et al. Preparing for 
PrEP & Immediate Treatment: Focus Group Discussions in Advance of a Demonstration 
Project in South Africa. Cape Town, South Africa; 2014. 
doi:10.1089/aid.2014.5606.abstract 
19.  United States Food and Drug Administration. Guidance for Industry E6 Good Clinical 
Practice: Consolidated Guidance [Internet]. 1996 [cited 23 Jul 2017]. Available: 
https://www.fda.gov/downloads/drugs/guidances/ucm073122.pdf 
20.  WHO | Adverse Drug Reactions Monitoring. In: WHO [Internet]. [cited 23 Jul 2017]. 
Available: 
http://www.who.int/medicines/areas/quality_safety/safety_efficacy/advdrugreactions/e
n/ 
21.  Fox MP, MPA SR. Retention of Adult Patients on Antiretroviral Therapy in Low- and 
Middle-Income Countries: Systematic Review and Meta-analysis 2008–2013. J Acquir 
Immune Defic Syndr 1999. 2015;69: 98–108. doi:10.1097/QAI.0000000000000553 
22.  South African National AIDS Council. The South African National Sex Worker HIV Plan, 
2016-2019 [Internet]. Pretoria, South Africa: South African National AIDS Council; 2016 
Mar. Available: http://southafrica.unfpa.org/publications/south-african-national-sex-
worker-hiv-plan-2016-2019 
23.  Department of Health. Guidelines for Expanding Combination Prevention and Treatment 
Options for Sex Workers: Oral Pre-Exposure Prophylaxis (PrEP) and Test and Treat (T&T) 
[Internet]. May 2016. Available: 
http://www.sahivsoc.org/upload/documents/PrEP%20and%20TT%20Guidelines%20-
%20Final%20Draft%20-%2011%20May%202016.pdf 
24.  Myers JE, Sepkowitz KA. A pill for HIV prevention: déjà vu all over again? Clin Infect Dis 
Off Publ Infect Dis Soc Am. 2013;56: 1604–1612. doi:10.1093/cid/cit085 
186 
 
 
25.  May C, Finch T, Mair F, Ballini L, Dowrick C, Eccles M, et al. Understanding the 
implementation of complex interventions in health care: the normalization process 
model. BMC Health Serv Res. 2007;7: 148. doi:10.1186/1472-6963-7-148 
26.  UCSF, Anova Health Institute, Wits RHI. South African Health Monitoring Survey 
(SAHMS): An Integrated Biological and Behavioural Survey among Female Sex Workers, 
South Africa 2013 – 2014. San Francisco: UCSF; 2015.  
27.  Slabbert M, Venter F, Gay C, Roelofsen C, Lalla-Edward S, Rees H. Sexual and 
reproductive health outcomes among female sex workers in Johannesburg and Pretoria, 
South Africa: Recommendations for public health programmes. BMC Public Health. 
2017;17: 17–27. doi:10.1186/s12889-017-4346-0 
28.  PrEP: Demonstration for Implementation. TUAC02. Vancouver, Canada; 2015. Available: 
http://pag.ias2015.org/Roadmap/Index 
29.  Smith JA, Anderson S-J, Harris KL, McGillen JB, Lee E, Garnett GP, et al. Maximising HIV 
prevention by balancing the opportunities of today with the promises of tomorrow: a 
modelling study. Lancet HIV. 2016;3: e289-296. doi:10.1016/S2352-3018(16)30036-4 
30.  Department of Health, South African National AIDS Council. South African HIV and TB 
Investment Case - Summary Report (Phase 1) [Internet]. Mar 2016. Available: 
http://sanac.org.za/2016/03/22/investment-case-report/ 
31.  McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure 
prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results 
from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2015; 
doi:10.1016/S0140-6736(15)00056-2 
 
  
187 
 
 
5.3.8. Supplementary Material 
 
 
 
188 
 
 
  
189 
 
 
6.0  Chapter 6: Individual perspectives of PrEP use among FSWs in TAPS 
 
6.1. Introduction 
Chapter 6 is the final results chapter and addresses the research question associated with PhD 
Objective 5: What are the perspectives and lived experiences of FSWs taking up and using PrEP 
in South Africa? This question examines women’s specific experiences of using PrEP. In a sense, 
the analysis and results presented here are coming full circle to the results produced in the 
systematic review, and extends this literature with PrEP-related experiences of FSWs in South 
Africa.  
 
The experiences of using PrEP presented in this paper are some of the first to be reported 
among FSWs worldwide. The hope is that this paper will help to provide insight into why and 
how women will use PrEP, or reasons that they might not, within the context of sex work. 
Within the TAPS project, these data were captured through in-depth interviews with a 
selection of the study participants. These were designed to be conducted in a serial fashion 
with each selected participant at three time-points over the first nine months of PrEP use 
and/or study participation. Note that participants were not required to stay on PrEP to remain 
in the study, but were allowed to cycle on and off according to their needs.  
 
These findings support the notions of applicability and acceptability as women were asked to 
reflect on their experiences with and perspectives of PrEP use, including how it fit into their 
lives, how they made meaning of PrEP, and their interactions with the services. This paper is 
also a reflection of the “fruits” of the formative work described in Chapter 3 where PrEP 
applicability was explored from a programming perspective, as well as the acceptability of the 
planned intervention presented in Chapter 4’s presentation of FGD results.  
 
By way of additional methodological background, in addition to what is presented in the 
paper, the IDI guides were developed using the MSEM framework adapted for this PhD and 
presented in Section 1.11.3. The VOICE C guides were used as a reference for design and 
formatting (1). IDIs were analysed using thematic analysis as defined by Braun and Clarke (2). 
They define thematic analysis as “…a method for identifying, analysing, and reporting patterns 
(themes) within data”. This approach to thematic analysis features a six-phase process: 
familiarisation with the data, generation of initial codes, searching for themes, reviewing 
themes, defining and naming themes, and finally producing the report. This particular 
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approach was chosen over others, such as grounded theory (3) or interpretive 
phenomenological analysis (4), because the aim of this research was to categorise and 
understand findings, not to develop a new theory, and thematic analysis provided a flexible, 
yet effective means of accomplishing this. The theoretical position of the analysis took a 
contextualist approach, meaning the analysis reported on the experiences and realities of the 
participants as well as how societal discourses and the external environment influence how 
the participants make meaning of their realities.  
 
Additionally, the IDIs were conducted at three time-points at 3, 6, and 9 months of 
participation in the study. This is explained in more detail in the paper, however, the reason 
for choosing the serial IDI approach was to allow for developing concepts around perceptions 
and experiences of PrEP use over time, and in depth. In this paper, the focus is on the themes 
arising from these IDIs, rather than only focusing on the change over time given that the latter 
would have limited the analysis to change, potentially diminishing the depth of theme 
exploration.  
 
Transcripts were simultaneously translated and transcribed, then uploaded into NVIVO 
software for coding and analysis. Overall organizational categories were initially developed 
according to the social-ecological framework used in the IDI guide, to help categorise the data 
into smaller, more manageable pieces given the serial nature of the interviews and volume of 
data. From this point, themes were derived in an iterative fashion by reviewing the data, 
assigning codes, comparing codes across the data and refining until a set of codes were 
consolidated and themes derived in relation to the research question. This process was 
performed by two researchers independently and then compared and aligned into a unified 
coding framework. Once all data were coded, findings were synthesized to explore 
commonalities and differences across the three IDI time points as well as across participant 
perspectives. The longitudinal analysis used a trajectory approach which focuses on 
understanding individuals’ experiences over time (which was the aim of these serial 
interviews), as compared to a recurrent cross-sectional approach which usually assesses two 
time-points and is used on more of a cohort level (5). The analysis examined the data on a 
semantic level describing participant experiences as reported, as well as interpreting these 
experiences to uncover underlying ideas and concepts, much like the process undertaken in 
the meta-ethnography approach to the systematic review.  
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Additionally, as described in the previous chapter, TAPS enrolment took much longer than 
originally anticipated. This was due to several unforeseen issues with local eruptions of 
xenophobic violence and student unrest near the clinics as well as delays in launching the 
Pretoria clinic. While the original 12-month recruitment and enrolment phase of the study was 
extended, the project did not enrol the original target of 400 women on PrEP. This affected the 
participation in the IDI component of the study which was planned based on the original TAPS 
target. The aim was to enrol a random selection of up to 10% of participants in the IDIs (which 
would have been up to 40 across the two sites). This was planned instead of using purposive 
sampling due to the large number of anticipated enrolees and according to the sample 
selection method used in studies with similarly larger sample sizes, for example in the VOICE 
and MDP 301 studies (1,6).  Unfortunately, by the time it was clear that TAPS would not reach 
its target of 400, it was too late to amend the sample selection method, and therefore the 
sample size remained aligned with the enrolled PrEP arm which reached 219 participants. 
Additionally, some women who signed up for the IDIs were lost to follow up, and though the 
sampling method was calibrated to select more than 10% to account for attrition, more were 
lost than the over-sampled selection. Perhaps a reflection of the vast difference in HIV 
treatment programming requirement versus those for prevention, there were many more 
women in the early ART arm of the study who participated in the IDIs, even though there were 
just over half the number enrolled in the cohort.  
 
The paper presented in this chapter reports on and analyses the first set of salient findings 
from a rich data set. In order to conduct a deep dive into themes around PrEP uptake and use, 
this paper focuses only on the PrEP participant’s perspectives (and does not include the 
women taking early ART). Many more qualitative data were collected through the course of 
TAPS which fall beyond the scope of this PhD.  Additional papers will be forth coming 
combining the PrEP and early ART user data, and including clinic observations conducted over 
time along with provider discussion group data.  
 
The information and consent form is attached in Appendix xi, as well as the three IDI guides 
which are attached in Appendix xii.  
 
This paper is planned for submission to the journal Social Science and Medicine.   
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6.3.1. Abstract 
Women remain highly vulnerable to HIV infection where in sub-Saharan Africa they make up 
56% of all people living with HIV, and female sex workers (FSWs) face some of the highest HIV 
prevalence and incidence rates. Oral pre-exposure prophylaxis (PrEP) is a new HIV prevention 
intervention with the potential to stem the epidemic among populations at highest risk, such 
as FSWs. In these early days of implementation, end-user perspectives of actual use in ‘real-
world’ settings are critical to the success of PrEP. This paper presents findings from serial in-
depth interviews (IDIs) conducted with FSW participants during the course of the Treatment 
And Prevention for Sex workers (TAPS) Demonstration Project in South Africa. The overall aim 
of the interviews was to elicit feedback on the uptake and use of both an early antiretroviral 
treatment (ART) for HIV-positive and PrEP intervention for HIV-negative FSWs integrated into 
an existing, comprehensive health programme tailored for sex workers. This paper specifically 
explores the lived experiences and perceptions of taking up and using PrEP among FSWs 
engaged in the TAPS Demonstration Project. Interviews were conducted with randomly 
selected participants during their 3, 6, and 9 month clinic visits, which aimed to allow for 
observation of change over time in reported experiences of PrEP use.  The thematic analysis 
primarily focuses on elucidating the broader perspectives and positioning of PrEP within 
women’s lives.  
 
This research provides insight into the risks and responsibilities that women perceive in their 
lives as prominent drivers in taking up and using PrEP, the ways in which women adopted PrEP 
to mitigate their risk or ameliorate these realities, and the characteristics of PrEP that they 
most valued, all of which are critical to consider within the context of implementation. 
Disbelief in the existence and/or efficacy of PrEP affected the motivation of women to come to 
the clinic and to maintain use. As one of the first reports of personal experiences and 
perspectives of actual use of oral PrEP among a group of FSWs outside of a clinical trial setting, 
this research shows that it will be important to ensure accurate, relevant, and widespread 
messaging in communities to generate demand and support for PrEP. To achieve its potential 
as an HIV prevention game-changer, PrEP implementation requires in-depth, qualitative 
research to understand if and how it impacts on women’s lives and what motivates them to 
take it up and adhere. 
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6.3.2. Introduction 
The efficacy of dual drug combination (tenofovir and emtricitabine) oral pre-exposure 
prophylaxis (PrEP) for preventing acquisition of HIV in HIV-negative individuals has been 
extensively investigated and reported (1). PrEP has been incorporated into combined 
antiretroviral guidelines for prevention and treatment by the World Health Organization 
(WHO); is featured in HIV prevention guidelines in several countries and regions; and has been 
approved by regulatory bodies in at least 15 countries (2). In most countries currently 
implementing or testing the implementation of PrEP, the delivery is focused towards key 
populations at highest risk of acquiring HIV, following recommendations from mathematical 
modelling (3,4) as well as the WHO guidelines.  
 
The focus on key populations stems from the relatively high cost of PrEP which would be 
mitigated by reducing new infections where they are highest, and from the need of these 
particular populations for new options to prevent HIV transmission when exposure occurs. 
Though not entirely termed as a key population, women in general are vulnerable where in 
sub-Saharan Africa they make up 56% of all people living with HIV (5). Female sex workers 
(FSWs) are a subsect of this population, who face some of the highest HIV prevalence and 
incidence rates (5). While FSWs were not included as a specific focus population in the oral 
PrEP efficacy studies (though they were inherently included in the studies of high risk women 
(6,7)), they are now the focus of many key population implementation studies in various 
phases of research across the globe(8). In South Africa, FSWs make up an estimated 91% of the 
sex worker population (9), and experience HIV prevalence rates as high as 72% in the greater 
Johannesburg area (10). 
 
As the newest, proven HIV prevention method, PrEP represents an additional opportunity for 
protection among FSWs who often experience difficulties in ensuring condom use. Key factors 
affecting their vulnerability include ability to negotiate condom use, violence, poverty, and 
substance use (11–16). These factors, in addition to the distinctive structural issue of 
criminalization of sex work in most countries, make FSWs both uniquely suited for PrEP but 
difficult to design interventions for. In this regard, ‘real-world’ PrEP studies for FSWs thus far 
have centred on using an implementation science approach to determine how to integrate 
PrEP into existing service structures. Beyond the practicalities of implementation, however, is 
the need to better understand FSWs’ individual perspectives of PrEP.  
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In these “early days”, end-user perspectives of actual use in ‘real-world’ settings are critical to 
the success of PrEP, and will ultimately determine the fate of future programming. This paper 
presents findings from serial in-depth interviews (IDIs) conducted with FSW participants during 
the course of the Treatment And Prevention for Sex workers (TAPS) Demonstration Project in 
South Africa. This sample represents one of the first set of FSWs to take up PrEP and report on 
individual perspectives of actual use. The line of inquiry was situated within a holistic approach 
based on a social-ecological framework, denoting reflections on the real and practical, rather 
than theoretical or trial-based use (17). This research provided the opportunity to examine 
motivations for and barriers to uptake, as well as what the women most valued about their use 
of PrEP.  Such data will help to inform social marketing and education campaigns to generate 
demand and encourage PrEP uptake and adherence.  
 
The overall aim of the interviews was to elicit feedback on the uptake and use of both an early 
antiretroviral treatment (ART) for HIV-positive and PrEP intervention for HIV-negative FSWs 
integrated into an existing, comprehensive health programme tailored for sex workers. This 
paper will specifically explore the lived experiences and perceptions of taking up and using 
PrEP among FSWs engaged in the TAPS Demonstration Project.  
 
6.3.3. Methods 
The qualitative research presented here was completed as a component of the TAPS 
Demonstration Project which was an implementation study designed to assess whether it was 
feasible, acceptable, safe and cost effective to roll out oral PrEP and early ART as part of an HIV 
intervention to FSWs in two urban clinics (Johannesburg and Pretoria) in South Africa (4). TAPS 
was launched in March 2015 and completed in July 2017. 
 
A selection of women enrolled in the TAPS PrEP arm were invited to participate in the 
additional IDI qualitative research component during their month 1 clinic visit. TAPS 
participants were selected using a random sampling algorithm set to select a sample of 15% of 
those enrolled with the aim of enrolling a sample of up to 10%. This was according to the 
original design which sought a total enrolled cohort of 400 women across two sites. Women 
who accepted were required to complete an additional informed consent process for 
participation in the IDIs at the month 1 visit, and were then scheduled for interviews to be held 
on or around their 3, 6, and 9 month clinic visits. After each completed IDI, participants were 
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given R50 (~4 USD) as travel money, however there was no other monetary incentive given in 
connection with TAPS participation.  
 
Initial interview guides were developed based on findings from a systematic review of 
qualitative evidence on women’s perspectives on use of female-initiated prevention products 
in sub-Saharan Africa (18,19), as well as results from formative research conducted in 
preparation for TAPS (20), including focus group discussions with potential users (21). The 
premise and structure of the interview guides were based on the Modified Social-Ecological 
Model (MSEM) designed by Baral et al (22) to facilitate a holistic and broad inquiry. In practice, 
we took the levels illustrated in the MSEM, and built questions expanding from an individual-
level to the broadest level as the HIV epidemic. The first interview guide was then adapted 
slightly for the second round of interviews, based on findings from the first round. The guide 
for the third round was similarly developed. In this way, themes were linked to follow stories 
of product use over time, but also adapted to changes observed over time to capture relevant 
topics.  
 
The overall aim of the serial interview (often called Longitudinal Qualitative Research or LQR 
(23)) approach was twofold: 1) to see if and/or how women’s realities changed over time with 
use of PrEP, and 2) whether they may become more open with the interviewer over time and 
provide richer narratives of their lives than those presented in the first interview, hopefully 
reducing social desirability bias in responses (24). While this method has been more prevalent 
in cancer-related research (23), it has more recently been employed in qualitative components 
of PrEP-related trial research (25). It should be noted, however, that the change over time is 
not the primary focus of this particular paper as it would have limited the exploration of 
themes to those in which change over time rather than allowing for a broader exploration of 
the data. It would be difficult to fully comprehend the change over time in this particular 
research without first looking at broader perspectives and positioning. Instead, this aspect will 
be examined in further detail in a future publication likely combining PrEP and early ART, 
however, it will be presented here as it relates to the key emerging thematic findings. IDIs 
were conducted in the participant’s preferred language, usually a combination of local 
vernacular and English, and lasted up to 1.5 hours. Interviews were later translated and 
transcribed simultaneously by research assistants into English.  
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Analysis of the data began with development of a coding framework created separately by two 
researchers and then compared. A final framework aligning codes was developed and 
employed in 100% coding by both researchers of all transcripts. The framework and transcripts 
were uploaded and coded in QSR NVIVO 10™. Each round of interviews was coded in a 
separate database using the same coding framework.  
 
After coding was complete, the two researchers compared findings and discussed any 
differences in coding to align results. This process was completed first, before the analysis of 
the serial aspect of the data. Thematic analysis was led by the first author, using the Braun and 
Clarke method (26). This approach involves a six-phase process: familiarisation with the data, 
generation of initial codes, searching for themes, reviewing themes, defining and naming 
themes, and finally producing the report. In this regard, we adopted a contextualist position, 
where the analysis aimed to report on the experiences and realities of the participants as well 
as how the external social environment influenced how the participants make meaning of their 
realities in relation to PrEP.  
 
All interviews were included in the analysis, even though there were not complete sets of 
three rounds for each participant. For those participants with second and third IDIs, change 
over time was explored by comparing the coded data associated with the prominent themes 
emerging from the initial analysis across the time points for each participant. This is called a 
trajectory approach, and was chosen since the aim was to take into account “individuals’ 
experiences over time” (27).  As there were fewer second and third round IDIs and the change 
over time was confined to the themes included for this analysis, it was possible to employ a 
simplified matrix approach and compare results worksheets (developed in Microsoft Word) for 
the three coded databases by hand. This was conducted independently by the first and second 
authors, and then findings were compared and found to have few discrepancies which were 
resolved. 
 
Ethical considerations 
All women participating in the IDI component of TAPS completed both the main TAPS study 
and separate IDI informed consent processes. The entire TAPS study was reviewed and 
approved by the Wits Human Research Ethics Committee (reference number: 140502), and the 
IDI component was also reviewed and approved as part of a PhD project by the London School 
of Hygiene and Tropical Medicine (reference number 10102). In addition, following any reports 
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of violence during the course of these IDIs, participants were offered relevant assistance, 
medical or otherwise, as needed. 
 
6.3.4. Results 
From those invited across the two sites, 18 women from the PrEP arm agreed to participate in 
the IDIs, 11 in Johannesburg and 7 in Pretoria. Following the first round, 10 women completed 
the second round of IDIs (4 in Johannesburg, 6 in Pretoria), and 6 completed the third round (1 
in Johannesburg, 5 in Pretoria). This dropout relates to the overall rates of loss to follow up 
across the larger TAPS study (28). In total, data from 34 interviews were coded and are 
included within this analysis.  
 
The ages of the PrEP IDI participants ranged between 23 and 40, with 10 between the ages of 
23-30, and 8 between the ages of 31-40. None of the women were married, though nine of 
them had a steady partner, three of whom lived with their partners. A majority of the women 
were originally from Zimbabwe (n=12), one from Lesotho, and the rest from Gauteng, 
Mpumalanga, and Eastern Cape provinces in South Africa. Most of the women had at least 
some high school education, with three only having completed primary school. Finally, most of 
the women worked in brothels (n=12), while the rest worked on the street or in other less 
formal settings such as vacant lots.  
 
The IDIs aimed to situate PrEP within women’s lives, including every day worries, relationships 
with family, friends, and partners, caring for children, and navigating their working situations. 
The data presented here fall into themes describing their perceptions of risks and 
responsibilities and how PrEP fit into their lives, their experiences of PrEP use, and reflections 
on related interactions with others. These data reflect both a practical implementation (or 
public health) perspective of services and lived experiences. Each participant quote is labelled 
with a pseudonym, the location (JHB = Johannesburg; PTA = Pretoria), and the IDI number (e.g. 
first, second, third round).  
 
Positioning PrEP in the wider context of women’s lives: risks and responsibilities 
Each of the IDIs began by exploring women’s personal realities: how they were feeling, their 
worries and concerns, and their everyday meaningful experiences beyond HIV or safer sex. It is 
within this broad context that PrEP was considered and enacted. Emerging as one of the 
strongest themes among and across the interviews was women’s articulations of risk and 
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personal responsibilities. Risks arose from their jobs in sex work resulting in poor health from 
STIs or HIV, or from violence which was common both in sex work and the inner cities in which 
they lived. There were also risks from main partners where condom use was limited. 
Responsibilities centred on money, needing income to support themselves and family 
members, as well as pursuing possibilities to improve their lives.  
 
In one way or another, risks and responsibilities were universal, in particular around sex work: 
“ No I worry about the life that I’m living …. that until when will I be living this life of this job, if I 
could just provide for my children and I just pray that if I can get a job so that I can live a 
normal life as other people” (Maggie, JHB, IDI 1). The burden of the job and its risks compared 
with the need to make money was a daily personal conflict: “Yeah it was like something that is 
torturing me every day. And if I’m doing it, I will be telling myself I am digging my own grave 
here” (Nancy, JHB, IDI 1). 
 
As reflected in their demographic descriptions and voiced in the IDIs, most of the women did 
not have a sufficient level of education nor skills to apply for other jobs. Some were attending 
school during the time of the project and were supporting themselves and family members 
through sex work. “I couldn’t study because of the baby …. I had to run away from them 
[school] because they kept asking me questions. There is a teacher who I told because she had 
seen me by the street and I had to explain it to her why I did what I was doing” (Polly, JHB, IDI 
3). Polly acknowledged through the course of her interviews her desire for an education which 
conflicted with the necessity of working to provide for her daughter, as well as with her ability 
to come to the clinic. Her story represented a conflicting dynamic common to many of the 
women where they wanted and needed to continue engagement in care but personal 
responsibilities made this difficult. In her final interview she articulated her specific desire 
around future employment: “I wanted to be a nurse but at the moment I can’t” (Polly, JHB, IDI 
3). While none of the women in these interviews had moved to new jobs during this project, 
over the course of the IDIs ideas for the future became more tangible. 
 
Many of the women were the sole providers for their families and felt the daily stress of 
supporting them resting heavily on their shoulders: “Mostly the main thing which is worries me 
is my kids, that is the most worrying. Me at home, that I must fix everything no matter even to 
do this situation of work is because of the family thing, like my kids and my mom and my dad” 
(Brenda, PTA, IDI 1). 
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The heavy weight of their perceived responsibilities emphasised a need to remain healthy and 
recognizing their risks as they related to the potential for HIV infection, was often a key factor 
in participants choosing to take up PrEP: “A month I was only telling myself I will go, I will go, 
cause I will be busy. Jah I just told myself I'll go, I'll go next week, I'll go tomorrow …. Other 
people are afraid to hear their statuses mostly” (Mbali, JHB, IDI 2). The fear of may have 
delayed interest in and initiation of PrEP for many of the participants, but it also seemed to 
contribute to a tipping point of motivation for those who joined the study and took up PrEP.   
 
When asked about their main motivations for taking PrEP, almost all of them said the same 
thing - that it was to protect their health given the risks of their work: “I am looking at the job 
that I am working its dangerous and it can give me diseases whereas I know that I am not sick” 
(Thembi, PTA, IDI 1). 
 
There was continuing underlying concern for the potential of HIV infection among these 
women, which remained even when using condoms and in their initial months of using PrEP. 
This was a pervasive sentiment. Condom breakage, a common occurrence, was a motivator to 
take PrEP: “I was so happy and wanted to join [TAPS] immediately because I had a problem of 
condoms breaking. So now even so I know that when the condom breaks there is a medication I 
have taken to prevent HIV infection” (Maggie, JHB, IDI 1). 
 
Condoms could break through the general course of sex, or when men wanted to break them 
on purpose which was a common experience and an ongoing fear: 
 
“Aaa what I can say about the pill is that the pill is good. It’s ok cause it helps us from 
getting HIV, cause sometimes you meet very rough clients to an extent that the 
condom break. Some will be knowing that he is sick, he becomes rough with us because 
he wants the condom to break. Some guys are very, I don’t know if I can say, they are 
rough or rude. I don’t know” (Hope, PTA, IDI 1). 
 
Many women described PrEP in such a way that it could be considered a second-line defence, 
which made them feel safer: “No it’s the reason to drink prevention [take PrEP] because maybe 
if I wasn’t taking it, then some clients bursts the condom and you don’t know what to do. So 
when the condom bursts and the person has a disease you will not get it” (Sisi, PTA, IDI 3).  
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This added protection also related to sex with main partners, where condoms were not usually 
employed. Women acknowledged condom use, or lack thereof, tended to define a romantic 
relationship versus sex with clients. This held true whether the women’s partners knew they 
were sex workers or not. Navigating sexual relations with main partners was challenging, but 
PrEP gave women peace of mind with their partners when they couldn’t be certain that they 
were the only lover in their partners’ lives. Among women who had main partners (e.g. 
regular, steady, or non-paying), most admitted that they couldn’t be sure they were in a 
monogamous relationship. PrEP was there to keep them safe within such relationships where 
condom use was less common.   
 
(Dis)believing in a pill to prevent HIV 
Over and above the motivation to use a product that could help to protect them from HIV and 
relieve some of the psychological burden in their lives, women needed to grapple with 
interpreting and understanding the stated efficacy of an entirely new technology. Given 
several decades of messaging that condoms were the only way to prevent HIV transmission 
during sexual intercourse, it was not surprising that the news of PrEP was sometimes met with 
disbelief: “So but on my side I'm still deciding continue taking them or stop. I don't know now. 
Like what I was saying that people they wanna know if these tablets they are working or they 
are not working. I don't know. For that one I've no idea” (Royal, JHB, IDI 1). 
 
Missy related how some of her colleagues did not believe that PrEP was real, and how she and 
her sisters investigated the PrEP product:  
 
“My younger sisters they do understand it because they even went online and check 
what is it that I am taking. And my friends, I explained to them. I even told them that 
it’s coming on public they will take it although I didn’t tell them that now its only sex 
workers that are taking this thing. I just told them that at the clinic they gave me this” 
(Missy, PTA, IDI 1).  
 
Reflecting on initial disbelief in PrEP came more often in later interviews. In her third IDI, 
Brenda reported how she had found colleagues in her room going through her bag. She 
worried they were stealing her pills, but she later found that they were actually trying to figure 
out what the pills were and whether they were real. They were all HIV-positive and couldn’t 
grasp the concept of PrEP:  
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“It seems like, the way I heard it is, like they were showing everyone ‘do you know how 
these tablets work?’ And themselves they can’t drink it …. I am still negative. They 
don’t believe it. They said ‘why you only? Us we are positive”, you see” (Brenda, PTA, 
IDI 3). 
 
The other women in Brenda’s workplace struggled to accept that, as a sex worker, Brenda 
could still be HIV-negative, therefore they grappled with the notion that she had been given 
pills to prevent HIV. They expressed genuine disbelief that preventive pills even existed. 
Brenda also admitted herself that she initially came to the TAPS clinic purely out of curiosity, 
not entirely believing that PrEP was real.  
 
This confusion about where PrEP was real and actually prevented HIV persisted because it was 
only available to FSWs in special clinics and not widely reported on in the media, as one 
participant articulated: “They ask me why it’s not on the TV or on the radio? Why is it private, 
it’s secretive? Jah they say if your clinic was real” (Nancy, JHB, IDI 1). Some participants 
described their initial apprehension about potentially being guinea pigs for drug testing, which 
was usually laid to rest during the first couple months of participation. However, interactions 
in the community were a different story. When participants told others that PrEP was made of 
ARVs, it immediately signalled illness and HIV:  
 
“Others were not happy for me they thought it was an ARV. And some understood, and 
some didn’t, and with my family they are fine. I told him [boyfriend] but at first he 
could not understand that. I sat him down and explained it to him, then he understood 
but he then asked why is only for women” (Polly, JHB, IDI 3). 
 
Another participant recounted how she asked another organization working in her community 
about PrEP: “So …. then I was asking her about the PrEP. She said they don’t have. And they 
don’t even know about it” (Brenda, PTA, IDI 3). This general lack of knowledge in the 
community about the existence of PrEP made it more difficult to believe in on a personal level 
and then to convince others, especially when only provided to a select few, as Polly’s boyfriend 
questioned in the earlier quote. Indeed, as the IDIs progressed, women suggested that 
promoting the message of PrEP to the broader community and making it available to others 
would help with supporting use by reducing the stigma around ARVs as being only for sick 
people: “jah because ah the other friend once saw that medication and asked me about it ….  
But she didn't understand, she wanted to say that they are ARV” (Polly, JHB, IDI 2).  
 
205 
 
 
Reconciling their own and others’ confusion or disbelief around PrEP was observed across the 
second and third waves of interviews. This process seemed to contribute to a commitment 
from these participants to take PrEP, and also circled back to the motivation of managing and 
mitigating risk. 
 
Disbelief in PrEP eventually dissipated for those who continued in the study, and part of 
eliminating the personal scepticism was by repeated HIV-negative test results. Motivations to 
test (and maintain PrEP use) were link to a firm desire to see continued negative results: “I 
don’t like it, but for the fact that, you guys need to see the results so I do it and I know that I am 
always negative” (Missy, PTA, IDI 1). 
 
Over time, personal belief paved the way for participants to prove to others that PrEP was real, 
since they were still HIV-negative. This elicited interest in PrEP from people outside of the 
study: “Yes, friends and neighbours. Because I want them to get the same services I got. Like 
my friend she wants to take it and I told her about mine” (Polly, JHB, IDI 3). After using PrEP for 
some time, women also wanted it for their main partners: “I want to ask about this PrEP. I 
have a boyfriend. Is it possible for him to come and take this PrEP?” (Lebo, PTA, IDI 2). 
 
Finding health, control, and well-being in PrEP 
Growing out of the acknowledgement of personal risks and responsibilities, as well as a 
confirmed belief that PrEP was real and playing a part in keeping women negative, was the 
notion of health and well-being reinforced by taking PrEP and through continuous engagement 
in care. This translated into a commitment to health, hope for the future, and a sense of 
strength and pragmatism in the present in relation to their work. Several women asserted 
their personal empowerment in taking PrEP, as Nancy told her friends: “me I’m doing it, if you 
don't it’s for your own good. I am doing this for my own life. Not for anyone” (Nancy, JHB, IDI 
1). 
 
Regular clinic visits created a sense of assurance: “No its good coming here ‘cause you will be 
knowing your health. Unlike just sitting, you are just sitting you don't know what is going on. At 
least when you come here you will be knowing at least some” (Royal, JHB, IDI 1). This, along 
with access to PrEP, created a level of added control in their lives, especially when armed with 
the knowledge that PrEP was not a forever regimen. This made it easier to rationalise use and 
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was equated with a potential end to sex work: “We just talk about that one day when we leave 
sex work we will quit the tablets” (Pinky, JHB, IDI 1).  
 
Practically, women were given the option to cycle on and off PrEP through the course of the 
study, and they were counselled on if or how they might do so with the support of a clinician. 
Many women explained how they decided to cycle off on their own, and would come back for 
retesting to be able to restart PrEP a few months later. Some of these women related how 
they would take a break when they went back to their home villages or if they stopped sex 
work for a time, which seemed again to contribute to a discourse of enhanced control that ran 
through many of the transcripts.  
 
Beyond control specifically, however, taking PrEP emerged from analysis as a source of 
positivity, stemming from an underlying feeling of safety: “I feel …. happy. I feel great taking 
Truvada. I know I am safe taking” (Anna, JHB, IDI 1). Healthiness and happiness was important 
and underscored by all of the participants in one way or another. Safety also denoted trust, 
often a synonym for control over women’s positions in their realities as sex workers: “Since I've 
been using this medication I'm feel myself like I'm healthy …. Mmm I'm just happy, just makes 
me happy and jah and I trust myself” (Polly, JHB, IDI 1). 
 
Some women felt that the pill was helping them beyond preventing HIV. In this regard, some 
of the participants reported previous feelings of illness which had dissipated: “…what I discover 
is like my health is like normal, normal I don’t feel pain like I’m shivering anytime like what I did 
last time before. Now I’m feeling a good health, a normal breathe” (Joy, JHB, IDI 1). They also 
reported overall relief from less concrete symptoms, which were more akin to general 
sensations: “’Cause sometimes I normally used, I used to like sleeping …. but now sometimes, 
something is changing in my body. I used to feel like weak, in the morning when I'm waking up. 
I think it’s helping” (Hilton, JHB IDI 1). 
 
When discussing how PrEP made them feel about sex, most women talked about the feeling of 
added safety, but not in a way which made them want to have more, or to have condomless 
sex. Most perceived changes in sex was related to their work. As one participant related:  
 
“According to the rumours, they say when you take TAPS, eeh PrEP or ARV, your inner 
vagina it becomes more hotter like when mens are penetrating they will say you are 
hot, you are hot things … like most of my clients they say ‘Yoh! You were so hot!’ So I 
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think that’s what changed. I don’t know because I cannot feel myself inside. No, I 
actually don’t like sex (Missy, PTA, IDI 1). 
 
Weight gain was a limited “side effect” (later attributed to feelings of well-being and not a 
clinical side effect), and tended to signify enhanced health and strength: “Even the weight, I 
feel like it gives me weight when I am looking at myself” (Thembi, PTA, IDI 1). While a small 
number of participants were not happy with the weight gain, for most who gained weight it 
was an explicit signifier of health, or a measure of personal fortitude and empowerment: “Mm 
I think they [pills] make me strong. It’s like now I, I am protected a lot since I use them, and me I 
can feel in my body that I am fine” (Lebo, PTA, IDI 1). 
 
Finally, there was a significant sense of altruism and a need to support their community among 
the participants who recognised value in PrEP and having access to it: “I wanted this 
programme to help all of us, sex workers” (Anna, JHB, IDI 1). This added to the sentiment of 
hope and the possibility of improving their perceived and physical positions in their work and 
life realities. Another participant felt that the act of offering PrEP to FSWs was a sign of change 
in how sex workers were perceived by wider society:  
 
“…. I feel happy there’s some of the government maybe is take care of people because 
they love everyone. They can’t choice that this one is prostitute and what. They love us. 
They put us together as one people because they care. So I have proud that if I feel like 
I have a problem, I go there and tell them what I feel and I’m negative …. they are 
preventing us rather than to sick and die, leave our kids (Joy, JHB, IDI1). 
 
Managing the practical complexities around PrEP use 
Though not as prominent a theme in the interviews as compared to the others presented here, 
the practicalities of managing PrEP use and the activities relating to it were still important to 
consider. In particular were the practical issues of daily pill taking, managing personal 
relationships in relation to PrEP use, developing supportive structures, considerations around 
behavioural disinhibition, and managing the practicalities of clinic attendance.  
 
Developing innovative strategies for pill taking was universal, including stashing a pill or two in 
a bra or a tissue in case of late or unpredictable nights, setting phone alarms, and placing the 
pill bottle in a routine location like next to a tooth brush. These were not always perfect. Like 
others, Mbali admitted to sometimes forgetting: “…. we do forget 'oh today I didn't take my 
pills!’. Before I was forgetting, I don't wanna lie. Now I don't forget” (Mbali, JHB, IDI 2). Often, 
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participants would admit when they missed doses or ended up sharing with someone else also 
taking PrEP to top up their stores when they couldn’t make it to the clinic on time:  
 
“We do share I don't wanna lie. You told us not to share, but if we run out we do share. 
We just told ourself it is one thing. We said how can we not share, but this is one thing. 
When I run out I can just say give me two. I will be drinking my sister’s” (Mbali, JHB, IDI 
2).  
  
Most of the women participating in second and/or third IDIs seemed to be more open or 
honest about struggles with pill taking, while others described becoming better and finding 
strategies for consistent pill taking. Some suggested, after taking PrEP for a while, that having 
an injectable would be better than the pill, to alleviate the burden of daily adherence, most 
likely related to their experiences with or knowledge of injectable contraception.  
 
One way or another, support systems for pill taking were important in maintaining use. Family, 
friends, or partners could be a source of support: “Jah like my sister we do take PrEP together, 
so when she is taking I take also” (Mbali, JHB, IDI 2). Loved ones who were HIV-positive could 
act as a support system for taking PrEP: “My sister is positive. So she is the one who say to me 
you must go and take” (Mandy, JHB, IDI 1).  
 
Others ended up losing family, friends, or partners over their participation in the study and 
PrEP use. This was an unfortunate development, but it also usually resulted in a reaction of 
asserting a sense of empowerment or control. For instance, Missy decided to stay in the study 
and lose her boyfriend who would not believe that she was taking ARVs for prevention, rather 
than give up taking PrEP:   
 
“I don’t have my partner anymore he dumped me because I am taking TAPS/PrEP and 
he doesn’t even believe this …. He, he dumps me because I am drinking this medication 
which he thinks I am drinking HIV ARV …. Hee ee I did explain, the thing is he lack 
information too much” (Missy, PTA, IDI 1). 
 
Disinhibition, or discontinuing condom use while using PrEP, was not reflected among most of 
the participants. Only one woman admitted to sometimes giving more oral sex without a 
condom than before she started taking PrEP, and a few women spoke of how they had 
considered not using condoms on occasion. However, given that most still relied on condoms 
to prevent pregnancy, most of them were discouraged from condom cessation: “I was scared 
because what if I get pregnant? So if I get pregnant I put my life risk” (Joy, JHB, IDI 2). Others 
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asserted the importance of maintaining broader sexual health, and highlighted the important, 
but incomplete, contribution that PrEP made in this regard:  
 
“I worry about my health. Because without my health I will not be able to provide for 
my family …. but I make sure that I prevent all of them. I prevent STI using condom, and 
prevent pregnancy again using condom and by eeh mmm using the injection, and I also 
prevent HIV by using PrEP” (Missy, PTA, IDI 1). 
 
Finally, personal treatment at the clinic made it easier to keep coming: “I like the fact that 
when I come to the clinic they tell me I look nice, they remember me, and they will ask me what 
month am I here for. They will tell me go to this one [staff member], go to that one” (Missy, 
PTA, IDI 1). The feeling of the clinic was a big draw for participants in both locations: “The 
study is a very good thing to attend and you feel comfortable and safe” (Maggie, JHB, IDI 1). All 
participants related how the service at the clinic supported their PrEP use and attendance: “…. 
because you guys are free, you are welcoming and one won’t be shy to express and say what 
they came to the clinic for” (Joy, JHB, IDI 2). 
 
6.3.5. Discussion  
This is one of the first reports of personal experiences and perspectives of actual use of oral 
PrEP among a group of FSWs outside of a clinical trial setting. This research provides insight 
into the risks and responsibilities that women perceive in their lives, the ways in which women 
adopted PrEP to mitigate their risk or ameliorate these realities, and the characteristics of PrEP 
that they most valued, all of which are critical to consider within the context of 
implementation.  
 
The findings produced from this research are grounded within the MSEM framework, where 
personal views and factors interact with and are influenced by social and sexual networks, 
community, societal and public policy, and the HIV epidemic itself. While the findings were not 
presented within this framework, the components are visible within the themes where 
community perceptions of PrEP influenced personal beliefs and experiences of use, or where 
knowledge of the vast epidemic made it difficult to believe there were still HIV-negative FSWs 
left to take advantage of new prevention methods.  
 
Disbelief in the existence and/or efficacy of PrEP was a prominent theme, which affected the 
motivation of women to come to the clinic (as reported by those in the IDIs), and also affected 
women trying to maintain use. When those around the users are constantly questioning 
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whether such a preventive product can be real, it may be difficult to continue use. This could 
speak to reasons for dropout in the larger TAPS study for which the primary, programmatic 
results have been presented (28). Indeed, targeting this PrEP intervention to a population at 
highest risk may have risked the trust in the product and its ability to prevent HIV as 
community education was not widespread. This disbelief was also a phenomenon seen in the 
VOICE-D sub-study and HPTN/ADAPT studies which found scepticism of PrEP efficacy to be a 
significant barrier to use (29,30). Both Normalization Theory (31) and the Diffusion of 
Innovations (32) speak to the imperative of community assimilation of interventions for 
successful implementation. Indeed, without belief in and demonstration of efficacy on a 
personal level (e.g. repeated negative HIV tests with PrEP use), little engagement can be 
expected. This was underscored by the participants in the IDIs in every round, and often raised 
ethical quandaries around not being able to provide others with PrEP. The clinic did, however, 
allow and promote couples testing as desired by the participants.  
 
Risk, and risk perception (33), have been extensively researched and debated in regards to 
translating into effective HIV prevention uptake (34–36). Research published from the 
FEMPrEP efficacy trial found that women in the study who did not maintain PrEP use also did 
not accurately assess their own risk (37). In the TAPS study, the primary results suggest that 
the population accessing PrEP women may be at self-acknowledged high risk, which was 
confirmed repeatedly through the IDIs (28). However, it is unclear whether those who dropped 
out were accurately assessing their own risk or not, though one woman who dropped out of 
the PrEP arm early returned later with an HIV-positive result. The risks articulated in these IDIs, 
however, were directly linked to the dangers of sex work and the response to these was 
closely intertwined with the acknowledgement of personal responsibilities. In addition, these 
personal responsibilities could also contribute to women’s abilities to maintain use if priorities 
for making money or going to school prevented them from making it to the clinic on time for 
visits and PrEP refills. At the same time, stress around condomless sex with main partners 
seemed to be reduced for some women who worried they might be at risk when partner 
fidelity was unclear.  
 
While sex work can be a choice and many women have been empowered in their engagement 
in it (38), women in this sample of sex workers overwhelming felt that they currently had no 
options to transition out. Most transition programmes have failed because they don’t offer 
women options to make enough money to meet their perceived responsibilities (39). In these 
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IDIs, women had mixed feelings about how to move on to other employment, with some 
asking for jobs in the clinic and others pursuing educations with the hope of empowering 
themselves to advance.  
 
The notions of empowerment and control were underlying currents throughout the findings of 
these IDIs. While most of their worries remained constant throughout the progression of the 
interviews, there was also an alleviation of stress which occurred as PrEP efficacy became a 
personal reality. PrEP is not a magic solution to all problems, however, it started to symbolize 
hope and future prospects, as well as added safety, where women could view their business as 
business without as much fear, and sexual interactions with partners were less worrisome.  
 
Interestingly, the findings in this paper at the thematic level are very similar to what has been 
published so far from qualitative research of PrEP use among MSM. Research published from 
an open-label PrEP study (following the iPrEX efficacy trial) presented relief from stress around 
the possibility of HIV infection and a sense of security as additional benefits of using PrEP (40). 
These feelings did not seem to change sexual behaviour, which from analyses conducted thus 
far and what was has been reported in our qualitative research, is also what happened in TAPS 
(28). Similar findings regarding the alleviation of fear around HIV were presented from another 
study of MSM in the United States (41). Encouragingly, this research suggests that PrEP use 
may provide sources of critical, constructive, and empowering HIV protection for those at 
highest risk of HIV without subsequent risk compensation, as was widely feared (40,42–45).  
 
Not as many women returned for second and third IDIs as hoped, which is a risk with any 
longitudinal research and in particular with more transient populations such as sex workers. It 
is difficult to assess why participants drop out over time when they do not provide specific 
reasons themselves. However, based on what we learned here and what was learned in earlier 
research preparing for the TAPS study (20,21), it is likely that a combination of social dynamics 
around belief in PrEP and its efficacy (including stigmatization of taking ARVs as a sign of 
illness), personal risk assessment which may fluctuate over time, personal responsibilities 
which supersede clinic visits and participation in research, and potential issues with substance 
use probably contributed to retention. For these reasons and to further unpack the dropout 
seen in TAPS to help support PrEP programming, additional research is being considered to 
potentially interview women who were lost to follow up, to determine the reasons.  
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Despite the limited number of second and third round IDIs, the process of serial interviews 
enabled us to examine progression of thinking and feeling around PrEP use. In most cases, the 
participants became more committed over time, and discovered personal strength in their 
commitment, even if adherence was not always perfect. Their willingness to be more open 
about issues with product use grew over time, which was a benefit of this method. The 
practicalities of use were not the central themes for any of the IDI participants, however, 
women were able to share how they managed adherence or cycled off and on PrEP over time. 
One prominent component of managing PrEP use, which became more and more apparent 
over time, was the development of supportive structures for pill taking. Some women found 
support from partners, but many more had family members or friends who were already HIV-
positive and could provide inside knowledge of pill taking habits. This reinforces the idea that 
synergies can be found among HIV-negative and positive populations, which may also help to 
destigmatise interventions.  
 
Limitations 
The study ended up only enrolling just over half the originally planned sample size, which 
therefore limited the range of perspectives possible to include. Additionally, we planned to 
capture perspectives of women using PrEP as well as those cycling off, however those women 
who cycled off rarely stayed in the study. The study sites were also limited to urban settings, 
therefore findings may not translate to other contexts. While these are clear limitations of this 
research, it should also be noted that the interviews did reach saturation of data, where 
personal stories did vary but themes were consistent across FSW accounts.  
 
6.3.6. Conclusion 
PrEP represents a valuable new HIV prevention option for women in sex work who are able to 
remain care. Risks and responsibilities were the main expressed drivers of PrEP uptake and use 
in these interviews, however, personal and community disbelief in the reality of PrEP efficacy 
challenged this. As PrEP programming is scaled-up, it will be important to ensure accurate, 
relevant, and widespread messaging is employed in communities to generate demand and 
support for PrEP use, even if use is to be focused for those at highest risk. PrEP could be one of 
the most significant game-changers in HIV prevention for the past 20 years, and requires this 
kind of in-depth, qualitative research to understand if and how it impacts on women’s lives 
and what motivates them to take it up and adhere. 
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7.0 Overall Discussion and Conclusions 
 
The findings in this PhD represent lessons learned in one of the first implementation studies of 
oral PrEP for FSWs in sub-Saharan Africa. This body of research is part of the beginning of a 
new wave of HIV prevention programming as well as the culmination of more than 20 years of 
scientific discovery and product development now being taken to market. This PhD reviewed 
the qualitative evidence on previous research concerning HIV prevention products initiated 
and controlled by women, described the process and lessons learned in designing a new PrEP 
intervention, presented community perspectives of PrEP immediately before implementation, 
assessed key characteristics of women taking up PrEP, and explored the perspectives of a 
selection of women who used PrEP to elucidate the reasons for PrEP use and how it fit into 
their lives. Each section of research addressed the overarching aim of examining the 
applicability and acceptability of PrEP for FSWs in South Africa.  
 
This chapter summarises and synthesizes the findings from this research by addressing each 
research question linked to the PhD objectives, discusses strengths and limitations, includes 
suggestions for future research, policy and practice, includes personal reflections on the 
research, and presents conclusions.  
 
7.1. Summary and Synthesis of Findings 
Objective 1: What are the motivations and barriers to uptake and use of female-initiated HIV 
prevention products in sub-Saharan Africa? 
The systematic review in the form of the adapted meta-ethnography brought together data 
from many populations of women in different countries in sub-Saharan Africa and examined 
several products. Although not all of the products were successful in preventing HIV or getting 
to market, the qualitative research derived from all of the studies provided important lessons 
which can be applied to future product development as well as implementation of newly 
proven products. While much of the earlier qualitative research has focused on the 
acceptability of specific product attributes or specific aspects of motivations for use, such as 
the ability to use a product covertly for women, the analysis in this review found that core 
elements of sexual satisfaction, trust, empowerment and control were more important to 
women in terms of HIV prevention product uptake and use. These elements do not operate 
independently of one another and are mediated by other influences, such as product use in 
relation to the social environment where stigma and other people’s perspectives may 
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influence uptake and use. Personal well-being, in terms of health and personal empowerment 
situated within the realities of women’s lives, also interacted with the core influencing factors 
by mediating the ability to trust a product or a partner depending on how the prevention 
product affected relationships, for example. Risk reduction and efficacy, and product attributes 
played a more peripheral, but important role in how the products were perceived, especially in 
regard to initial acceptability. For instance, while covert use could be part of strengthening 
empowerment and control, this could all be suddenly removed by lack of trust from a romantic 
partner or if suspicion arose from discussion with friends or family that the product was 
actually designed to cause illness rather than prevent it. Effectively, the systematic review in 
Chapter 2 argues that all of these elements must be taken into account when developing and 
implementing a new HIV prevention product for women, or risk it not meeting the needs of 
the end-users.  
 
The findings from this paper provided the basis for exploring a holistic approach to fill gaps in 
PrEP implementation knowledge through the entire process of designing, developing, 
implementing, and analysing the TAPS Demonstration Project. The design and development 
process was specifically built using an adaptive, grounded approach in order to allow for 
holistic, comprehensive thinking and responsiveness to the needs of the women who were 
potential study participants and PrEP users. Therefore, the elements from this review were 
built into the continuing lines of inquiry throughout this PhD and the larger TAPS project, also 
using the MSEM to situate the research.  
 
Objective 2: What are the practical and contextual factors which might affect the uptake and 
use of PrEP among FSWs in South Africa?  
With lessons learned in mind, the process of designing a PrEP intervention for FSWs in South 
Africa to be implemented and evaluated as part of the TAPS project was undertaken by 
examining all possibilities for modes of delivery, programming, end-user and stakeholder 
perspectives, as well as what was feasible. This was a learning process as well as a nearly 
simultaneous decision-making process. Additionally, final decisions often ended up very 
differently from where the research began. This was especially true for site selection, where 
the original plan was to choose three diverse sites from among the large network of sex 
worker clinics already supported by Wits RHI. However, after physically seeing the sites, talking 
to the clinicians, local DoH representatives, and FSWs, it was clear that the differences 
between sites were so vast, and sites spread so far apart, that having two sites closer together 
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where there were greater similarities was going to make for better management and 
measurable outcomes overall. The factors contributing to these differences were the types of 
sex work locales, continuous versus intermittent migration of the FSW populations, and social 
and economic factors, in addition to some sites not having adequate clinical facilities or links to 
appropriate laboratories, or support from the local health departments. These lessons were 
not only important for designing the PrEP intervention for TAPS, but also for the eventual 
government rollout which began on 1st  June 2016 in South Africa.  
 
In addition, through the process of this design exploration, it became very clear that PrEP and 
early ART should and could be implemented together. This viewpoint came from stakeholders 
themselves, who in early consultations underscored that bringing in a new prevention method, 
especially ARV-based, would be better accepted by the community if options were also 
available to those who were already HIV-infected. This was highlighted by representatives 
from other PrEP demonstration project country teams during an international sex worker 
stakeholder meeting on PrEP, where they described how PrEP could threaten the community’s 
sex work market, and therefore early ART (or treatment as prevention as it was termed at that 
time) had to be a part of the mix (1). This was further supported by consultations in South 
Africa, where the argument was less about displacing the sex work market and more about 
ensuring unified messaging around HIV prevention (ARVs could offer protection if given to HIV-
negative and positive sex workers). This was in addition to prioritising options for a population 
with the highest prevalence rates of HIV (2), and preserving an important ethical standpoint of 
not risking treatment for those who were already infected by appropriating budget and drugs 
to those who were not (3). The latter was a highly debated topic concerning PrEP before 
implementation studies were launched (4–6), and therefore one of the aims of the TAPS 
development and implementation was to demonstrate the synergistic feasibility of 
programming PrEP and early ART together, as well as the benefits to the community (7). While 
the larger answers as to how these synergies developed in terms of feasibility lie beyond the 
scope of this PhD, it was important to include here the existence of implementing early ART 
alongside PrEP, as PrEP could not be delivered in a vacuum, and indeed valuable lessons were 
learned from interactions with HIV-positive women who could represent a strong source of 
support for PrEP and PrEP users.  
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Objective 3: What are the community-level perceptions of PrEP in terms of acceptability 
within the context of imminent implementation among FSWs in South Africa?  
In order to holistically approach the impending implementation of PrEP (and early ART), the 
FGDs conducted at the end of the TAPS formative research process and immediately before 
project launch combined both HIV-negative and HIV-positive women as well as discussions of 
both products. These discussions built on the findings of the systematic review and the earlier 
design process, where the questions posed in the FGDs began from a more general view of 
FSW’s previous experiences with healthcare, what was important to them in terms of care, and 
how their social circles and lives interacted with services. This set the context of experiences in 
clinics as well as with the larger community, how partners and other loved ones may have 
influenced engagement in care, and how perceptions of the HIV epidemic may have fed into 
the participants’ previous motivations for seeking care. This allowed for PrEP and early ART to 
be conceived of by the groups within these contexts and be able to discuss as a group how the 
interventions might relate, and work or not work.  
 
Although both HIV-negative and positive women were combined in the FGDs, the paper 
presented in this PhD focused specifically on the groups’ consensus regarding PrEP. The overall 
finding was that PrEP was highly anticipated and endorsed. Many of the women in the groups 
added their names to waiting lists for the study, and were anxious to know when PrEP would 
be available. Concerns voiced among the groups revolved around the possibility of 
discontinued condom use, issues with pill taking in relation to the ability to form adherence-
related habits, and potential issues with substance use which are generally prolific throughout 
the sex worker community, mostly as a coping mechanism (8). Interestingly, women 
acknowledged (on their own) the potential for risk disinhibition and risks in rumours that could 
develop around fear of side effects, which have been concerns voiced in other studies and in 
the larger PrEP field (9–11). This connects back to the trust in product element, as well as in 
information circulating about a given product, illustrated in the systematic review. The fact 
that these issues were quickly recognised by potential future users, as well as those who might 
support those users, could provide some reassurance and signal to implementers that the 
community could handle the PrEP intervention given their keen insights and understanding of 
the likely complexities.  
 
The normalization of PrEP was also highlighted in the FGDs as an important factor to consider 
in advance of and during implementation. A common thread through the discussions was the 
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stress which comes with the fear of HIV and being HIV-positive, which is accompanied by ARV 
treatment which has traditionally been a symbol of illness (12). From the participants’ 
perspectives, with the introduction of PrEP came an opportunity to destigmatise ARVs since 
both HIV-negative and positive women would then be taking them. ARVs could then have the 
potential to become a symbol of wellness, and the inevitability of becoming HIV-positive and 
sick would no longer be a foregone conclusion for those who were still negative.  
 
These insights were invaluable in tailoring the final messaging for the TAPS project, and helped 
to provide evidence of desire for PrEP among FSW communities in South Africa to the 
international community, which was not convinced that PrEP would be positively received at 
the time (1). This research created a logical bridge from formative research to the actual 
implementation of PrEP in TAPS.  
 
Objective 4: What are key characteristics of FSWs who take up and use PrEP?  
The key demographic characteristics of women taking up PrEP in TAPS, as defined by the 
literature and South African context (13–17), were: age, relationship status, level of education, 
place of work, and place of birth. The majority of the TAPS study population taking up PrEP 
was between 21-30 years of age (with a full range between 18-60 years); married, living with, 
or had a steady partner; worked in brothels; and were born in Zimbabwe. While there was not 
a population-based sample with which to compare both Johannesburg and Pretoria TAPS 
demographics, the characteristics of the women in the Johannesburg sample were similar to 
those in a recent analysis of the Wits RHI Sex Worker Programme data (18), and the SAHMS 
study (2), with one exception to the latter: there were fewer single women in TAPS than in 
SAHMS (which was a much more diverse sample than the programme data). While this is likely 
a reflection of women already attending the existing sex worker clinics, it may also be an 
indication of accurate risk perception where condom use was reportedly low with main 
partners throughout the course of the study. This links with discussions among the FGD 
participants, many of whom said they had been infected with HIV from their boyfriends or 
husbands. Indeed, some of the women in the FGDs had asked whether PrEP could be given to 
married women in general since there were not always familiar with their husbands’ 
whereabouts, or their extra-marital sex.  
 
Another interesting finding was that women had higher rates of STIs at the TAPS baseline, than 
throughout the rest of the study, which suggests that condom use was not replaced by PrEP 
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use or at least that women were paying more attention to general prevention than at the start 
of the study. It is important to take into account that this effect is difficult to definitively 
measure statistically due to the large drop off over time, therefore diminishing data points. 
However, directionally this is a positive finding for those concerned with disinhibition in a high-
risk population where monetary incentives to drop condom use with clients have been 
hypothesized to have serious, deleterious effects (e.g. rising rates of STIs and unwanted 
pregnancy) (19,20).  
 
These findings are also well situated within the MSEM framework where individual, social and 
community, as well as epidemic related factors interact and start to develop a picture of the 
PrEP user among FSWs in South African urban populations. These characteristics, combined 
with the FGD data and the qualitative findings from the IDIs, present a narrative of self-
selection and risk awareness among these populations which will be valuable to consider using 
the holistic perspective of a social-ecological framework during scale-up.  
 
Objective 5: What are the perspectives and lived experiences of FSWs taking up and using 
PrEP in South Africa? 
The findings from the IDIs contribute a critical piece in developing the larger picture of PrEP 
use among FSWs in urban South Africa as one of the first sets of data on PrEP use among FSWs 
outside of a trial setting. This research took place in actual sex worker specific, primary health 
care clinics, and these perspectives help to solidify important considerations around risk 
perception, motivations for uptake and use, as well as barriers to uptake and use arising in the 
complex context of women’s lives. These notions began development in the systematic review, 
and progressed with each step of the PhD until they could be explored in further depth with 
the serial IDIs.  
 
Over the course of 34 interviews, the prominent theme of daily risks and responsibilities 
emerged as an important reason to seek PrEP and stay healthy, but these aspects could also 
contribute to women’s abilities to maintain use if priorities for making money or going to 
school prevented them from making it to the clinic on time for visits and refills. Initial and 
continued scepticism of whether PrEP was a real product and, if it was, whether it really 
prevented HIV was also a prominent and consistent theme discussed throughout the IDIs. This 
disbelief permeated women’s minds when initially considering PrEP, and even after they first 
started taking it leading some of them to admit they were not taking it all the time. Such 
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scepticism also spread throughout the community, where many colleagues and friends refused 
to believe there was such a thing as a pill to prevent HIV. One woman’s partner left her 
because he could not believe that PrEP really existed. Instead he was convinced she was HIV-
positive. This element plays back into the dynamics of trust, both in the product and among 
people, which came through as a core construct in the systematic review. The constant 
questioning of PrEP existence and efficacy may have contributed to the less than ideal 
recruitment and retention in the study, which reinforces a need to focus on educating key 
populations on these points in any future scale-up and rollout. 
 
Following on from the notion of disbelief is the need for normalizing oral PrEP as a viable and 
accepted product within the sex worker community, but also among the larger social 
environment within which use takes place. Once oral PrEP is more normalised, then the 
disbelief will dissipate and create a more supportive environment for PrEP use. Additionally, 
there is an opportunity for destigmatizing ARVs as a symbol of illness, if both HIV-negative and 
positive women are using them. This was underscored by participants in the IDIs who wished 
that more people could have access to PrEP, both because they needed the prevention option 
and because then it would help them to understand exactly what PrEP is.  
 
Interestingly, while the notion of sexual satisfaction with PrEP use was probed in the IDIs, most 
women talked about the reduction in fear of HIV over time with continued PrEP use as a 
source of contentment, and in actuality, a source of personal empowerment through control 
over their own safety. Some similarly acknowledged a reduction of stress around condomless 
sex with main partners where not using a condom defined the romantic relationship, however 
there was still worry from the women’s perspectives of potential exposure to HIV with 
unknown partner fidelity.  
 
The change over time captured by the serial nature of the IDIs was not the sole focus of the 
paper included in this PhD, as it would have limited the exploration of themes which do not 
necessarily feature change. However, the serial IDIs did support this particular analysis in 
revealing the aspects within the themes explored here which did evolve, such as the ability of 
women to talk about PrEP more openly as they became more comfortable with it themselves. 
This is clearly a feature of the women in the study who were committed to the study, to 
engaging in preventive care, and to providing feedback. A key consideration moving forward 
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will be how to build on these participant (or clinic client) attributes in scaled-up prevention to 
encourage and support more women at high risk of HIV to also engage in care.   
 
The MSEM framework was useful in organizing the research questions employed in the IDIs as 
well as ensuring the approach was holistic and allowed for discussions to span across the 
framework spheres (see Introduction Section 1.11.3). This research did not intend to prove or 
disprove the validity of the framework (as one might with a theory) and did not find that 
particularly significant changes would have been necessary for it to fit better with the data. 
Potentially, dynamics around poverty and substance use could be imbedded to add depth, as 
these may have mediated the ability to continue PrEP use according to participants in the IDIs, 
as well as experiences from the larger TAPS study. Perhaps the greatest utility of the MSEM 
more broadly is the principled notion of taking into account the element of risk and the 
disease epidemic in addition to the social-ecological spheres of influence which further 
prompted this research to add FSW specific adaptations as well as the element of HIV 
prevention to create a framework incorporating nuance. Nuance is often omitted from such 
frameworks or theories, and usually the source of criticism for many of these in the broader 
health promotion literature (21).  
 
7.2. Strengths and Limitations 
The primary strength of this research is that it is one of the first to investigate and report a 
progression of thinking and perspective from conception of the intervention for women to 
individual experience of PrEP use among FSWs. While many papers published in the last 
several years have examined the theoretical acceptability of PrEP among key populations, this 
body of work represents some of the first research to examine the real-life uptake and use of 
the product among female sex workers. This progression of research from start to primary 
results of intervention implementation is another important strength of this research, where 
each step informed the next in a cumulative fashion to develop a significant knowledge base.  
 
This work also contributes an end to end narrative of intervention design and development 
illustrating the depth and scope which can be considered within the Implementation Science 
paradigm. As discussed in Chapter 1, traditional definitions and approaches have centred on 
top-down approaches, where the nuances of programming and delivery inclusive of target 
population perspectives are not always accounted for or at least reported. In the research 
presented here, this was the starting point and fulcrum from which all work proceeded, 
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allowing for depth in design and development of the PrEP intervention which will serve as a 
source of learning for continuing scale-up.  
 
There are also several limitations to this research. First is that, while every effort was made to 
preserve a ‘real-world’ environment and experience for participants in TAPS, it was still a 
research study and carried with it certain research related attributes which could have swayed 
participant experiences in a variety of ways. For example, the informed consent process was 
lengthy due to national requirements when distributing pharmaceuticals in a research study 
not yet registered (as Truvada was for use as PrEP at the time TAPS was launched), and may 
have deterred women from enrolling (22). There were also questionnaires and most likely 
more frequent clinic visits than will eventually become the standard in South Africa and 
elsewhere, which would detract from the ‘real-world’ implementation aspect where lessons 
learned may not always be applicable to occurrences in a broader programme setting. The 
quality of care in TAPS was also different from what is typically received in general public 
health clinic settings, where nurses were able to spend more time with participants and they 
had regular access to a doctor which is also not always typical, but was necessary for ensuring 
participant safety in PrEP use. The quality of care, though not discussed in-depth in this PhD, 
was often cited by participants as an important part of their continued participation in the 
study and may have influenced PrEP use. This aspect will be explored in greater detail in 
additional, future publications.  
 
While this PhD took a relatively broad, holistic approach to the lines of inquiry developed, 
there were many additional questions which were not addressed. For instance, cost-
effectiveness and intervention impact, as well as retention in TAPS and clinical outcomes, were 
not included here as they were beyond the scope, however they are important factors which 
would further complete the implementation picture. These aspects were investigated as part 
of the larger TAPS study, however, and will be presented in separate, forthcoming 
publications. Additional areas not covered, but highly relevant to this work are the issues of 
criminalization of sex work in South Africa, migration, and violence. These are slightly touched 
upon here, but were not explored in great detail in this work. 
 
The TAPS project did not reach the 400 PrEP participants intended as the original enrolment 
goal for the study. This was due to many factors including local unrest making it impossible to 
get to the clinics, as well as issues with launching the Pretoria clinic due to local pharmacy 
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approvals. These were ‘real-life’ experiences which would affect any health programme and 
were taken into account as part of implementation research outside of a clinical trial, however 
they also contributed to a reduced sample size by almost half thereby also reducing the 
number of women included in the IDIs. This may have resulted in skewed sample 
demographics and qualitative perspectives, although comparison with other samples seems to 
confirm that the former was not the case (2,18).  
 
Finally, the populations included in the majority of this research, except for the systematic 
review and design process paper, were concentrated in specific urban locations within the 
same province in South Africa. Throughout the design process, it was clear that no two sex 
worker locales are the same, and while there can be similarities upon which health 
programming can be built, it is the differences which should be meaningfully considered. 
Therefore, the results of the latter part of this research may not be entirely generalizable to 
other settings, however the research questions are likely to be relevant.  
 
7.3. Next steps and Future Research  
All of the research contained within this PhD has already been shared in one form or another 
(publications, presentations, or data sharing with stakeholders) to help develop learning 
around PrEP implementation to progress the scale-up process in South Africa, in the African 
region, and internationally. The systematic review findings have been presented at the 2014 
AIDS conference in Melbourne, Australia (23), and also at several meetings focusing on 
exploration of data to support decision making on future prevention product and guideline 
development. The TAPS design directly influenced the designs of several studies in sub-
Saharan Africa and India through a multi-country PrEP working group. The TAPS data and 
expertise developed during the course of the study provided the foundation of the national 
South African guidelines for PrEP and test and treat for sex workers which was launched in 
2016 (24). In particular, near real-time feedback was provided to the NDoH in terms of lessons 
learned in managing recruitment, screening, enrolment, and retention as well as the synergies 
of implementing PrEP and early ART together. Additionally, this expertise and data were used 
to develop national PrEP training programmes for providers.  
 
Next steps will include further analysis of the early ART and larger service delivery qualitative 
data from the FGDs and IDIs, as well as additional analyses of the clinical, demographic and 
behaviour data, cost and impact of TAPS. These will all be shared with central databases as 
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well as published for broader comparison and learning across studies and contexts to better 
develop PrEP interventions throughout the world. Additionally, the results from the research 
can provide data for developing the current national PrEP interventions, particularly in South 
Africa where little community-based preparatory work was conducted in advance of the 
launch of the initial national pilot. An evaluation of the pilot and subsequent expansion of the 
PrEP programming is planned, and earlier findings from this PhD have fed into the design of 
research tools which could be further updated. These findings are also supporting the 
development of pilot (government-led demonstration projects) in Swaziland which are 
focusing on higher risk populations such as sex workers, but striving to expand the opportunity 
to try PrEP to a wider audience.  
 
In addition, research is being considered to follow-up with participants who were lost to 
follow-up in TAPS, as well as tracking those who were captured as informed about the study 
but did not come to the clinic for screening or enrolment to explore reasons for lack of uptake. 
This would help to balance the understanding of whether the main reasons were really the 
lack of belief in PrEP or personal responsibilities preventing clinic attendance, or whether there 
were other factors not immediately apparent which could be addressed in scale-up.  
 
In the medium and longer-term, the lessons learned in this PhD and the larger TAPS project 
can be used to help with conception of new ARV-based HIV prevention product options as well 
as those beyond the drug-based modalities. While the specifics around daily pill taking may not 
translate to a new injectable product, the women’s values and preferences (25) should remain 
consistent as shown in the systematic review. An interesting line of research would be to 
examine where some of these preferences and values may develop or change over time. In the 
interim, products and interventions built around them which respond to and support women’s 
desires to maintain their romantic relationships, safeguard against exposures to HIV, and 
confer and preserve personal health and well-being will have more success in serving the 
overall needs of women, in particular in high risk situations such as sex work. Additionally, 
particular attention should be paid to community education, or at least addressing, rumours 
which may arise regarding the efficacy or lack thereof of new products as they become 
available. Potentially the most damaging aspect of new intervention introduction is the lack of 
accurate awareness and disbelief in the existence and efficacy of a product, which is a core 
tenant of Normalization theory (26). If the community at large has doubts in an intervention, 
which could be particularly the case in relation to pharmaceuticals which enter the body and 
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can have potentially (perceived) lasting, unpredictable effects, then gaining any momentum in 
uptake beyond the innovators and early adopters who sit in the front of the Diffusion of 
Innovations curve will be slow and potentially impossible (27).  
 
7.4. Recommendations for policy and practice 
PrEP represents a game-changer in HIV prevention, but must be implemented with 
consideration for how it will be integrated into people’s lives. It is important for policy makers 
and implementers to take into account the vast body of knowledge already produced from the 
past 20 years in research and development of new HIV prevention options, as well as the 
emerging data on PrEP use as the early stages of delivery unfold. It is easy to focus on the ‘low-
hanging fruit’ regarding the practicalities of implementation – where PrEP should be delivered 
in terms of clinics, who should deliver it in terms of practitioners, and initial messaging about 
its availability. However, none of this will make a difference in successful implementation if 
there is wide-spread disbelief in the existence or efficacy of PrEP, or it is stigmatised as a “sex 
worker pill”, for instance. Social normalization will need to play a key role in PrEP programming 
if there is to be any measurable success in reaching those who need it most. This will require 
early and constant engagement with communities until a ‘tipping-point’ of understanding, or 
saturation of education, is reached. In addition, the PrEP intervention will need to be situated 
appropriately in terms of applicability within the contexts of potential users’ realities for it to 
be assimilated. If all of these facets of implementation are carefully considered, PrEP may also 
help to strengthen existing services as it provides multiple opportunities for refreshing HIV 
prevention training of health care staff as well as a new incentive for people in communities to 
seek care and explore their HIV prevention options.  
 
As shown in this research, the differences between sex worker contexts can be vast, and 
therefore a certain amount of formative exploration before implementation is merited. This is 
suggested as a best practice before introducing oral PrEP, or any other new intervention, into 
standard of care in clinics. In addition, including community members in every step of the 
process to develop and rollout PrEP interventions will be critical. Participatory research has 
been advocated, particularly in the HIV/AIDS field, but UNAIDS and AVAC who developed a 
guidance document called Good Participatory Practice (GPP) (28) which mirrors Good Clinical 
Practice (GCP) as an essential research standard. Throughout this PhD research and the larger 
TAPS project, sex workers were engaged in design and decision-making, which helped bolster 
the credibility of the research overall.  
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Continuing along the theme of inclusion, it will be important to involve, or at least allow for 
the involvement of partners in PrEP uptake and use. While the research presented here from 
the TAPS study illustrated that most women would take PrEP with or without their partner’s 
involvement, the research presented as part of the systematic review and in part from TAPS 
shows that partners will influence decision-making. Not all women will be empowered to take-
up and use PrEP, and those women are potentially at even higher risk if they are in a position 
of disempowerment. Programming for PrEP will need to allow for the maintenance, and 
potentially even strengthening of relationships which should have the added benefit of social 
support for PrEP use.  
 
7.5. Final Thoughts and Reflections 
This research spanned a number of phases, methods, contexts, and regularly interacted with 
policy and normative guidance development at local, national, and international levels. These 
were exciting and satisfying aspects of this PhD endeavour, but also challenging alongside the 
management and leadership of the TAPS project where there were high expectations of 
quality and rapid outputs. Nevertheless, this was a learning experience of a lifetime. 
 
Implementation research is never straightforward, and part of undertaking it is expecting the 
unexpected. Almost all of the aspects of the entire process, from design to analysis, were filled 
with unpredictable turns of events, however these were also important learning opportunities. 
Navigating regulatory hurdles, political relationships, and becoming accepted and a trusted 
friend of the local community brought many challenges and rewards. Perhaps the most 
rewarding on a personal level was having the opportunity to build capacity of staff from long-
time public health nurses with more than 20 years of experience in the public sector but no 
previous experience in research, to sex worker peer educators who had never had the 
opportunity to give presentations or lead their own areas of research-based work (such as 
study recruitment). This was a personal source of daily joy to see team member grow in their 
jobs and build an incredibly productive and solid team, which will be dearly missed now that 
the work is coming to an end.  
 
One of the interesting aspects of this work not discussed previously in detail in this PhD, or 
elsewhere, was the process of decision-making around options for the overall research 
approach which took place even before the demonstration project design and engagement in 
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South Africa. Early in the discussions about pursuing a demonstration project in the South 
African FSW context, considerations were discussed among the four primary TAPS 
investigators as to whether it would be possible (and/or necessary) to conduct the research as 
a randomized control trial in order to directly evaluate impact. After much debate, several 
conclusions were reached. First, that it would be unethical not to offer the interventions to a 
control group as we knew at the time that early ART (or test and treat) would eventually 
become the standard of care, and most likely during the course of the study. The PROUD study 
is an example of where the study ended up being unblinded when the PrEP intervention was 
shown to be so effective it was no longer ethical to withhold it (29). While we did not know at 
the time that this would be the case for PROUD, we did strongly suspect an RCT would be 
difficult to pursue from start to finish with no significant deviations which would make it 
unnecessarily complex. Second, there were not enough concentrated FSW populations in areas 
where we could operate and sufficiently randomize to account for heterogeneity. This was also 
considered in relation to potentially incorporating randomized, nested adherence 
interventions such as using a medication event monitoring system (MEMs) bottle caps (30) to 
more objectively look at adherence in addition to drug level analyses, however statistically it 
was not going to be possible given estimated sample sizes and the desire to only evaluate 
intervention components which could then be incorporated in a national rollout. The drug 
level analyses were justified as they did not require a large amount of blood and that could be 
drawn at the same time as standard monitoring (for creatinine) without disruption to 
participants. Third, was the limited funding for the TAPS study, which was supported through a 
number of channels, starting primarily with the Bill and Melinda Gates Foundation grant, then 
supplemented by USAID funding with donations from Gilead and Mylan of study drug and 
other in-kind support from partner projects within Wits RHI.  
 
These considerations are what led to the choice of a relatively straight forward 
implementation study with as few obvious research components as possible to avoid the 
participant experience becoming to akin to research and less real-world. In terms of the 
internal and external validity related to efficacy and effectiveness research, as discussed by 
Singal et al (31), demonstration projects fall at the far end of the effectiveness side of the 
continuum. This means, that in the end, this research had to live with a certain level of 
uncertainty around validity in the quantitative findings, especially with a reduced sample size 
and no comparison group. However, the point was always to practically answer the 
programmatic aspects (including applicability and acceptability) of delivering PrEP to FSWs in 
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clinics servicing urban sex work environments. The research presented here provides a large 
piece of that story.  
 
7.6. Conclusions 
This body of PhD research has illustrated the personal, social, and environmental nuances 
within which oral PrEP as an HIV prevention product for FSWs is taken up and used in urban 
settings in South Africa. The applicability of PrEP for FSWs is dependent upon their sex work 
contexts and the ways in which PrEP is made accessible in tailored delivery. Acceptability is a 
nuanced dynamic influenced by situating the need for PrEP within the complexities of FSW’s 
personal risks and responsibilities, reconciling trust and belief in the product, developing habits 
for ease of use, and navigating relationships. Through the research in-country, the thematic 
constructs explored in the systematic review were tested in practice and developed in more 
depth, where relationship dynamics, trust in partners and social circles as well as oral PrEP 
itself played a significant role in decision-making around uptake and use. Sexual satisfaction 
was not as central a component in this work, but empowerment and control in having the 
ability to maintain personal safety at work and in romantic relationships was still very central.  
 
The MSEM framework, linked with principles of Implementation Science, was useful in 
situating the research questions and findings in an organised and easily translatable format for 
providing evidence to further the rollout of oral PrEP in South Africa and beyond. Key 
demographic and behavioural characteristics of women who took up PrEP signal an accurate 
perspective of self-assessed risk, driven by the realities of sex work and personal 
responsibilities to support families, which were further illuminated through in-depth individual 
discussions with participants. The holistic nature in which this research was undertaken 
represented a large managerial undertaking with multiple, simultaneous processes and 
learning pathways which led to important findings around the diversity of sex work markets 
and the fluidity of social-contextual interactions which ultimately interact with the 
effectiveness of oral PrEP use. Successful policy and practice should take these complexities 
into account when developing and scaling-up oral PrEP interventions for FSWs. While the 
specifics of these complexities may not necessarily apply to all contexts and other populations, 
many lines of inquiry around motivations and barriers to use will be universal.  
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Appendix vii. Focus group participant information sheet and consent form 
 
PROJECT INFORMATION SHEET AND INFORMED CONSENT 
 
PROJECT TITLE: Focus Groups for the Sex Worker ART for Prevention Project: Assessing the 
acceptability and feasibility of a comprehensive prevention, treatment and care programme 
tailored for female sex workers, including new and current HIV prevention technologies as 
well as the test and treat approach to treatment and care. 
 
This consent form is for participants who agree to participate in a focus group interview as part 
of a research project. The following statement is to be read to the participant. 
_____________________________________________________________________________ 
 
PROJECT INFORMATION 
 
My name is ____________. I am working with Wits RHI the organization supporting the project 
to assess the acceptability of comprehensive prevention, treatment and care services for 
female sex workers (FSW).  
 
I would like to talk to you about participating in a focus group study to better understand what 
you think about the current health services you receive and whether there are additional 
services you would like access to. This information will help us understand whether there is an 
opportunity to provide new services along with existing ones. 
 
We are asking you to participate in a focus group discussion to help us understand your 
opinion about these proposed services and if you feel they make sense for your needs. We 
would like to ask you questions regarding your experiences of health services in general, if you 
have experienced any difficulties in accessing care and, if so, what those were. We would also 
like to know about your opinions of new potential options for HIV prevention and treatment. 
 
A focus group is a formal group discussion. We are asking groups of up to 10 women to join us 
for an hour and a half. If you feel uncomfortable with any of the questions asked, you can 
chose not to answer them without any consequences. You can also stop your participation at 
any time, without any consequence. If you decide not to participate in the focus group 
discussion this will not affect the services you receive from the clinic. 
 
During the focus group discussion, we will provide drinks and snacks.   
 
We have been sponsored by the AIDS Fonds Netherlands to conduct these focus groups.  
 
REIMBURSEMENT 
 
You will be reimbursed as a participant in this study for travel expenses at R50.  
 
CONFIDENTIALITY 
 
Efforts will be made to keep your information confidential through the use of participant 
identification numbers or fake names.  We will ask participants to maintain confidentiality 
however there is no way to ensure this will be respected. We will be audio-recording the focus 
group discussions, and you may choose to use a different name during the discussions. 
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However, it is not possible to guarantee confidentiality. In addition, your personal information 
may be disclosed if required by law.  Any publication of this study will not use your name or 
identify you personally. 
 
Your records may be reviewed by: 
 Wits Human Research Ethics Committee, University of the Witwatersrand, an Ethics 
Committee is a committee that watches over the safety and rights of research 
participants  
 Study staff 
 
In giving consent to participate in these interviews, you will be consenting for these people to 
review the study data. These records will be utilised by them only in connection with carrying 
out their obligations relating to this study. 
 
The researchers will do everything they can to protect your privacy. All information will be 
securely stored under lock and key for two years after publications of results or six years if 
there are no publications, after which time the information will be destroyed. 
 
YOUR RIGHTS AS A RESEARCH PARTICIPANT/VOLUNTEER 
 
Voluntary:  
 Your participation in this focus group is entirely voluntary and you can refuse to 
participate or stop at any time without stating any reason. Your withdrawal will not 
affect your access to other medical care.  
 You must inform the study team if you wish to stop participation in the focus group as 
soon as possible.  
 
ETHICAL APPROVAL OF THIS STUDY 
 
This focus group study has been submitted to the University of The Witwatersrand, Human 
Research Ethics Committee and written approval has been granted by the committee.   
 
PARTICIPANT QUESTIONS 
 
Do you as the participant have any questions? 
YES / NO  (Please list if yes) 
 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
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INFORMED CONSENT 
 
I hereby consent to participate in a focus group discussion to help assess the acceptability of a 
comprehensive HIV prevention, treatment and care service programme tailored for female sex 
workers. By signing this form, I acknowledge the following: 
 
• I have read (or have had read to me) and understood the project information 
statement. 
• I understand that the focus group is for the purposes of this research project only. 
• I am aware that the results of the study, including personal details will be 
anonymously processed into a study report. 
• Participation is voluntary and that I can withdraw at any time and for any reason. 
However, I understand that my contribution to the focus group discussions will, by 
the nature of the focus group, be known to the members of the group. 
• The focus group will be conducted at Wits RHI, in Hillbrow. 
• I will participate in a focus group of up to 10 people, conducted by two members 
of the research team and this will take approximately an hour and a half. 
• The research team members will periodically ask me to confirm during the 
discussions that my statements have been accurately understood and interpreted. 
• The focus group will be audiotaped and the tapes will be stored separately from 
this consent form.  
• I have had sufficient opportunity to ask questions and (of my own free will) declare 
myself prepared to participate in the focus group discussions. 
• These arrangements have been approved by the Human Research Ethics 
Committee of the University of the Witwatersrand in South Africa.   
 
Focus Group Consent: 
 Yes, I agree to participate in this focus group 
    
 No, I do not want to participate in this focus group 
 
Audio recording consent:  
 I agree to the audio recording of this focus group 
    
 I do not agree to the audio recording of this focus group 
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Signature of volunteer: 
Signature/mark 
or thumbprint 
 
 
Date of 
signature 
   
DD MMM YYYY 
Print name  
Time of 
signature 
: 
 
Signature of witness (if applicable): 
Signature/mark 
or thumbprint 
 
 
Date of 
signature 
   
DD MMM YYYY 
Print name  
Time of 
signature 
: 
 
Signature of study staff taking consent: 
Signature/mark 
or thumbprint 
 
 
Date of 
signature 
   
DD MMM YYYY 
Print name  
Time of 
signature 
: 
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Appendix viii. FGD Discussion Guide 
 
Interviewer ________________  Site/Venue: ____________________Date:_________________________ 
 
INSTRUCTIONS FOR THE INTERVIEWER – How to use this IDI Guide 
1. There are 3  levels of questions: 
 Numerical research questions/topic areas highlighted in gray: the questions/areas that we as researchers want to get answers to. These 
don’t need to be read aloud. 
 Discussion questions: the questions that you as the Interviewer will ask respondents in order to get answers to the research questions. 
These questions will be underlined and in bold.  
 Probes: they are indicated with a bullet. The interviewer should ensure that key topics listed in the probes have been 
addressed/discussed during the interview. So, depending on what has already been discussed, and the IDI context, you may ask these 
probes or not. 
2. Instructions/suggestions to interviewer are in italics and brackets [ ]. 
3. The discussion guide is divided into three columns.  
 The left-hand column contains the research questions, discussion questions and probes. The discussion questions are suggestions for 
getting the discussion going. It is not required to read them verbatim, but they are written to ensure some consistency across discussion. 
You may adapt the question, depending on how the discussion develops, and you as the Interviewer will have to ensure that at the end 
the research questions have been answered.  
 The right-hand column is for summarising the themes brought up by the women in the discussions. These should be summaries of the 
general issues raised in connection with the research question. These summaries should be more than just yes/no, but not longer than a 
few sentences of bullet points. They do not need to be detailed, as we have the details on the tape. Note: the summaries and yes/no 
answers should be filled by the Interviewer immediately after the FGD. 
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INTRODUCTION  
Welcome the participants and thank them for coming.  
 
Explain the general purpose of the discussion: 
“We are holding a few discussions with up to 10 women at a time to talk about experiences with health care in general and more specifically HIV 
testing, prevention and care services. These discussions will help us understand whether we can put together a set of services tailored especially for 
female sex workers that will support their needs. We would like to find out what you think about current services, what is missing from them, what 
kinds of services you wish were available, difficulties in accessing testing and care, and your thoughts about new potential services.” 
Introduce the team and the different roles of the members. 
 
Outline general ground rules such as the importance of everyone speaking up, talking one at a time, and being prepared for the moderator to 
interrupt to assure that all the topics can be covered. 
 
Address the issue of confidentiality: Inform the group that information discussed is going to be analysed as a whole and that the participants' names 
will not be used in any analysis of the discussion. 
 
Explain the presence and purpose of audio recording equipment. 
 
Before starting the discussion, the Interviewer explains to the group (please state verbatim): 
 
We will begin the tape recorder now.  [Interviewer: start the tape recorder.] 
 
As you know from your informed consent, this focus group discussion will be tape recorded today.  Please verbally indicate that you are aware 
that we are tape recording this session and that it is okay with you.  [Interviewer:  be sure to get a verbal okay from the group.] 
 
Have the group members introduce themselves. They should create a nickname for the discussion. Have them write it down on a sheet of paper that 
they will keep. Ask for any questions.  
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FOCUS GROUP QUESTIONS 
 
 Research Question, IDI Questions, Probes Summary/Notes 
GENERAL HEALTH SERVICES KNOWLEDGE SECTION 
1.  What are the group’s experiences with general health care 
services? 
 
What sort of experiences have you had getting general 
healthcare?  
 
 Where do you usually go to get general healthcare? 
(e.g. location and proximity to home and work, type 
of facility) 
 What makes a clinic good? 
 Are there services you wish you could get but are 
unable to?  
 What are some of the services you wish you could 
get, if any? 
 What are some things that get in the way of going 
to the clinic or getting services? (e.g. location of 
clinics, opening hours, waiting times, staff attitudes, 
having to pay, etc.) 
 Why would someone not want to go back to a 
certain clinic? 
 
 
 
 
 
 
HIV PREVENTION KNOWLEDGE SECTION 
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2.  What are the group’s knowledge and perceptions about HIV 
testing?  
 
What are your experiences with HIV testing?  
 
 What do you think is a good reason to get tested for 
HIV?  
 What reasons do you most commonly hear from 
others?  
 Where is the best place to get tested for HIV? Why?  
 What do you think could be done to improve and 
increase HIV testing and care service accessibility 
for women specifically?  
 
 
 
3.  What does the group know about HIV prevention? 
 
What methods are available to protect yourself from HIV 
and other diseases? 
 
 Is there anything besides condoms that people use?  
 What do you think is best? 
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4.  What does the group know about prevention for HIV-
positives? 
 
If someone is HIV positive, what can they do to protect 
their partners and/or clients?  
 
 Is there anything besides condoms that people use 
or do?  
 What do you think is best? 
 
 
 
 
 
 
5.  Is the group familiar with post-exposure prophylaxis (PEP)? 
 
Have you ever heard of someone taking tablets after they 
thought they may have been exposed to HIV?  
 
 If you know someone who has used PEP, why did 
they use it?  
 What do you think about that option?  
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6.  Does the group know anything about new HIV prevention 
options? 
 
Have you heard about any new ways to protect yourself 
from HIV?  
 
 If so, what are they?  
 
 
 
 
 
 
PrEP SECTION 
 
Introduce PrEP  
 
If they have heard about PrEP, probe on knowledge (oral PrEP, microbicides – what exactly have they heard and from where?) 
 
If no one knows about PrEP continue with the following: 
There is a new HIV prevention method called oral PrEP. It is a pill you can take once a day to prevent getting HIV. It has some side 
effects and you have to take it every day or it won’t work. If someone takes PrEP, they have to get tested regularly to make sure they 
haven’t become HIV-positive. It has been tested in clinical trials, but it is not yet available at the clinic. Some clinics may try offering 
PrEP to small groups of people to see if they will use it. 
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7.  How does the group feel about oral PrEP as an HIV 
prevention option? 
 
What do you think about prep as an option to prevent 
getting HIV?  
 
 What are the good aspects? 
 What are the bad aspects?  
 
 
 
 
 
 
 
8.  What does the group think about regular testing to be able 
to take PrEP? 
 
Do you think women would be willing to get tested for HIV 
every 3 months to be able to keep taking PrEP? 
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9.  Does the group think there is an ideal candidate for taking 
PrEP?  
 
What sort of woman should use PrEP? What sort of 
woman shouldn’t?  
 
 Should someone have certain habits in order to 
take a pill every day to prevent getting HIV? 
 Would someone need certain support to take PrEP?  
 Would someone need to have a certain lifestyle to 
take PrEP? 
 
 
IMMEDIATE TREATMENT SECTION 
10.  What does the group think about having immediate 
treatment available?  
 
What do you think about getting treatment right away 
when someone finds out that they are HIV positive?  
 
 Would people want to start treatment right away?  
 Why or why not? 
 What would be a good reason to start right away?  
 Why do you think it might not be a good idea?  
 
 
 
 
 
 
 
COMBINED SERVICES 
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11.  Does the group think combining HIV prevention and 
treatment services is a good idea?  
 
What do you think about having a clinic where prevention 
and treatment options are all in one place especially for 
women/sex workers, including HIV testing, counselling, 
PrEP and Immediate treatment?  
 
 Would women/sex workers come to a clinic where 
all of these things were offered? 
 Why or why not?  
 Are there services or features that would make a 
clinic like this better? 
 What are some examples of those things? 
 
 
 
ADHERENCE SECTION 
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12.  What does the group think about ability to take pills 
everyday such as in the case of PrEP? 
 
What do you think about taking a tablet every day for a 
long period of time?  
 
 Do you think it is possible? 
 What experiences have you had with taking 
medications everyday over a period of time? (e.g. 
antibiotics or other medication) 
 What might get in the way of taking a pill every 
day? 
 Is it easier to take a pill every day when you feel 
sick? 
 What if you don’t feel sick? 
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13.  What kind of support does the group think a sex 
worker/woman would need to be able to take a pill every 
day? 
 
What do you think would help a woman take tablets every 
day if she decided she wanted to take prep if she were HIV 
negative, or go on treatment right away if she tested HIV 
positive?  
 
 Are there certain methods or tools that would help?  
 Would social support help? If so, what type of social 
support? 
 Could a woman/ sex worker set up reminders of 
some kind?  
 What kinds of reminders? 
 Would SMS to phones help?  
 Why or why not? 
 Any other ways? (e.g. setting up a routine…) 
 
 
END DISCUSSION 
14.  Thank you for participating. Any questions or comments??  
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Appendix ix. TAPS Information sheet and consent form 
 
Participant No: ___________ 
 
 
 
Pre-Exposure Prophylaxis (PrEP) Intervention Screening and 
Enrolment Information Sheet and Informed Consent Form  
 
 
 
Study Title: 
The TAPS Demonstration Project: Expanded use of ART for 
Treatment And Prevention for female Sex workers in South 
Africa 
 
Study number WRHI046 
Study Sponsor Wits Reproductive Health and HIV Institute 
Principal Investigator Helen Rees 
Co-Investigators Robyn Eakle, Francois Venter, Gabriela Gomez 
Site Address 7 Esselen Street, Hillbrow, 2001 
Site contact numbers 0616043097 / 011 358 5424 
 
 
To the potential participant: This consent form may contain words that you do not understand.   
Please ask the study staff to explain any words or information that you do not clearly 
understand.   You may take home an unsigned copy of this consent form to think about or 
discuss with family or friends before making your decision. 
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INTRODUCTION 
Hello, my name is __________________ and I am a member of staff for this research study.  
We are inviting you to take part in a research study for female sex workers. Before you decide 
whether to take part in the study, we would like to explain the purpose of the study, the risks 
and benefits, and what would be expected of you if you agree to be in the study.  This study is 
sponsored by the Wits Reproductive Health and HIV Institute (Wits RHI), located in 
Johannesburg, South Africa. 
 
PURPOSE OF THE STUDY 
Recent studies have shown that taking antiretrovirals (ARVs) can reduce the chances of getting 
HIV in uninfected individuals, and can reduce the chances of transmitting HIV by infected 
individuals.   
 
HIV uninfected individuals can take an ARV pill every day called Truvada®, which can reduce 
the chances of getting HIV by about 75 percent. One particular study showed that the 
participants who took their medication consistently had as high as 90 percent protection from 
HIV infection. When HIV-uninfected people take medication in this way to prevent getting the 
HIV virus it is called pre-exposure prophylaxis or PrEP. PrEP has been found to be safe to take, 
meaning it does not have any significant effects on the health of the person taking it. 
 
Other research found that HIV-infected men and women who took ARVs at higher CD4 counts 
took longer to develop AIDS and were 96% less likely to pass the virus to their sexual partner. 
This use of ARVs soon after infection is called Treatment as Prevention (TASP) or Immediate 
Treatment (IT).  
 
In this study, we would like to learn about how easy or hard it is for women to take 
medications to prevent and treat HIV. Approximately 700 women over 18 years of age will be 
enrolled in this study – 400 will be HIV-uninfected women taking PrEP and 300 will be HIV-
infected women taking IT. 
 
YOUR PARTICIPATION IS VOLUNTARY 
This consent form gives information about the study that we will discuss with you. Once you 
understand what the study is about, and if you agree to participate, you will be asked to sign 
this consent form or make your mark in front of a witness to confirm that you are willing to 
participate. We will give you a copy of this form to keep at home. As we read through the form 
there may be some unfamiliar words, so we ask that you please ask us to explain anything you 
may not understand. 
 
Before you learn about the study procedures, it is important that you know the following: 
 You do not have to join this study if you do not want to, and you will not lose any routine 
medical care benefits at the clinic. 
 If you decide to take part in this study, after your enrolment visit you will be in the study 
for up to 24 months. 
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 You are free to leave the study at any time if you want. If you choose to leave at any time, 
you will not lose any routine medical care benefits at the clinic. 
 If you decide not to take part in this study, you can still join other research studies later if 
they become available and you are eligible. 
 
STUDY APPROACH 
As mentioned, this study seeks to learn how easy or hard it is for both HIV-infected and HIV-
uninfected women to take medications to prevent and treat HIV. Therefore, there will be two 
arms of the study: a pre-exposure prophylaxis (PrEP) arm for participants who are HIV-
uninfected and an Immediate Treatment (IT) arm for participants who are HIV-infected. 
 
Your HIV test shows that you are HIV-uninfected, and therefore eligible to take part in the Pre-
exposure prophylaxis (PrEP) arm of the study. This consent form is therefore focused on the 
PrEP arm of the study, however it is important for you to still know what will happen for those 
who are HIV infected and in the IT arm. 
 
Pre-exposure prophylaxis (PrEP) arm 
HIV-uninfected participants who are willing and eligible to take part in the study will be offered 
an antiretroviral (ARV) combination called Truvada®. This is a single pill that is to be taken by 
participants every day during the study. It is a combination of two medications: 200 mg 
emtricitabine and 300 mg tenofovir. We call this medication oral PrEP.  
 
This medication was chosen for this study because it can be taken once every day with minimal 
side effects. Also, recent studies have shown that HIV does not easily become resistant to it, 
and that it can reduce the risk of getting HIV if exposed. It will be provided by this clinic free of 
charge during the study. This arm of the study will be called the pre-exposure prophylaxis or 
PrEP arm. 
 
Immediate Treatment (IT) arm 
The other arm of the study is called the Immediate Treatment (IT) arm. Only HIV infected 
women with a CD4 count higher than the nationally implemented guidelines for South Africa 
are eligible to join this arm of the study. Eligible participants who are willing to take part in the 
study will be started on a combination of ARVs, namely tenofovir disoproxyl fumarate (TDF) 
plus lamivudine /emtricitabine (3TC/FTC) plus efavirenz (EFV). This combination pill of three 
ARVs is known by the brand name Atripla, which also comes in a generic form.   
 
STUDY PROCEDURES 
 
Screening visit 
You will need to read about, discuss, and understand the study before you can agree to 
participate. If you decide to participate, you must sign or make your mark on this form. 
 
If you are willing to be in the study, during today’s visit, several things will happen: 
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 We will ask for your permission to obtain a blood sample at 9 of your study visits. No more 
than 30 ml (about 6 teaspoons) will be collected at a time. This blood sample will be used 
for tests at the clinic and by study researchers to check if you have any medical condition 
that may need to be monitored during the study, or that may prevent you from being 
eligible to be in the study. 
 You will be offered the option of getting SMS’s to remind you of clinic visits and to receive 
weekly supportive messages. You will be asked to sign a separate consent form to confirm 
that you agree to receive the SMS messages. 
 You will be asked when your last menstrual period was and if you may be pregnant. You 
can elect to take a urine pregnancy test if you would like to confirm whether you are 
pregnant.  
 You will be requested to provide your contact information, as well as a list of people we 
may contact if we are unable to contact you for any reason. Please note, if we contact 
anyone on the list you provide, we will not tell them why we are trying to reach you.  
 
Today’s visit will last approximately 2 hours. 
 
Follow up visits 
After today’s visit, you will have regular follow-up visits to monitor your use of Truvada® and 
to check your health status.  The following activities will take place at your follow-up visits: 
 Each month, you will receive enough Truvada® pills to last one month. You should take one 
pill once every day, by mouth. The study staff will counsel you on methods to not forget to 
take the pills every day. You will be asked about the pills you took during the previous 
month and the pharmacy staff will provide you with new bottles with pills to last until the 
following month. 
 You will be asked questions about your health since your last visit, your sexual practices 
and other behaviours, and your experiences of taking medications for HIV prevention. 
 You will be asked about things you have done to avoid HIV infection and any other sexually 
transmitted infections. 
 You will receive medical care or referrals for medical care and other services if you need 
them. 
 You will be asked to update your contact information especially phone numbers and where 
you live, and if there are any changes to the list of people you had given.  
 You will be asked when your last monthly period was, and a urine pregnancy test may be 
done to check if you are pregnant. 
 Blood samples will be collected to check how your body is responding to the medication. 
No more than 30 ml (about 6 teaspoons) will be collected at a time. If at any time you have 
an abnormal result, we will contact you to let you know and to schedule a visit to recheck 
the result and evaluate your health.  
 The blood samples collected will also be used to check your HIV status; if your HIV test is 
negative you can continue to receive Truvada®.  If your HIV test is positive during any of 
the follow-up visits you will not receive any more Truvada®. Instead, we will take an 
additional sample of your blood for resistance testing and you will be referred for care.  
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 If you consent, a small portion of the blood collected from you will be stored for future 
drug level testing. Study staff will take you through a separate informed consent form to 
confirm that you are willing to have your blood samples stored for future testing. 
 In addition to using the blood you give for future drug level and resistance testing, we 
would like permission to store samples for any possible additional tests that may need to 
be done. At the moment we cannot provide details of what will be looked at as this is not 
yet known, but we give assurance that no research will be done on the specimens from 
Wits Entities without the approval of the Wits Human Research Ethics Committee as well 
as the applicable Research Ethics Committees (REC) at the analysis sites. 
Your follow-up visits will last approximately 30 minutes, but could take up to one hour 
depending on any concerns or issues you might have and want to discuss. If you have any 
questions or concerns at any time during the study, you may request to speak with a member 
of the study staff. 
 
PREGNANCY  
If you are pregnant you are not eligible to join in the study.  
 
At each study visit you will receive counselling about the possibility of becoming pregnant and 
will be asked about your plans to have children in the future. Your options for contraception 
will also be explored, but you may choose whether or not you want to receive contraception. 
You can receive some forms of contraception from the study clinic or be referred to an 
appropriate clinic for contraception.  
 
We do not know if Truvada® has an impact on the unborn baby in HIV-uninfected women who 
become pregnant. If you are taking PrEP and become pregnant during the course of this study, 
you will be counselled on the possible risks and benefits of continuing PrEP while pregnant. If 
you choose to discontinue the medication, you will be retained in the study unless you elect to 
dropout. After your pregnancy you may choose to start taking PrEP again, and will be 
counselled on the use of PrEP during breastfeeding. 
 
All participants who become pregnant during the study will be referred for antenatal care.   
 
IMPORTANCE OF NOT SHARING THE STUDY MEDICATION 
Truvada® cannot be used by itself to treat individuals with HIV. It can only treat HIV if it is used 
with other drugs. It could be harmful for individuals who have HIV to take it. Therefore, only 
people who are not infected with HIV should take Truvada®. Similarly, the HIV treatment 
medication used in the IT arm is only for HIV infected people, and must be used every day. It is 
very important that you only use the study medication that you are assigned to, and that you 
do not share it with anyone else. If people who have not been to see a doctor take these 
medications, they could be harmed by the medications. 
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POTENTIAL RISKS AND/OR DISCOMFORTS:  
 During screening and study visits, you may experience discomfort or pain when your blood 
is being drawn. You may also feel dizzy or faint, and/or develop a bruise, swelling, or 
infection where the needle is inserted. 
 You may become embarrassed, worried, or anxious when receiving HIV related 
counselling, and if you are found to be HIV infected during the course of the study, may 
experience anxiety or depression related to your test results.  
 Although study sites will make every effort to protect your privacy and confidentiality, it is 
possible that your involvement in the study could become known to others, and that social 
harms may result, for example, you could be treated unfairly or discriminated against, or 
could have problems being accepted by families and/or the community. 
 At study visits, study staff will ask you a series of questions to monitor your participation in 
the study and ensure the study is not putting you at risk. Some of these questions may 
request sensitive information which could make you uncomfortable. You can choose not to 
answer a question if you are uncomfortable and you will not be penalized. 
 Risks and side effects, occurring in a minority of individuals, related to PrEP include: 
gastrointestinal intolerance (e.g. nausea, diarrhoea, vomiting, and flatulence), kidney 
problems, weakened bones and hypersensitivity. 
 Risks and side effects related to IT include dizziness, headache, trouble sleeping, 
drowsiness, trouble concentrating, unusual dreams, gastrointestinal intolerance (e.g. 
nausea, diarrhoea, vomiting, and flatulence), kidney problems, weakened bones and 
hypersensitivity. Some participants may also experience a rash which usually goes away 
without having to change the treatment. Some patients may also experience allergic 
reactions (including swelling of the face, lips, tongue, or throat). 
 We do not know if Truvada® has an impact on the unborn baby in HIV-uninfected women 
who become pregnant.  
 
POTENTIAL BENEFITS: 
 HIV uninfected participants will benefit from free access to PrEP during the study period, 
as well as access to comprehensive HIV, STI and reproductive health services.  
 HIV infected participants will benefit from access to standard clinical services, in addition 
to immediate treatment and monitoring of clinical status. 
 There may be no other direct benefits to participants in this study. However, participants 
and the broader community may also benefit in the future from information learned from 
this study. 
 
NEW FINDINGS 
You will be informed if there is any new information learned during this study that is important 
for your health or might cause you to change your mind about staying in the study. You will be 
told when the results of the study may be available, and how to learn about them. 
 
COSTS TO YOU 
There is no cost to you for being in this study.  Truvada® pills will be given to you free of 
charge. 
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WITHDRAWAL FROM STUDY 
You are free to leave the study at any time. If you choose to do so, we ask that you come for 
one final visit.  
 
You may also be removed from the study without your consent if the study is stopped or 
cancelled or if study staff feel that staying in the study would be harmful to you. 
 
ALTERNATIVES TO PARTICIPATION 
There may be other studies going on that you may be eligible for. If you wish, we will tell you 
about other studies that we know about. There also may be other places where you can go for 
HIV counselling and testing. We will tell you about those places if you wish.  
 
For your own safety you should not be involved in more than one study at the same time that 
offers medication. We shall be using fingerprinting technology to ensure that no participants 
are involved in multiple studies where they could be harmed by receiving different 
medications at the same time, as well as to confirm their identity during study visits. You can 
participate in other studies which do not offer other medications. For instance, another study 
asking you to complete a questionnaire is ok.  
 
REIMBURSEMENT 
You will not receive any reimbursement for your participation in the study. 
 
CONFIDENTIALITY 
All information obtained during the course of this study, including hospital records, personal 
data and research data will be kept strictly confidential.  Data that may be reported in scientific 
journals will not include any information that identifies you as a participant in this study. 
 
This information will be reviewed by authorised representatives of Wits RHI. 
The information might also be inspected by the Bill and Melinda Gates Foundation (BMGF),  
the National Health Research Ethics Council (NHREC), University of the Witwatersrand, Human 
Research Ethics Committee (HREC), the South African Medicines Control Council (MCC) and/or 
the United States Food and Medicine Administration (FDA), as well as your personal doctor.  
 
Based on the above statement, you hereby authorise me to release your medical records to 
Wits RHI, its employees or agents, domestic and foreign regulatory health authorities, the Bill 
and Melinda Gates Foundation (BMGF), the South African Medicines Control Council (MCC), 
the National Health Research Ethics Council (NHREC), and the University of the Witwatersrand, 
Human Research Ethics Committee (HREC). 
 
These records will be utilised by them only in connection with carrying out their obligations 
relating to this clinical study. 
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Any information uncovered regarding your test results or state of health as a result of your 
participation in this study will be held in strict confidence.  You will be informed of any finding 
of importance to your health or continued participation in this study but this information will 
not be disclosed to any third party in addition to the ones mentioned above without your 
written permission.  
 
 The only exception to this rule will be cases of communicable diseases where a legal duty of 
notification of the Department of Health exists.  In this case, you will be informed of my intent 
to disclose such information to the authorised state agency. 
 
RESEARCH-RELATED INJURY 
The study staff will monitor your health while you are in this study. If you have any health 
problems or medical emergency at any stage of the study please contact the study staff to let 
them know. It is important that you tell the clinic staff if you feel that you have been injured 
because of taking part in this study.  
 
You will be given treatment at the study clinic free of charge, and if you require medical care 
that the study clinic cannot provide you will be referred for additional care. 
 
INSURANCE AND THE ABPI STATEMENT 
Wits RHI, through trial insurance, will provide compensation for reasonable medical expenses 
incurred as a result of study-related injury or illness, determined according to the guidelines 
laid out by the Association of the British Pharmaceutical Industry (ABPI Guidelines), and 
Guidelines for Good Practice in the Conduct of Clinical Trials in Human Participants in South 
Africa. 
 
Please notify the study staff immediately of any complications, side effects and/or injuries 
during the study and the nature of the expenses to be covered. If a research related injury 
occurs, you have not waived any of the legal rights which you otherwise would have as a 
participant in this study by signing this form. Further detailed information on the payment of 
medical treatment and compensation due to injury can be obtained from me or other study 
staff. We have a copy of the ABPI Guidelines and the Insurance Certificate, should you wish to 
review them. 
 
The insurance does not cover and the study sponsor will not pay for:  
 Medical treatment for other injuries or illnesses 
 Injury caused by non-observance of the protocol 
 
Please note that if you have a life insurance policy you should enquire whether your insurance 
company requires notification of your intention to participate in a clinical study.  Information 
to date is that it should not affect any life insurance policy taken out.  Nevertheless, you are 
strongly advised to clarify it with the company concerned. 
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ADDITIONAL ACTIVITIES 
 
In-depth Interviews 
At some point during the study, the staff will invite a random selection of about 70 participants 
to take part in interviews where they will be asked about their experiences, including reasons 
for participating in the study; motivators and barriers to use of the study medications; 
acceptability of SMS technology; perceived gaps in service delivery and their HIV prevention 
preferences over time.  
 
Costing Study 
During study visits at specific time points (12 months, 24 months, and study exit), study staff 
will collect information from  participants to learn about their household, type of sex work, 
immigration status and income, out-of-pocket expenditures including transport and food, any 
time lost due to  appointments at the clinic, including travel time, consultation time, and loss 
of income. 
 
PARTICIPANT PROTECTION 
This study has been reviewed by the Wits Human Research Ethics Committee (HREC) and the 
Medicines Control Council (MCC) as per Good Clinical Practice (GCP) and South African 
regulations.  
 
The study has been structured in accordance with the Declaration of Helsinki (last updated: 
October 2013), which deals with the recommendations guiding doctors in biomedical research 
involving human participants.   
 
A copy may be obtained from me should you wish to review it. The interview component has 
been reviewed by the ethics committee at the London School of Hygiene and Tropical 
Medicine.  These two ethics committees are responsible for watching over the safety and 
rights of people taking part in research.  
 
SOURCES OF ADDITIONAL INFORMATION: 
If you have any questions about the study, please contact one of the people listed below: 
 
Prof. Helen Rees 
Principal Investigator 
Wits RHI, Research Centre 
No. 7 Esselen Street 
Hillbrow 
Tel: 011 358 5300 
Robyn Eakle 
Co-investigator 
Wits RHI, Research Centre 
No. 7 Esselen Street 
Hillbrow 
Tel: 011 358 5350  
This study is conducted in accordance with the Department of Health Guidelines for Good Practice in 
the Conduct of Clinical Trials in Human Participants in South Africa (2006), and has received ethical 
approval from the University of the Witwatersrand. If you have questions about your rights as a 
research participant, or complaints about how you were treated or feel that the study has caused you 
harm, please contact: 
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After you have consulted with the study doctor and/or Ethics Committee, and if they have not 
provided you with answers to your satisfaction, you should write to the MCC at: 
 
The Registrar 
Medicines Control Council SA 
Department of Health 
Private Bag X828 
PRETORIA 0001 
Fax: (012) 395 9201 
E-mail: helam@health.gov.za and mogobm@health.gov.za  
 
NOTIFICATION OF PERSONAL DOCTOR: 
Please indicate whether you would like us to inform your personal doctor about your 
participation in this study 
 Yes I want you to inform my personal doctor 
 No I do not want you to inform by personal doctor 
 I do not have a personal doctor. 
 
WRITTEN PARTICIPANT INFORMED CONSENT 
Participant 
⎕ I hereby confirm that I have been informed by the study staff member about the nature, 
conduct, benefits and risks of this study.  
⎕ I have also received, read and understood the above written information regarding the 
study. 
⎕ I understand that all participants’ fingerprints will be used to confirm their identity and to 
ensure that no participants are involved in multiple studies. 
⎕ I am aware that my personal information and health information will be stored 
anonymously and only a few select individuals will have access to my information.  
⎕ I understand that I may, at any stage, without prejudice, withdraw my consent and 
therefore cease further participation in the project.  
⎕ I have had sufficient opportunity to ask questions and (of my own free will) declare 
permission to participate in this programme. 
 
Signature/mark 
or thumbprint 
 
 
Date of 
signature 
   
DD MMM YYYY 
Participant 
Name (PRINTED) 
 
Time of 
signature 
: 
 
Prof. Peter Cleaton-Jones 
Chairperson for the Committee for Human 
Research Ethics Committee 
University of the Witwatersrand 
Tel: 011 717 2301 
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Study Staff Member 
⎕ I confirm that the above participant has been fully informed about the nature, conduct and 
risks of the above study. 
 
Signature 
 
 
Date of 
signature 
   
DD MMM YYYY 
Study Staff 
Member Name 
(PRINTED) 
 
Time of 
signature 
: 
 
Impartial Witness 
(Applicable only when participants cannot read and/or write) 
⎕ I have received and read this Pre-Exposure Prophylaxis (PrEP) Intervention Enrolment 
Information Sheet and Informed Consent Form and any other written information 
provided to the participant. 
⎕ I have attended all verbal discussions between the study clinic staff and participant about 
the study. 
⎕ By signing, I agree that the information provided was accurately explained to and 
apparently understood by the participant and that informed consent was freely given. 
 
Signature 
 
 
Date of 
signature 
   
DD MMM YYYY 
Witness Name 
(PRINTED) 
 
Time of 
signature 
: 
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Appendix ix. TAPS Enrolment questionnaire 
 
ELIGIBILITY – PARTICIPANT INFORMATION AND DEMOGRAPHIC SCREENING FORM  
 
1.  Date of Birth   _ _ / _ _ _ / _ _ (DD/MMM/YY)     OR      Age: _ _ (years) 
2.  Is the participant enrolled in any 
other research study?  
[   ]   YES 
[   ]   NO    
3.  What is your relationship status? [   ]   Married and living together 
[   ]   Married and living apart 
[   ]   Not married but living with a partner     
[   ]   Steady partner, not married and not living 
together 
[   ]   Several partners at present 
[   ]   Single, no partners at present 
[   ]   Divorced or separated    
[   ]   Chooses not to answer    
4.  What is your ethnic group or 
tribe? 
______________________________________(please 
list) 
5.  Where were you born? ______________________________________(please 
list) 
6.  What is your highest level of 
education? 
[   ]   Primary 
[   ]   Secondary 
[   ]   Matric     
[   ]   Tertiary –Technicon or Further 
Education/Training 
[   ]   Tertiary - University 
[   ]   Post-graduate 
[   ]   Don’t know    
[   ]   Chooses not to answer    
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7.  In the past three months, have 
you received money and/or 
goods in exchange for sex?  
[   ]   YES 
[   ]   NO    
[   ]   Chooses not to answer   
 Note, the participant must confirm they are a sex 
worker in order to participate in the study.   
8.  For how long have you been 
doing sex work here in 
Johannesburg/Pretoria? 
Indicate 
(days/weeks/months/years):____________________ 
9.  Where do you normally work 
from?  
[   ]   Hotel/Brothel 
[   ]   Street 
[   ]   Home (if living outside a hotel or brothel) 
[   ]   Other (please list) 
____________________________________________ 
 
NOTES/COMMENTS: 
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________
_____________________________________________________________________________ 
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DEMOGRAPHICS AND BEHAVIOUR QUESTIONNAIRE 
 
This questionnaire aims to collect data on the participant’s living status, background, HIV 
knowledge, sexual behaviour, ability to adhere to medications, and interactions with their 
environment and networks.  
 
The Interviewer should read the italicised text in each section to the participant. The 
Interviewer should make sure the participant understands what each section is about and that 
the participant is ok to continue before moving on with questions.   
 
Interviewer introduction: 
I’m going to ask you some very personal questions. You may find these questions difficult to 
answer. Your answers are completely confidential. Your name will not be written on this form, 
and will never be used in connection with any of the information you tell me. You do not have 
to answer any questions that you do not want to answer, and you may end this interview at 
any time you want to. However, your honest answers to these questions will help us better 
understand your background, your needs in relation to HIV prevention/treatment (read one 
according to status), and how we might make services better. 
 
Section 1: Demographics 
I am going to start by asking you some questions about yourself. Please try and relax, there are 
no right or wrong answers. Remember that everything you tell me will be kept secret and that 
you can refuse to answer any question you do not wish to answer. 
1.  How many living children do you 
have?  
______ Living with you 
______ Living with other carers (family/friends) 
[   ]   Chooses not answer 
2.  How many people depend on your 
income including you?  
______ Adults 
______ Children 
[   ]   Chooses not answer 
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3.  Where do you currently stay? [   ]   Urban – Hotel or Brothel 
[   ]   Urban – Flat or house 
[   ]   Township  
[   ]   Rural  
[   ]   Other: ____________ 
[   ]   Chooses not answer  
If NOT Hotel or Brothel skip to Q5 
4.  Which Hotel or Brothel do you 
stay in? 
Please 
list:________________________________________ 
[   ]   Chooses not answer 
5.  In the past [4 weeks], did it 
happen that there was no food to 
eat of any kind in your house, 
because of lack of resources to get 
food? 
 
 
[   ]   Often 
[   ]   Sometimes    
[   ]   Never    
[   ]   Rarely    
[   ]   Chooses not answer 
6.  In the past [4 weeks], did it 
happen that you or any household 
member went to sleep at night 
hungry because there was not 
enough food? 
[   ]   Often 
[   ]   Sometimes    
[   ]   Never    
[   ]   Rarely    
[   ]   Chooses not answer 
7.  In the past [4 weeks], did it 
happen that you or any household 
member went a whole day and 
night without eating anything at 
all because there was not enough 
food? 
[   ]   Often 
[   ]   Sometimes    
[   ]   Never    
[   ]   Rarely    
[   ]   Chooses not answer 
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8.  How long have you lived where 
you currently stay? 
[   ]   less than 6 months    
[   ]   6 to 12 months 
[   ]   more than 12 months    
[   ]   Chooses not answer 
9.  In the last month, how many 
nights did you spend away from 
where you currently stay because 
you were travelling (for instance 
to your home to see family or 
friends)?  
_______________(# days/month) 
 [   ]   Refuse to answer 
10.  In the last year, how many nights 
did you spend away from where 
you currently stay because you 
were travelling (for instance to 
your home to see family or 
friends)?  
_______________(# nights/year) 
[   ]   Chooses not answer  
Section 2: Knowledge and Practice 
 
In this section I will ask you some questions about your knowledge of testing and HIV.  
 
11.  How old were you when you first 
had an HIV test? 
_______________(List age) 
[   ]   Don’t know 
[   ]   Chooses not answer 
12.  When did you last have an HIV 
test, before today? 
[   ]   In the past 3 months 
[   ]   In the past 6 months 
[   ]   In the past 12 months 
[   ]   More than 12 months 
[   ]   N/A, this was my first HIV test 
[   ]   Chooses not answer 
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13.  FOR PREP PARTICIPANTS ONLY:  
You don’t have HIV now, how 
likely do you think it is that you 
will get HIV in the next 12 
months? 
[   ]   Very likely 
[   ]   Somewhat likely 
[   ]   Not sure 
[   ]   Somewhat unlikely 
[   ]   Very unlikely 
[   ]   Chooses not answer 
14.  FOR IT PARTICIPANTS ONLY: 
 
You have HIV now, how likely do 
you think it is that you will pass on 
HIV in the next 12 months? 
[   ]   Very likely 
[   ]   Somewhat likely 
[   ]   Not sure 
[   ]   Somewhat unlikely 
[   ]   Very unlikely 
[   ]   Chooses not answer 
15.  Can you know whether a person 
has HIV by looking at them?   
[   ]   YES  
[   ]   NO   
[   ]   Chooses not answer  
If yes, indicate how you would know: 
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________ 
16.  What can you do to prevent getting HIV?   List all that apply (probe for traditional 
medicines, etc.) 
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
_________________________________________________________________________
________________________________________________________________________ 
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Section 3: Sexual Behaviour 
 
In this section, we will discuss condom use and different partners you may have sex with. 
Please remember to stop me at any time to ask questions if you are unsure about anything we 
are discussing. Feel free to choose not to answer any question that might make you 
uncomfortable.  
 
17.  Are the condoms you use mostly 
bought ones or ones you get for 
free? 
[   ]   Don’t use condoms  Skip to 21  
[   ]   Bought 
[   ]   Free 
[   ]   Both 
[   ]   Chooses not answer 
18.  Do you use male condoms, female 
condoms, or both?  
[   ]   Male condoms only 
[   ]   Female condoms only 
[   ]   Both 
[   ]   Chooses not answer 
19.   In the past month, have you had 
the experience of a condom 
breaking while it was being used? 
[   ]   YES  
[   ]   NO    
[   ]   Chooses not answer  
If NO skip to Q21 
20.  What did you do when the 
condom broke? 
[   ]   Nothing 
[   ]   Went to clinic for advice 
[   ]   Went to clinic for post-exposure prophylaxis 
[   ]   Took traditional herbs or medicines 
[   ]   Cleansed the vagina 
[   ]   Other___________________ 
[   ]   Chooses not answer 
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3.1 Main and/or Casual Partners 
Now I am going to ask you about your different sexual partners. You may have different types 
of sexual partners. One type is a main partner, like a husband, boyfriend, or someone you 
might call an emotional partner that you see regularly whom you do not see as a client and 
who does not necessarily give you money or gifts in exchange for sex. Another type is a casual 
partner, someone you might see from time to time but whom you do not consider to be 
someone you are in a serious relationship with. Finally, another type of partner will be your 
client, someone who gives you money or other goods/gifts in exchange for sex. You may have 
clients you see just once which we will call occasional clients, or you may have clients you see 
on a regular basis, which we will call regular clients. Can you explain back to me your 
understanding of what these different types of partners are? For instance, who did you last 
have sex with? Which type of partner would they be?    
 
21.  Do you have a main partner? [   ]   YES 
[   ]   NO  if NO, skip to Q25 
[   ]   Chooses not answer 
22.  In the past 7 days, how many 
times did you have sex with your 
main partner (including only 
vaginal and anal)? 
_ _ _ number of times 
[   ]   Chooses not answer 
23.  How often do you use condoms 
with your main partner?  
[   ]   Every time 
[   ]   Sometimes (about half the time) 
[   ]   Never 
[   ]   N/A 
[   ]   Chooses not answer 
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24.  What are the reasons for not 
using condoms all the time with 
your main partner (check all 
applicable)? 
[   ]   Personal preference 
[   ]   No condoms available 
[   ]   Main partner refused 
[   ]   Chooses not answer  
[   ]   Other – please list: 
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________ 
25.  Do you have a casual partner or 
partners?  
[   ]   YES  if yes, indicate how many: 
__________ 
[   ]   NO   if NO, skip to Q30 
[   ]   Chooses not answer 
26.  In the past 7 days, how many 
casual partner(s) did you have 
sex with (including only vaginal 
and anal)? 
_ _ _ number of casual partners 
 [   ]   Chooses not answer 
27.  Thinking of the last time you had 
sex with a casual partner, how 
many times did you have sex 
with him (including only vaginal 
and anal)? 
_ _ _ number of times 
 [   ]   Chooses not answer 
28.  How often do you use condoms 
with your casual partner(s)?  
[   ]   Every time 
[   ]   Sometimes (about half the time) 
[   ]   Never 
[   ]   N/A 
[   ]   Chooses not answer 
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29.  What are the reasons for not 
using condoms all the time with 
your casual partner(s) (check all 
applicable)? 
[   ]   Personal preference 
[   ]   No condoms available 
[   ]   Casual partner refused 
[   ]   Chooses not answer  
[   ]   Other – please list: 
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________ 
3.2 Occasional and Regular Clients 
(Prompt participant to remind them of the definitions for different clients – occasional and 
regular) 
30.  Do you have occasional clients? [   ]  YES 
[   ]  NO  if NO, skip to Q36 
[   ]   Chooses not answer 
31.  How many occasional clients did 
you see on the most recent day 
you worked? 
_ _ _ (number of occasional clients)  
[   ]   Chooses not answer 
32.  How many occasional clients did 
you see in the last 7 days? 
_ _ _ (number of occasional clients)  
[   ]   Chooses not answer 
33.  Thinking of your last occasional 
client, how many times did you 
have sex with him (including 
vaginal and anal)? 
_ _ _ number of times  
[   ]   Chooses not answer 
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34.  How often do you use condoms 
with your occasional clients? 
[   ]   Every time 
[   ]   Sometimes (about half the time) 
[   ]   Never 
[   ]   Chooses not answer  
If “Every time”, skip to Q36 
35.  What are the reasons for not 
using condoms all the time with 
your occasional clients (check all 
applicable)? 
[   ]   Personal preference 
[   ]   No condoms available 
[   ]   Client(s) refused 
[   ]   Chooses not answer  
[   ]   Other – please list: 
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________
___________________________________________ 
36.  Do you have regular clients? [   ]  YES 
[   ]  NO  if NO, skip to Q42 
[   ]   Chooses not answer 
37.  How many regular clients did you 
see on the most recent day you 
worked? 
_ _ _ (number of regular clients)  
[   ]   Chooses not answer 
38.  How many regular clients did you 
see in the last 7 days? 
_ _ _ (number of regular clients)  
[   ]   Chooses not answer 
39.  Thinking of your last regular 
client, how many times did you 
have sex with him (including 
vaginal and anal)? 
_ _ _ (number of times last regular client)  
 [   ]   Chooses not answer 
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40.  How often do you use condoms 
with your regular clients? 
[   ]   Every time 
[   ]   Sometimes (about half the time) 
[   ]   Never 
[   ]   Chooses not answer  
If “Every time”, skip to Q42 
41.  What are the reasons for not 
using condoms all the time with 
your regular clients (check all 
that apply)? 
[   ]   Personal preference 
[   ]   No condoms available 
[   ]   Client(s) refused 
[   ]   Chooses not answer  
[   ]   Other – please list: 
___________________________________________
___________________________________________
___________________________________________
___________________________________________ 
42.  How are you usually paid for your 
services? 
[   ]   Cash     
[   ]   Other goods (clothing, food, housing, gifts)     
[   ]   Cash and other goods     
[   ]   Salary 
[   ]   Other: ______________________________ 
[   ]   Chooses not answer 
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43.  What was the price paid by your 
last three clients (including 
occasional and regular)?  
1. _____________  [rands] please tick: [   ] regular or 
[   ] occasional 
2. _____________  [rands] please tick: [   ] regular or 
[   ] occasional 
3. _____________  [rands] please tick: [   ] regular or 
[   ] occasional 
[   ]   Chooses not answer  
Note - If paid with Other Goods, please list here 
(estimated value): 
___________________________________________
___________________________________________
___________________________________________
___________________________________________
________________________________________ 
Section 4: Substance Use 
In this section, I will briefly ask you about whether you drink or use other substances. As a 
reminder, these responses will be kept confidential, but please let me know if you have 
questions or are uncomfortable at any time.  
44.  At what age did you first start 
drinking alcohol? 
_______ (list age) 
[   ]   I don’t drink alcohol  Skip to Q49 
[   ]   Chooses not answer 
45.  How often do you have a drink 
containing alcohol? 
[   ]   Monthly or less 
[   ]   2 to 4 times a month 
[   ]   2 to 3 times a week 
[   ]   4 or more times a week 
[   ]   Chooses not answer 
292 
 
 
46.  How many drinks containing 
alcohol do you have on a typical 
day when you are drinking? 
[   ]   1 or 2 
[   ]   3 or 4 
[   ]   5 or 6 
[   ]   7, 8 or 9 
[   ]   10 or more 
[   ]   Chooses not answer 
47.  How often do you have six or 
more drinks on one occasion? 
[   ]   Daily or almost daily 
[   ]   Weekly 
[   ]   Less than monthly 
[   ]   Monthly  
[   ]   Never 
[   ]   Chooses not answer 
48.  In the past 7 days, have you had 
sex with a client while under the 
influence of alcohol? 
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
49.  In the past week, have you used 
any of the following drugs (tick all 
that apply)? 
[   ]   Tik 
[   ]   Dagga/Marijuana 
[   ]   Mandrax 
[   ]   Crack or rock 
[   ]   Nyaope 
[   ]   Heroin 
[   ]   Other_______________ (broncleer, etc.) 
[   ]  N/A (don’t use drugs) 
[   ]   Chooses not answer 
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Section 5: Sexual History and Sex Work 
 
Now we will briefly discuss your experiences with sex and doing sex work.  
 
50.  How old were you when you first 
had sex? 
_ _ _ (Age) 
[   ]   Chooses not answer 
51.  Was your first sex act forced? 
("forced" means he/multiple 
perpetrators physically held you 
down or threatened to harm you 
if you did not perform a sexual 
act) 
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
52.  Was your first sex act coerced? 
("Coerced" means feelings of 
being violated - for example you 
felt extreme pressure, he 
threatened to start rumours, 
badgering, and bribing, including 
the use of his physical size) 
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
53.  How old were you when you first 
exchanged sex for money or 
other goods? 
_ _ _ (Age) 
[   ]   Chooses not answer 
54.  In the last month, where did you 
meet or make contact with most 
of your clients? 
[   ]   Brothel/hotel 
[   ]   Street or public place 
[   ]  Bar 
[   ]  Nightclub 
[   ]  Shebeen 
[   ]  Escort agency 
[   ]  Through an advert (client phoned me) 
[   ]   Other__________________ 
[   ]   Chooses not answer 
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55.  Where else (cities or towns) 
besides Johannesburg/Pretoria, if 
any, have you practiced sex work 
other than here in the last six 
months? 
(Write down all places here) 
Section 6: Health Behaviour 
 
In this section, we will discuss where you go to get healthcare and experiences with accessing 
services.  
56.  Where do you usually go when 
you feel sick? 
[   ]   Clinic 
[   ]   Traditional healer 
[   ]    Pastor  
[   ]    Friend/family 
[   ]   Stay at home 
[   ]   
Other:____________________________________ 
[   ]   Chooses not answer  
 
57.  Do you go to the clinic to keep 
healthy, such as for HIV testing, 
check-ups, or other purposes? 
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
58.  Think of the most recent time 
you had to take medication for 
several days in a row. Were you 
able to take the medication every 
day? 
[   ]   YES 
[   ]   NOIf NO skip to Q60 
[   ]   Chooses not answer 
59.  Were you able to finish all of the 
medication?  
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
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60.  Have you ever had difficulty 
getting healthcare when you 
tried to access it?  
[   ]   YES 
[   ]   NO If NO skip to Q63 
[   ]   Chooses not answer 
61.  What was the reason you had 
difficulty accessing care? 
[   ]   Refused treatment/care by clinic staff 
[   ]   Police harassment 
[   ]   Community harassment 
[   ]   Too expensive 
[   ]   Could not take time off from working 
[   ]   Long waiting times 
[   ]   
Other______________________________________ 
[   ]   Chooses not answer 
62.  If you were refused treatment, 
can you tell me why?  
Reason: (probe for stigma, immigration status, 
language barriers) 
___________________________________________
___________________________________________
___________________________________________
___________________________________________
________________________________________ 
Section 7: Violence 
In this section, we will briefly discuss experiences with violence you may have had with different 
partners. The questions in this section can be difficult to answer for some people so remember 
that you do not have to answer if you choose not to. First we will ask about main or casual 
partners. Next we will ask about clients. 
63.  Within the last year, have you 
been hit, slapped, kicked, or 
otherwise physically hurt by your 
main and/or casual partner(s)?  
[   ]   YES 
[   ]   NO 
[   ]   Don’t have a main or casual partner Skip to 
Q67 
[   ]   Chooses not answer  
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64.  Are you afraid of your partner? [   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
65.  Within the last year, has your 
main and/or casual partner(s) 
forced you to have sexual 
activities by threatening you, 
holding you down or hurting you 
in some way?  
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer  
66.  Within the past year, did you 
seek medical attention as a result 
of violence you experienced from 
your main and/or casual 
partner(s)? 
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
67.  Within the past last year, have 
you been slapped, kicked, or 
otherwise physically hurt by a 
client or clients?  
 
[   ]   YES 
[   ]   NO  
[   ]   Chooses not answer 
68.  Within the last year, has a client 
ever forced you to have sexual 
activities by threatening you, 
holding you down or hurting you 
in some way?  
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
69.  Are you afraid of any of your 
clients? 
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
70.  Within the last year, did you seek 
medical attention as a result of 
violence from a client or clients? 
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
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71.  Within the past year, have you 
experienced violence from a 
police officer?  
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
72.  Have you ever used post-
exposure prophylaxis (PEP) after 
sexual violence? 
[   ]   YES 
[   ]   NOIf NO skip to Q77 
[   ]   Chooses not answer 
73.  Where did you go to get the PEP?  [   ]   Hospital or clinic 
[   ]   Directly from pharmacy 
[   ]   From a friend 
[   ]   Other 
____________________________________ 
[   ]   Chooses not answer 
74.  For how long did you take the 
PEP?  
[   ]   Less than one week 
[   ]   One to two weeks 
[   ]   Two to three weeks 
[   ]   Four weeks 
[   ]   Chooses not answer 
75.  Did you have any difficulty 
finishing the PEP? 
[   ]   YES 
[   ]   NO If NO skip to Q77 
[   ]   Chooses not answer 
76.  If yes, please explain: ___________________________________________
___________________________________________
___________________________________________ 
Section 8: Social Connections 
Now I am going to ask you about some of your social relationships and experiences.  
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77.  Do your family and/or friends 
know that you are a sex worker?  
[   ]   YES, family 
[   ]   YES, friends 
[   ]   YES, both 
[   ]   NO, neither 
[   ]   Chooses not answer  
 
78.  Are you connected with any sex 
worker groups such as Sisonke or 
SWEAT?  
[   ]   YES 
[   ]   NOIf NO skip to Q80 
[   ]   Chooses not answer 
79.  In the past year, have you 
participated in any SWEAT or 
Siskonke activities, or the 
Creative Space activities through 
the Sex Worker Project?  
[   ]   YES 
[   ]   NO 
[   ]   Chooses not answer 
80.  Do you go to any other 
organisations or people 
(family/friends) for emotional or 
social support?  
[   ]   YES 
[   ]   NO [   ]   Chooses not answer 
81.  Where do you go for emotional 
or social support? 
List: 
___________________________________________
___________________________________________
___________________________________________ 
 
 
Questions/Comments 
 
Do you have any questions or comments about the study, the medication, or the services 
you will receive in the study?  
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________ 
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Appendix x. IDI participant information sheet and consent form 
 
         Participant 
No:___________ 
 
 
Participant Qualitative Study Information Sheet and Informed 
Consent Form  
 
 
 
Study Title: 
The TAPS Demonstration Project: Expanded use of ART for 
Treatment And Prevention for female Sex workers in South 
Africa 
 
Study number WRHI046 
Study Sponsor Wits Reproductive Health and HIV Institute 
Principal Investigator Helen Rees 
Co-Investigators Robyn Eakle, Francois Venter, Gabriela Gomez 
Site Address 7 Esselen Street, Hillbrow, 2001 
Site contact numbers 0616043097 / 011 358 5424 
 
 
 
 
 
 
To the potential participant: This consent form may contain words that you do not understand.   
Please ask the study staff to explain any words or information that you do not clearly 
understand.   You may take home an unsigned copy of this consent form to think about or 
discuss with family or friends before making your decision. 
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INTRODUCTION 
Hello, my name is ___________. I am a member of staff with the Wits Reproductive Health 
and HIV Institute (Wits RHI); an organisation associated with the University of the 
Witwatersrand and I am assisting with the TAPS project. You have already consented to 
participate in the main study, and we would like to invite to you participate in a series of 
interviews to help us understand your perspective of participating in the study. 
 
This information leaflet is to help you to decide if you would like to take part in the interviews. 
You should fully understand what is involved before you agree to take part. If you have any 
questions, do not hesitate to ask me.   
 
You should not agree to sign up unless you are satisfied with the information you receive 
today. 
 
If you agree to participate in the interviews, you will be asked to sign this document to confirm 
that you understand what is involved.  
 
PURPOSE OF THE INTERVIEWS 
The purpose of the interviews is to understand what makes it easy or difficult to start using 
and to continue use of PrEP or immediate treatment.  
 
We would also like to find out if PrEP and immediate treatment will be accepted by people 
who need them; to learn more about your preferred HIV prevention method to find out how 
easy it is to use of SMS service to support women using PrEP or immediate treatment, and to 
find out about any gaps in health services, including in quality of services. 
 
PROCEDURES 
A select group of participants from the main study, the TAPS demonstration project, will be 
asked to participate in one on one interviews over the course of the study. The participants to 
be interviewed will be chosen randomly, this means every participant has the same chance of 
being selected. Each participant who agrees to participate in the interview component will be 
asked to sign a separate consent form and will be reimbursed for her travel costs. There will be 
a total of three interviews per participant at 3, 6, and 9 months during the course of her 
participation in the study.  
 
Interviews will be conducted in Setswana, isiZulu, or English, depending on your preference.  
 
Each interview will last approximately an hour and a half. The three interviews will be 
conducted at different time points during the study to provide an opportunity for you and the 
researcher to build on the information over time. Each interview will be audio-recorded. Audio 
files for interviews will not contain identifying information and will be kept in a secure location 
until such time as they are destroyed by the researcher.  
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POTENTIAL RISKS: 
There are no direct risks to you, however, you may become embarrassed, worried, or anxious 
when talking about your experiences. We are aware of this and we will respect your right to 
confidentiality and privacy. Your interviews will always take place in private. You do not have 
to answer all questions if you prefer not to. 
 
POTENTIAL BENEFITS: 
There may be no direct benefits to participants from participating in the interviews, however, 
participants and the community as a whole may benefit in the future from information learned 
from the interviews. 
 
RIGHTS AS A PARTICIPANT IN THIS STUDY 
Your decision to participate in the interviews is completely free and you can decline to be 
interviewed or be part of the primary study at any time, without stating any reason.   
 
Your decision to participate in this study or in the interviews will not affect the care you 
receive in the clinic or your relationship to the hospital in any way.  
 
REIMBURSEMENT 
Participants who take part in the interviews will receive R50 to cover their transport costs. 
 
CONFIDENTIALITY 
All information obtained during the course of this study, including hospital records, personal 
data and research data will be kept strictly confidential.  Data that may be reported in scientific 
journals will not include any information that identifies you as a participant in this study. 
 
The information might be inspected by the Bill and Melinda Gates Foundation (BMGF), the 
University of the Witwatersrand, Human Research Ethics Committee (HREC), the National 
Health Research Ethics Council (NHREC) and the South African Medicines Control Council 
(MCC).  Therefore, by signing this document you hereby authorise me to release your medical 
records to the Bill and Melinda Gates Foundation (BMGF), the South African Medicines Control 
Council, the National Health Research Ethics Council (NHREC) and the University of the 
Witwatersrand, Human Research Ethics Committee (HREC). 
 
These records will be utilised by them only in connection with carrying out their obligations 
relating to this clinical study. 
 
Any information uncovered regarding your test results or state of health as a result of your 
participation in this study will be held in strict confidence.  This information will not be 
disclosed to any third party in addition to the ones mentioned above without your written 
permission.  
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The only exception to this rule will be cases of communicable diseases where a legal duty of 
notification of the Department of Health exists.  
 
ETHICAL APPROVAL 
The primary research study protocol, including the in-depth interviews, has been submitted to 
the University of the Witwatersrand, Human Research Ethics Committee (HREC) and written 
approval has been granted by that committee.  
The study has been structured in accordance with the Declaration of Helsinki (last updated: 
October 2013), which deals with the recommendations guiding doctors in biomedical research 
involving human participants.  A copy may be obtained from me should you wish to review it.  
 
SOURCES OF ADDITIONAL INFORMATION: 
If you have any questions about the study, please contact one of the people listed below: 
 
Prof. Helen Rees 
Principal Investigator 
Wits RHI, Research Centre 
No. 7 Esselen Street 
Hillbrow 
Tel: 011 358 5300 
Robyn Eakle 
Co-investigator 
Wits RHI, Research Centre 
No. 7 Esselen Street 
Hillbrow 
Tel: 011 358 5350  
 
After you have consulted with the study doctor and/or Ethics Committee and if they have not 
provided you with answers to your satisfaction, you should write to the MCC at: 
 
The Registrar 
Medicines Control Council SA 
Department of Health 
Private Bag X828 
PRETORIA 0001 
Fax: (012) 395 9201 
E-mail: helam@health.gov.za and mogobm@health.gov.za  
 
 
 
This study is conducted in accordance with the Department of Health Guidelines for Good 
Practice in the Conduct of Clinical Trials in Human Participants in South Africa (2006), and has 
received ethical approval from the University of the Witwatersrand. If you have questions 
about your rights as a research participant, or complaints about how you were treated or 
feel that the study has caused you harm, please contact: 
Prof. Peter Cleaton-Jones 
Chairperson for the Committee for Human 
Research Ethics Committee 
University of the Witwatersrand 
Tel: 011 717 2301 
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WRITTEN PARTICIPANT INFORMED CONSENT 
⎕ I hereby confirm that I have been informed about the nature, conduct, benefits and risks of 
agreeing to participate in the in-depth interviews connected to The TAPS Project.  
⎕ I am aware that the interview will be audio-taped. 
⎕ I am aware that the information obtained from the study, including personal details 
regarding my sex, age, initials and diagnosis will be anonymously processed into a report. 
⎕ In view of the requirements of research, I agree that the data collected during the 
interviews can be processed in a computerised system by the Wits Institute of the 
University of the Witwatersrand.  
⎕ I may, at any stage, without prejudice, withdraw my consent and participation in the 
interviews. 
⎕ I have had sufficient opportunity to ask questions and (of my own free will) declare 
permission to participate in the interviews. 
 
Participant: 
 Yes, I agree to participate in in-depth interviews* 
    
 No, I do not want to participate in in-depth interviews 
 
Signature/mark 
or thumbprint 
 
 
Date of 
signature 
   
DD MMM YYYY 
Participant 
Name (PRINTED) 
 
Time of 
signature 
: 
 
*If Yes:  
 I agree to the audio recording of the in-depth interviews 
    
 I do not agree to the audio recording of the in-depth interviews 
 
 
Signature/mark 
or thumbprint 
 
 
Date of 
signature 
   
DD MMM YYYY 
Participant 
Name (PRINTED) 
 
Time of 
signature 
: 
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Study Staff Member 
⎕ I confirm that the above participant has been fully informed about the nature, conduct and 
risks of the in-depth interviews. 
 
Signature 
 
 
Date of 
signature 
   
DD MMM YYYY 
Study Staff 
Member Name 
(PRINTED) 
 
Time of 
signature 
: 
 
 
 
Impartial Witness 
(Applicable only when participants cannot read or write) 
⎕ I have received and read this Participant Qualitative Study Information Sheet and Informed 
Consent Form and any other written information provided to the participant. 
⎕ I have attended all verbal discussions between the study clinic staff and participant about 
the in-depth interview. 
⎕ By signing, I agree that the information provided was accurately explained to and 
apparently understood by the participant and that informed consent was freely given. 
 
Signature 
 
 
Date of 
signature 
   
DD MMM YYYY 
Witness Name 
(PRINTED) 
 
Time of 
signature 
: 
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Appendix xi. TAPS IDI Guides 
 
IDI 1 GUIDE (MONTH 3) 
 
 
Interviewer ________________  Site/Venue: _______________ 
 
INTRODUCTION 
This guide represents the first in a set of three interviews in which female sex workers participating in the TAPS Demonstration Project will be 
randomly selected and invited to participate. The primary objective of this research is to explore the individual perspectives and lived experiences of 
FSWs willing to take up and use PrEP or Immediate Treatment in South Africa. These serial interviews conducted by research assistants working on 
the project will aim to answer the following questions: 
 
 What factors influence effective PrEP/Immediate Treatment uptake and use by female sex workers in South Africa?  
 What factors should be considered for future scale-up, rollout, and implementation of PrEP/Immediate Treatment?  
 
The questions within the interview guides feed into a larger social-ecological framework and follow a specified flow depicted in the flow chart below.  
    
 
 
It is important while conducting the interview that the interviewer remembers the answers the participant gives as the conversation goes along in 
order to react appropriately to given questions and prompts. The interviewer may need to encourage the participant to speak freely and remind the 
participant of their previous answers. One particular aspect which may need repeated clarification is the different between clients and partners. The 
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definitions for clients and partners used in the demographics questionnaire is listed below for easy reference and can be read to the participant at any 
time.  
 
Main and Casual Partners 
In this interview we may discuss different types of sexual partners. One type is a main partner, like a husband, boyfriend, or someone you might call an 
emotional partner that you see regularly whom you do not see as a client and who does not necessarily give you money or gifts in exchange for sex. 
Another type is a casual partner, someone you might see from time to time but whom you do not consider to be someone you are in a serious 
relationship with. Finally, another type of partner will be your client, someone who gives you money or other goods/gifts in exchange for sex. You may 
have clients you see just once which we will call occasional clients, or you may have clients you see on a regular basis, which we will call regular 
clients. Can you explain back to me your understanding of what these different types of partners are? For instance, who did you last have sex with? 
Which type of partner would they be?    
 
INSTRUCTIONS FOR THE INTERVIEWER – HOW TO USE THIS IDI GUIDE 
1. There are 3  levels of questions: 
 Numerical research questions/topic areas highlighted in gray: the questions/areas that we as TAPS researchers want to get answers to. 
These don’t need to be read aloud. 
 IDI questions: the questions that you as the Interviewer will ask respondents in order to get answers to the research questions. These 
questions will be underlined.  
 Probes: they are indicated with a bullet, and will not be translated. The interviewer should ensure that key topics listed in the probes have 
been addressed/discussed during the interview. So, depending on what has already been discussed, and the IDI context, you may ask 
these probes or not. 
 
2. Instructions/suggestions to interviewer are in italics and brackets [ ]. 
 
3. The IDI guide is divided into two columns.  
 The left-hand column contains the research questions, IDI questions and probes. The IDI questions are suggestions for getting the 
discussion going. It is not required to read them verbatim, but they are written in local language to ensure some consistency across IDIs. 
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You may adapt the question, depending on how the interview develops, and you as the Interviewer will have to ensure that at the end the 
research questions have been answered. . 
 The right-hand column is for summarising the themes brought up by the woman in the IDI. These should be summaries of the general 
issues raised in connection with the research question. These summaries should be more than just yes/no, but not longer than a few 
sentences of bullet points. They do not need to be detailed, as we have the details on the tape. Note: the summaries and yes/no answers 
should be filled by the IDI interviewer immediately after the IDI. 
 
 
 
DAY OF INTERVIEW 
First make the participant comfortable. Offer her something to drink and explain who you are and introduce yourself if you haven’t met before.   
 
Before starting the IDI, the Interviewer explains to the respondent: 
  
Now I am going to start the recorder.  [Interviewer: start the tape recorder.] 
 
As you know from your informed consent, this IDI will be tape recorded today.  Please verbally indicate that you are aware that we are tape recording 
this session and that it is okay with you.  [Interviewer:  be sure to get a verbal okay from the respondent.] 
 
Today we will be discussing some of your life experiences, your experience taking PrEP/IT, and your experience coming to the clinic. There is no right 
or wrong answer to any of these questions so you should just tell me whatever comes to your mind. I also want to assure you that although we will be 
recording the interview, we will not be using your name on this tape, nor anyone else’s. We will keep this recording confidential, and any information 
I pass back to the clinic team will not be in connection with your name. Please feel free to tell me anything you want about your experiences, positive 
or negative, and please tell me if there is anything you are uncomfortable with or want to skip over. We will begin now. Do you have any questions 
before we start?  
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 Research Question, IDI Questions, Probes SUMMARY 
1.  How does HIV rank as a concern within the lives of FSWs? 
 
When you wake up in the morning, what are your main 
concerns on a daily basis?  
 
 Do you worry about your family or things at 
home? 
 Do you worry about things to do with work (e.g. 
how do you cope, are you worried about getting 
sick or paying rent)? 
 Do you worry about your health? 
 
 
 
 
 
 
 
 
 
 
2.  What are specific concerns the participant has around sex 
and HIV?  
 
What concerns have you had about sex (both generally and 
in terms of clients and partners)? 
 Do you worry about STIs? 
 Do you worry about HIV? 
 Do you worry about your clients? 
 Do you worry about your other partners?  
 Do you have worries directly related to your work 
(e.g. family or friends finding out, violence? 
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3.  What does the participant do to manage concerns and 
what do they experience in the process (e.g. difficult 
partnerships, trouble negotiating protection)?  
 
Reflecting back on what you just told me, how have you 
managed your concerns about sex?  
 What sorts of problems did you experience 
managing these concerns?  
 What did you do?  
 Were you able to use condoms?  
 Did you pick certain clients or partners over others? 
 Did you have sex differently (e.g. ask client or 
partner to pull out before ejaculation or only have 
anal sex)?  
 Do you have any specific washing practices?  
 Who did you talk to about your concerns or what 
you did to handle them?  
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4.  What were the participant’s specific experiences last time 
she had sex without a condom?  
 
Let’s talk about the last time you had sex without a condom.  
 Who was it with?  
 Why did you not use a condom? 
 Did you talk about using a condom? 
 Where were you?  
 How did you feel afterwards (worry, etc.)? 
 Did you feel any different now that you are taking 
PrEP/IT? 
 Is this kind of experience something typical or 
different to your usual experiences with sex?  
 Did you do anything afterwards like washing? Or 
visit the clinic? 
 
 
5.  Does the participant understand PrEP/Immediate 
treatment and where do they get their information? This is 
specifically getting at knowledge and rumours.  
 
What do you know about PrEP/IT? 
 What is the purpose of taking PrEP/IT? 
 Where did you hear about it?  
 What have you heard from friends? 
 What have you heard from family?  
 What have you heard in the clinic?  
 What, if anything, have you heard people say about 
TAPS (this specific study)? 
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6.  What might have kept the participant from starting PrEP/IT 
sooner? What were their initial concerns?  
 
What concerns did you have initially about PrEP/IT before 
you started taking it?  
 Were you worried about side effects?  
 Were you concerned about what other people 
might think? Why?  
 Did these concerns prevention you from starting the 
PrEP/IT sooner?  
 
 
7.  How does the participant feel about taking PrEP/IT? 
 
What do you think and/or feel now about PrEP/IT 
 What were your main reasons for taking PrEP/IT?  
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8.  Did the participant change her sexual behaviour after 
starting her medication?  
 
Remember back to your concerns around sex you had 
before and how you handled them. Is the sex you have 
different now that you are taking PrEP/ IT?  
 Have you changed how often you use condoms? 
 Do you use different methods for contraception 
now? 
 Do you do anything different with your clients?    
 If you have a main partner or casual partner, have 
they asked you to change how you have sex?   
 Does it help or hinder your sexual relationships? In 
what ways? Increase or decrease sexual 
desire/pleasure? 
 Does it affect the level of protection and comfort 
with sexual practices? 
 
 
9.  Has taking PrEP/Treatment had any effect/impact on the 
general health and well-being, and/or relationships? 
 
What do you think the PrEP/IT does for you in terms of your 
health and well-being?  
 What impact has it had on your life in general?  
 Do you feel like it makes you feel weaker or 
stronger?  
 Does it have any effect in other aspects of your 
relationship with your regular partner or clients? 
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10. How does the participant take her medication? Is she 
taking her pills every day? Where and how?  
 
Can you walk me through how you take your PrEP/IT?  
 When do you take it?  
 Where do you take it?  
 How do you remember to take it?  
 
 
11. What problems is the participant experiencing in terms of 
adherence to the medication?  
 
Have you experienced any problems in taking the 
medication?  
 Is there anything about your home environment or 
where you stay that makes it difficult to take your 
PrEP/IT? 
 Is there anything about your work environment or 
where you stay that makes it difficult to take your 
PrEP/IT? 
 Are there any people in your life who make it easy or 
difficult to take your PrEP/IT (e.g. friends, family 
members, partners, clients, police) 
 How do you feel supported by the clinic to take your 
PrEP/IT?  
 Do other participants help support you to take your 
PrEP/IT? 
 Is there anyone else who supports you? If so, what 
do they do and who helps you? 
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12. What role do side effects play, if any, on the participant’s 
adherence to her medication?  
 
What side effects have you experienced from taking your 
PrEP/IT? 
 How did you feel about the side effects?  
 How did you deal with them?  
 Have they caused you to stop taking the 
medication?  
 
[NOTE: skip if previously mentioned in detail] 
 
 
13. Is the SMS messaging service helpful to the participant in 
attending the clinic and remembering to take study 
medication? 
 
Have you found the SMS messaging service to be useful? [If 
they aren’t receiving the messages or if this was discussed in 
detail earlier, skip to next question] 
 Do you receive both the visit reminders and the 
supportive messages?  
 Do the visit reminders help you get to the clinic, or 
do they make no difference? 
 Do you like the supportive messages?  
 If there are things you don’t like about the visit 
reminders or supportive messages, what are they?  
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14. Has the participant disclosed product use to anyone and 
have they found any social support?  
 
Have you told anyone that you are taking PrEP/IT?  
 Who was it?  
 What did they think/say?  
 What did you think about their reaction?  
 
 
15. Has the participant shared their PrEP/IT with another 
person?  
 
Sharing things with family and friends is part of our lives. 
Have you ever shared your PrEP/IT with someone else?  
 Who did you share it with?  
 Why did you share?  
 
[NOTE: skip if previously mentioned] 
 
 
16. Has the PrEP/IT ever been stolen or sold? 
 
Has anyone ever stolen your PrEP/Treatment? Or have you 
ever had to sell your PrEP/IT? 
 If you’ve had it stolen, who stole it and do you know 
why?  
 If you sold your PrEP/IT, why did you sell it?  
 
[NOTE: skip if previously mentioned] 
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So we’ve been discussing what your experiences have been in life before taking PrEP/IT, and then what it’s been like taking the medication. Now I am 
going to ask you about your experiences at the clinic. We are very interested in hearing any feedback you may have so we can ensure we are providing 
the best services possible, so please feel free to share any opinions and experiences you have. 
 
17. How did the participant find out about the clinic and the 
study?  
 
How did you hear about the clinic?  
 Who told you?  
 How did you get here?  
 Did you have difficulties in finding the clinic or 
getting to it?  
 
 
18. What motivated the participant to come to the clinic?  
 
Why did you decide to start coming to the clinic? 
 
 What’s your biggest reason for coming to the clinic?  
 What was your reason originally and what is your 
reason now? 
 Did your friends or family encourage you to come?  
 Did you have any health related concerns that 
brought you to the clinic?  
 Were you interested in getting tested and taking 
care of your health more generally?  
 Did you want to get PrEP/IT specifically?  
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19. Does the participant interact with other participants? What 
sorts of things does she hear?  
 
What do you talk about with your friends who also come to 
the clinic? [If no, then skip to next question]  
 Have you shared impressions of the study, 
medications, or clinic experiences with other 
participants? 
 If yes, how have you felt about other experiences 
you have heard about?  
 What have others said about experiences at the 
clinic?  
 Are there things you or others would change?  
 
 
20. How does the participant feel about the clinic?  
 
Would you recommend this clinic to other people? [If no, 
then skip to last prompt] 
 Who would you tell to come here? 
 Why?  
 What do you like most about coming to the clinic?   
 What would you change about the clinic? [skip if 
answered above] 
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21. How does the participant feel about PrEP/IT? 
 
Would you recommend taking PrEP/IT to other people? 
 Who would you recommend it to?  
 Why?  
 What if PrEP/IT were available to more people than 
just sex workers?  
 
 
 
We are coming to the end of the interview now. I just have two more questions for you. These are quite broad questions so just tell me whatever 
comes to your mind. Remember there is no right or wrong answer, so you can answer these in any way you want.  
 
22. What aspects within the participant’s life most affect their 
perceived quality of life? Does HIV come up? 
 
If you could change one thing in your life today to make it 
better, what would it be?  
 
Examples: 
 Working situation or type of work 
 Relationships with clients or regular partners 
 Friend or family relationships 
 Education  
 Health issues 
 Legal/policy frameworks 
 
 
319 
 
 
23. Any other questions? 
 
Is there anything else you would like to tell me about the 
study products or your experience using PrEP/Treatment?  
 
 Ask if they have any questions for you  
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IDI 2 Guide (Month 6) 
 
Interviewer ________________  Site/Venue: _______________ 
 
INTRODUCTION 
This guide represents the first in a set of three interviews in which female sex workers participating in the TAPS Demonstration Project will be 
randomly selected and invited to participate. The primary objective of this research is to explore the individual perspectives and lived experiences of 
FSWs willing to take up and use PrEP or Immediate Treatment in South Africa. These serial interviews conducted by research assistants working on 
the project will aim to answer the following questions: 
 
 What factors influence effective PrEP/Immediate Treatment uptake and use by female sex workers in South Africa?  
 What factors should be considered for future scale-up, rollout, and implementation of PrEP/Immediate Treatment?  
 
The questions within the interview guides feed into a larger social-ecological framework and follow a specified flow depicted in the flow chart below.  
    
 
 
It is important while conducting the interview that the interviewer remembers the answers the participant gives as the conversation goes along in 
order to react appropriately to given questions and prompts. The interviewer may need to encourage the participant to speak freely and remind the 
participant of their previous answers. One particular aspect which may need repeated clarification is the different between clients and partners. The 
definitions for clients and partners used in the demographics questionnaire is listed below for easy reference and can be read to the participant at any 
time.  
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Main and Casual Partners 
In this interview we may discuss different types of sexual partners. One type is a main partner, like a husband, boyfriend, or someone you might call an 
emotional partner that you see regularly whom you do not see as a client and who does not necessarily give you money or gifts in exchange for sex. 
Another type is a casual partner, someone you might see from time to time but whom you do not consider to be someone you are in a serious 
relationship with. Finally, another type of partner will be your client, someone who gives you money or other goods/gifts in exchange for sex. You may 
have clients you see just once which we will call occasional clients, or you may have clients you see on a regular basis, which we will call regular 
clients. Can you explain back to me your understanding of what these different types of partners are? For instance, who did you last have sex with? 
Which type of partner would they be?    
 
INSTRUCTIONS FOR THE INTERVIEWER – HOW TO USE THIS IDI GUIDE 
1. There are 3  levels of questions: 
 Numerical research questions/topic areas highlighted in gray: the questions/areas that we as TAPS researchers want to get answers to. 
These don’t need to be read aloud. 
 IDI questions: the questions that you as the Interviewer will ask respondents in order to get answers to the research questions. These 
questions will be underlined.  
 Probes: they are indicated with a bullet, and will not be translated. The interviewer should ensure that key topics listed in the probes have 
been addressed/discussed during the interview. So, depending on what has already been discussed, and the IDI context, you may ask 
these probes or not. 
 
2. Instructions/suggestions to interviewer are in italics and brackets [ ]. 
 
3. The IDI guide is divided into two columns.  
 The left-hand column contains the research questions, IDI questions and probes. The IDI questions are suggestions for getting the 
discussion going. It is not required to read them verbatim, but they are written in local language to ensure some consistency across IDIs. 
You may adapt the question, depending on how the interview develops, and you as the Interviewer will have to ensure that at the end the 
research questions have been answered. . 
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 The right-hand column is for summarising the themes brought up by the woman in the IDI. These should be summaries of the general 
issues raised in connection with the research question. These summaries should be more than just yes/no, but not longer than a few 
sentences of bullet points. They do not need to be detailed, as we have the details on the tape. Note: the summaries and yes/no answers 
should be filled by the IDI interviewer immediately after the IDI. 
 
DAY OF INTERVIEW 
First make the participant comfortable. Offer her something to drink and explain who you are and introduce yourself if you haven’t met before.   
 
Before starting the IDI, the Interviewer explains to the respondent: 
  
Now I am going to start the recorder.  [Interviewer: start the tape recorder.] 
 
As you know from your informed consent, this IDI will be tape recorded today.  Please verbally indicate that you are aware that we are tape recording 
this session and that it is okay with you.  [Interviewer:  be sure to get a verbal okay from the respondent.] 
 
Today we will be discussing some of your life experiences, your experience taking PrEP/IT, and your experience coming to the clinic. There is no right 
or wrong answer to any of these questions so you should just tell me whatever comes to your mind. I also want to assure you that although we will be 
recording the interview, we will not be using your name on this tape, nor anyone else’s. We will keep this recording confidential, and any information 
I pass back to the clinic team will not be in connection with your name. Please feel free to tell me anything you want about your experiences, positive 
or negative, and please tell me if there is anything you are uncomfortable with or want to skip over. We will begin now. Do you have any questions 
before we start?  
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 Research Question, IDI Questions, Probes SUMMARY 
1.  How does HIV rank as a concern within the lives of FSWs? 
 
Since we last spoke, you told me your daily concerns were 
XXX. Have these changed since then, in the last few months?  
 
 Do you worry about your family or things at 
home? 
 Do you worry about things to do with work (e.g. 
how do you cope, are you worried about getting 
sick or paying rent)? 
 Do you worry about your health? 
 
 
 
 
 
 
 
 
 
 
2.  What are specific concerns the participant has around sex 
and HIV?  
 
When we last spoke you had XXX concerns about sex, how 
have these changed since then?  
 Do you worry about STIs? 
 Do you worry about HIV? 
 Do you worry about your clients? 
 Do you worry about your other partners?  
 Do you have worries directly related to your work 
(e.g. family or friends finding out, violence? 
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3.  What were the participant’s specific experiences last time 
she had sex without a condom?  
 
Last time we spoke we discussed one of your experiences 
having sex without a condom. Can you tell me about an 
experience you’ve had since the last time we spoke when 
you had sex without a condom?    
 Who was it with?  
 Why did you not use a condom? 
 Did you talk about using a condom? 
 Where were you?  
 How did you feel afterwards (worry, etc.)? 
 Did you feel any different now that you are taking 
PrEP/IT? 
 Is this kind of experience something typical or 
different to your usual experiences with sex?  
 Did you do anything afterwards like washing? Or 
visit the clinic? 
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4.  Does the participant understand PrEP/Immediate 
treatment and where do they get their information? This is 
specifically getting at knowledge and rumours.  
 
Now that you’ve been coming to the clinic for a couple of 
months, can you tell me what do you know about PrEP/IT? 
 What is the purpose of taking PrEP/IT? 
 Where did you hear about it?  
 What have you heard from friends? 
 What have you heard from family?  
 What have you heard in the clinic?  
 What, if anything, have you heard people say about 
TAPS (this specific study)? 
 
 
5.  What might have kept the participant from starting PrEP/IT 
sooner? What were their initial concerns?  
 
What concerns did you have initially about PrEP/IT before 
you started taking it?  
 Were you worried about side effects?  
 Were you concerned about what other people 
might think? Why?  
 Did these concerns prevention you from starting the 
PrEP/IT sooner?  
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6.  How does the participant feel now about taking PrEP/IT? 
 
What do you think and/or feel now about PrEP/IT 
 What were your main reasons for taking PrEP/IT?  
 
 
 
 
 
 
 
 
 
 
7.  Did the participant change her sexual behaviour after 
starting her medication?  
 
Is the sex you have different now that you are taking PrEP/ 
IT [modify slightly if participant has rolled off PrEP]?  
 Have you changed how often you use condoms? 
 Do you use different methods for contraception 
now? 
 Do you do anything different with your clients 
[negotiation, pricing, etc]?    
 If you have a main partner or casual partner, have 
they asked you to change how you have sex?   
 Does it help or hinder your sexual relationships? In 
what ways? Increase or decrease sexual 
desire/pleasure? 
 Does it affect the level of protection and comfort 
with sexual practices? 
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8.  Has taking PrEP/Treatment had any effect/impact on the 
general health and well-being, and/or relationships? 
 
So far, how has the PrEP/IT influenced your health and well-
being?  
 What impact has it had on your life in general?  
 Do you feel like it makes you feel weaker or 
stronger?  
 Does it have any effect in other aspects of your 
relationship with your regular partner or clients? 
 
 
9.  How does the participant take her medication? Is she 
taking her pills every day? Where and how?  
 
Can you walk me through how you take your PrEP/IT?  
 When do you take it?  
 Where do you take it?  
 How do you remember to take it? 
 Has anything changed since we last spoke? 
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10. What problems is the participant experiencing in terms of 
adherence to the medication?  
 
Since we last spoke, have you experienced any problems in 
taking the medication?  
 Is there anything about your home environment or 
where you stay that makes it difficult to take your 
PrEP/IT? 
 Is there anything about your work environment or 
where you stay that makes it difficult to take your 
PrEP/IT? 
 Are there any people in your life who make it easy or 
difficult to take your PrEP/IT (e.g. friends, family 
members, partners, clients, police) 
 How do you feel supported by the clinic to take your 
PrEP/IT?  
 Do other participants help support you to take your 
PrEP/IT? 
 Is there anyone else who supports you? If so, what 
do they do and who helps you? 
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11. What role do side effects play, if any, on the participant’s 
adherence to her medication?  
 
Since we last spoke, what side effects have you experienced 
from taking your PrEP/IT, if any? 
 How did you feel about the side effects?  
 How did you deal with them?  
 Have they caused you to stop taking the 
medication?  
 
[NOTE: skip if previously mentioned in detail] 
 
 
12. Is the SMS messaging service helpful to the participant in 
attending the clinic and remembering to take study 
medication? 
 
Now that it has been a couple of months, what do you think 
about the  SMS messages? [If they aren’t receiving the 
messages or if this was discussed in detail earlier, skip to 
next question] 
 Do you receive both the visit reminders and the 
supportive messages?  
 Do the visit reminders help you get to the clinic, or 
do they make no difference? 
 Do you like the supportive messages?  
 If there are things you don’t like about the visit 
reminders or supportive messages, what are they?  
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13. Has the participant disclosed product use to anyone and 
have they found any social support?  
 
Since we last spoke, have you told anyone that you are 
taking PrEP/IT?  
 Who was it? 
 Why did you decide to tell that person in particular?   
 What did they think/say?  
 What did you think about their reaction?  
 
 
14. Has the participant shared their PrEP/IT with another 
person?  
 
Sharing things with family and friends is part of our lives. 
Have you ever shared your PrEP/IT with someone else?  
 Who did you share it with?  
 Why did you share?  
 
[NOTE: skip if previously mentioned] 
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15. Has the PrEP/IT ever been stolen or sold? 
 
Has anyone ever stolen your PrEP/Treatment? Or have you 
ever had to sell your PrEP/IT? 
 If you’ve had it stolen, who stole it and do you know 
why?  
 If you sold your PrEP/IT, why did you sell it?  
 
[NOTE: skip if previously mentioned] 
 
 
 
 
 
So we’ve been discussing what your experiences have been in life before taking PrEP/IT, and then what it’s been like taking the medication. Now I am 
going to ask you about your experiences at the clinic. We are very interested in hearing any feedback you may have so we can ensure we are providing 
the best services possible, so please feel free to share any opinions and experiences you have. 
 
16. What motivated the participant to come to the clinic?  
 
What keeps you coming back to the clinic? 
 
 What’s your biggest reason for coming to the clinic?  
 Do your friends or family encourage you to come?  
 Do you have any health related concerns that bring 
you to the clinic?  
 Does regular HIV testing play a big role in coming to 
the clinic?  
 Did you want to get PrEP/IT specifically?  
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17. Does the participant interact with other participants? What 
sorts of things does she hear?  
 
What do you talk about with your friends who also come to 
the clinic? [If no, then skip to next question]  
 Have you shared impressions of the study, 
medications, or clinic experiences with other 
participants? 
 If yes, how have you felt about other experiences 
you have heard about?  
 What have others said about experiences at the 
clinic?  
 Are there things you or others would change?  
 Have you talked to anyone new about the clinic? 
 
 
18. How does the participant feel about the clinic?  
 
How do you feel about the clinic now that you have been 
coming for several months? Would you recommend it to any 
one you know?  [If no, then skip to last prompt] 
 Who would you tell to come here? 
 Why?  
 What do you like most about coming to the clinic?   
 What would you change about the clinic? [skip if 
answered above] 
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19. How does the participant feel about PrEP/IT? 
 
Now that it’s been a couple of months, would you 
recommend taking PrEP/IT to other people? 
 Who would you recommend it to?  
 Why?  
 What if PrEP/IT were available to more people than 
just sex workers?  
 
 
 
We are coming to the end of the interview now. I just have two more questions for you. These are quite broad questions so just tell me whatever 
comes to your mind. Remember there is no right or wrong answer, so you can answer these in any way you want.  
 
20. What aspects within the participant’s life most affect their 
perceived quality of life? Does HIV come up? 
 
If you could change one thing in your life today to make it 
better, what would it be?  
 
Examples: 
 Working situation or type of work 
 Relationships with clients or regular partners 
 Friend or family relationships 
 Education  
 Health issues 
 Legal/policy frameworks 
 
 
334 
 
 
21. Any other questions? 
 
Is there anything else you would like to tell me about the 
study products or your experience using PrEP/Treatment?  
 
 Ask if they have any questions for you  
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IDI Guide 3 (Month 9) 
 
Interviewer ________________  Site/Venue: _______________ 
 
I. INTRODUCTION 
This guide represents the third in a set of three interviews in which female sex workers participating in the TAPS Demonstration Project will be 
randomly selected and invited to participate. The primary objective of this research is to explore the individual perspectives and lived experiences of 
FSWs willing to take up and use PrEP or Immediate Treatment in South Africa. These serial interviews conducted by research assistants working on 
the project will aim to answer the following questions: 
 
 What factors influence effective PrEP/Immediate Treatment uptake and use by female sex workers in South Africa?  
 What factors should be considered for future scale-up, rollout, and implementation of PrEP/Immediate Treatment?  
 
The questions within the interview guides feed into a larger social-ecological framework and follow a specified flow depicted in the flow chart below.  
    
 
 
It is important while conducting the interview that the interviewer remembers the answers the participant gives as the conversation goes along in 
order to react appropriately to given questions and prompts. The interviewer may need to encourage the participant to speak freely and remind the 
participant of their previous answers. One particular aspect which may need repeated clarification is the different between clients and partners. The 
definitions for clients and partners used in the demographics questionnaire is listed below for easy reference and can be read to the participant at any 
time.  
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Main and Casual Partners 
In this interview we may discuss different types of sexual partners. One type is a main partner, like a husband, boyfriend, or someone you might call an 
emotional partner that you see regularly whom you do not see as a client and who does not necessarily give you money or gifts in exchange for sex. 
Another type is a casual partner, someone you might see from time to time but whom you do not consider to be someone you are in a serious 
relationship with. Finally, another type of partner will be your client, someone who gives you money or other goods/gifts in exchange for sex. You may 
have clients you see just once which we will call occasional clients, or you may have clients you see on a regular basis, which we will call regular 
clients. Can you explain back to me your understanding of what these different types of partners are? For instance, who did you last have sex with? 
Which type of partner would they be?    
 
INSTRUCTIONS FOR THE INTERVIEWER – HOW TO USE THIS IDI GUIDE 
1. There are 3  levels of questions: 
 Numerical research questions/topic areas highlighted in gray: the questions/areas that we as TAPS researchers want to get answers to. 
These don’t need to be read aloud. 
 IDI questions: the questions that you as the Interviewer will ask respondents in order to get answers to the research questions. These 
questions will be underlined.  
 Probes: they are indicated with a bullet, and will not be translated. The interviewer should ensure that key topics listed in the probes have 
been addressed/discussed during the interview. So, depending on what has already been discussed, and the IDI context, you may ask 
these probes or not. 
 
2. Instructions/suggestions to interviewer are in italics and brackets [ ]. 
 
3. The IDI guide is divided into two columns.  
 The left-hand column contains the research questions, IDI questions and probes. The IDI questions are suggestions for getting the 
discussion going. It is not required to read them verbatim, but they are written in local language to ensure some consistency across IDIs. 
You may adapt the question, depending on how the interview develops, and you as the Interviewer will have to ensure that at the end the 
research questions have been answered. . 
 The right-hand column is for summarising the themes brought up by the woman in the IDI. These should be summaries of the general 
issues raised in connection with the research question. These summaries should be more than just yes/no, but not longer than a few 
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sentences of bullet points. They do not need to be detailed, as we have the details on the tape. Note: the summaries and yes/no answers 
should be filled by the IDI interviewer immediately after the IDI. 
 
DAY OF INTERVIEW 
First make the participant comfortable. Offer her something to drink and explain who you are and introduce yourself if you haven’t met before.   
 
Before starting the IDI, the Interviewer explains to the respondent: 
  
Now I am going to start the recorder.  [Interviewer: start the tape recorder.] 
 
Just a reminder, as we discussed when we did your informed consent, this IDI will be tape recorded today.  Please verbally indicate that you are aware 
that we are tape recording this session and that it is okay with you.  [Interviewer:  be sure to get a verbal okay from the respondent.] 
 
Today we will be discussing some of your life experiences, your experience taking PrEP/IT, and your experience coming to the clinic as we have done 
in the past interviews. We want to see if anything has changed in your life over time and whether you have any new thoughts about taking PrEP/IT. 
There is no right or wrong answer to any of these questions so you should just tell me whatever comes to your mind. I also want to assure you that 
although we will be recording the interview, we will not be using your name on this tape, nor anyone else’s. We will keep this recording confidential, 
and any information I pass back to the clinic team will not be in connection with your name. Please feel free to tell me anything you want about your 
experiences, positive or negative, and please tell me if there is anything you are uncomfortable with or want to skip over. We will begin now. Do you 
have any questions before we start?  
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 Research Question, IDI Questions, Probes SUMMARY 
1.  Have there been any major changes in the participant’s life 
since she has been in the study?  
 
Since you joined the project, have you had any major life 
changes?  
 Have you had a change in your living and/or working 
situation?  
 Any changes in your family or with friends?  
 Any changes with partners?  
 Any changes in making money?  
 
 
2.  How does HIV rank as a concern within the lives of FSWs? 
 
What have been your daily concerns recently? Have these 
changed since the last time we spoke and/or since you 
joined the project?  
 
 Do you worry about your family or things at 
home? 
 Do you worry about things to do with work (e.g. 
how do you cope, are you worried about getting 
sick or paying rent)? 
 Do you worry about your health? 
 
 
 
 
 
 
 
 
 
 
339 
 
 
3.  What are specific concerns the participant has around sex 
and HIV?  
 
Since the last time we spoke, what kinds of concerns have 
you had around sex?  
 Do you worry about particular health issues 
(general, STIs, HIV)? 
 Do you worry about your clients? 
 Do you worry about your other partners?  
 Do you have worries directly related to your work 
(e.g. family or friends finding out, violence? 
 
 
4.  What does the participant do to manage concerns and 
what do they experience in the process (e.g. difficult 
partnerships, trouble negotiating protection)?  
 
What have you done to deal with these concerns?  
 What sorts of problems did you experience 
managing these concerns?  
 What did you do?  
 Were you able to use condoms?  
 Did you pick certain clients or partners over others? 
 Did you have sex differently (e.g. ask client or 
partner to pull out before ejaculation or only have 
anal sex)?  
 Do you have any specific washing practices?  
 Who did you talk to about your concerns or what 
you did to handle them?  
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5.  How have experiences of violence affected the participant 
since she has been in the study?  
 
How have any experiences of violence and/or abuse 
affected you since you joined the project?  
 Have you had any of these issues with clients or 
partners? If yes, what happened?  
 Have you experienced abuse from friends, family, 
colleagues, or others? If yes, what happened?  
 How have any of these experienced affected being 
able to take PrEP/IT? Easier or harder?  
 
 
 
6.  How does the participant feel about PrEP/Immediate 
treatment and what do they hear potentially from others? 
This is specifically getting at their personal perceptions as 
well as knowledge and rumours.  
 
Now that you’ve been taking PrEP/IT for a while, what do 
you think and/or feel about it? 
 Why do you take PrEP/IT? 
 What do other people say about PrEP/IT (friend, 
family, colleagues, clients, partners)? 
 What, if anything, have you heard people say about 
TAPS (this specific study)? 
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7.  What have been the participant’s specific experiences over 
time in trying to maintain condom use with PrEP/IT?  
 
How has it been trying to keep using condoms now that you 
are taking PrEP/IT?    
 Is it difficult? 
 Who do you have problems not using a condom 
with (client/partner)  
 Why did you not use a condom? 
 Did you talk about using a condom? 
 Where were you?  
 How did you feel afterwards (worry, etc.)? 
 Is this kind of experience something typical or 
different to your usual experiences with sex?  
 Did you do anything afterwards like washing? Or 
visit the clinic? 
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8.  Did the participant change her sexual behaviour after 
starting her medication?  
 
How has sex changed for you now that you have been taking 
PrEP/ IT  for some time [modify slightly if participant has 
rolled off PrEP]?  
 Have you changed how often you use condoms? 
 Do you use different methods for contraception 
now? 
 Do you do anything different with your clients 
[negotiation, pricing, etc]?    
 If you have a main partner or casual partner, have 
they asked you to change how you have sex?   
 Does it help or hinder your sexual relationships? In 
what ways? Increase or decrease sexual 
desire/pleasure? 
 Does it affect the level of protection and comfort 
with sexual practices? 
 
 
343 
 
 
9.  Has taking PrEP/Treatment had any effect/impact on the 
general health and well-being, and/or relationships? 
 
Since you’ve been taking it, how has the PrEP/IT changed 
your overall health and well-being?  
 What impact has it had on your life in general?  
 Do you feel healthier or do you feel like you get sick 
more often? 
 Do you feel like it makes you feel weaker or 
stronger?  
 Does it have any effect in other aspects of your 
relationship with your regular partner or clients? 
 
 
10. How does the participant take her medication? Is she 
taking her pills every day? Where and how?  
 
How do you continue to take your PrEP/IT every day? What 
are your strategies? 
 When do you take it?  
 Where do you take it?  
 How do you remember to take it? 
 Have you made any changes over time to keep 
taking the pills?  
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11. Has the participant disclosed product use to anyone new?  
 
Since we last spoke, have you told anyone new that you are 
taking PrEP/IT?  
 Who was it? 
 Why did you decide to tell that person in particular 
(or why not)?   
 What did they think/say?  
 What did you think about their reaction?  
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12. What support systems does the participant rely on to take 
her medication?  
 
What support system do you have to help you to take your 
medication, if any? Has this changed over time?  
 
 Are there any people in your life who make it easy or 
difficult to take your PrEP/IT (e.g. friends, family 
members, partners, clients, police) 
 How do you feel supported by the clinic to take your 
PrEP/IT?  
 Do other participants help support you to take your 
PrEP/IT? 
 Is there anyone else who supports you? If so, what 
do they do and who helps you? 
 If things have changed, what, how, and why have 
they changed in terms of support systems?  
 Do you interact with any of the community 
organizations for sex workers or others (SWEAT, 
Sisonke, Church, etc.) 
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13. What problems is the participant experiencing in terms of 
adherence to the medication?  
 
Since the last time we spoke did it happen that you were 
unable to take the pill? What happened?  
 
 Is there anything about your home environment or 
where you stay that makes it difficult to take your 
PrEP/IT? 
 Is there anything about your work environment or 
where you stay that makes it difficult to take your 
PrEP/IT? 
 
 
 
14. What role do side effects play, if any, on the participant’s 
adherence to her medication?  
 
Since we last spoke, what side effects have you experienced 
from taking your PrEP/IT, if any? 
 How did you feel about the side effects?  
 How did you deal with them?  
 Have they caused you to stop taking the 
medication?  
 
[NOTE: skip if previously mentioned in detail] 
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15. Is the SMS messaging service helpful to the participant in 
attending the clinic and remembering to take study 
medication? 
 
Now that it has been a couple of months, what do you think 
about the  SMS messages? [If they aren’t receiving the 
messages or if this was discussed in detail earlier, skip to 
next question] 
 Do you receive both the visit reminders and the 
supportive messages?  
 Do the visit reminders help you get to the clinic, or 
do they make no difference? 
 Do you still like the supportive messages?  
 If there are things you don’t like about the visit 
reminders or supportive messages, what are they?  
 
 
 
 
16. Has the participant shared their PrEP/IT with another 
person?  
 
Sharing things with family and friends is part of our lives. 
Have you ever shared your PrEP/IT with someone else?  
 Who did you share it with?  
 Why did you share?  
 
[NOTE: skip if previously mentioned] 
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17. Has the PrEP/IT ever been stolen or sold? 
 
Has anyone ever stolen your PrEP/Treatment? Or have you 
ever had to sell your PrEP/IT? 
 If you’ve had it stolen, who stole it and do you know 
why?  
 If you sold your PrEP/IT, why did you sell it?  
 
[NOTE: skip if previously mentioned] 
 
 
 
 
 
So we’ve been discussing what your experiences have been in life before taking PrEP/IT, and then what it’s been like taking the medication. Now I am 
going to ask you about your experiences coming to the clinic, and new policies coming online. We are very interested in hearing any feedback you may 
have so we can ensure we are providing the best services possible, so please feel free to share any opinions and experiences you have. 
 
18. Why does the participant continue to come to the clinic?  
 
What keeps you coming back to the clinic? 
 
 What’s your biggest reason for coming to the clinic?  
 Do your friends or family encourage you to come?  
 Do you have any health related concerns that bring 
you to the clinic?  
 Does regular HIV testing play a big role in coming to 
the clinic?  
 Did you want to get PrEP/IT specifically?  
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19. What barriers does the participant face in trying to come to 
the clinic?  
 
What are some problems you have had with coming to the 
clinic for your appointments?  
 
 Do you miss the appointments to pick up your 
PrEP/IT, or to come for your clinic visit more often? 
 Do transport issues get in the way of coming to the 
clinic? Are you coming from far away?  
 What about leaving where you work/live, does that 
sometimes cause an issue?  
 Or needing to pay rent?  
 
 
20. Does the participant interact with other participants? What 
sorts of things does she hear?  
 
What do you talk about with your friends who also come to 
the clinic? [If no, then skip to next question]  
 Have you shared impressions of the study, 
medications, or clinic experiences with other 
participants? 
 If yes, how have you felt about other experiences 
you have heard about?  
 What have others said about experiences at the 
clinic?  
 Are there things you or others would change?  
 Have you talked to anyone new about the clinic? 
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21. How does the participant feel about the project and being 
a part of it?  
 
How do you feel about being a part of the project now that 
you have been coming for a while?  [If no, then skip to last 
prompt] 
 What have been the best and worst parts?  
 Would you recommend it to any one you know? 
 Who would you tell to come here? 
 Why?  
 What do you like most about coming to the clinic?   
 What would you change about the clinic? [skip if 
answered above] 
 
 
22. What does the participant think about the national rollout 
of PrEP/IT?  
 
What do you think about PrEP and IT being given to 
everyone coming to the sex worker clinics? [explain new 
policy if she doesn’t already know] 
 Do you think other sex workers will want these 
interventions? Why or why not?  
 Would other people like to take PrEP or IT? If so, 
who?  
 Do you already know clients or partners who want 
PrEP or IT? 
 Do you know any sex workers not coming to the 
clinic who want PrEP or IT? If so, why aren’t they 
coming?  
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We are coming to the end of the interview now. I just have two more questions for you. These are quite broad questions so just tell me whatever 
comes to your mind. Remember there is no right or wrong answer, so you can answer these in any way you want.  
 
23. What aspects within the participant’s life most affect their 
perceived quality of life? Does HIV come up? 
 
If you could change one thing in your life today to make it 
better, what would it be?  
 
Examples: 
 Working situation or type of work 
 Relationships with clients or regular partners 
 Friend or family relationships 
 Education  
 Health issues 
 Legal/policy frameworks 
 
 
24. Any other questions? 
 
Is there anything else you would like to tell me about the 
study products or your experience using PrEP/Treatment?  
 
 Ask if they have any questions for you  
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